



ISRV

International Society for
Respiratory Viruses

Options XIII Conference for the Control of Influenza

30 August - 2 September 2026

Washington DC Convention Center, Washington, DC

FULL PROGRAM

Table of Contents

Sponsors and Supporters	3
Organizing Committees	4
Award Information	5
Travel Awards	5
Welcome Messages	6
Welcome Message from the OPTIONS XIII Chairs	6
Welcome Message from the ISRV Chair	7
General Information	8
Venue Floor Plans	11
Washington DC Convention Center	11
About Washington DC	12
Experience Washington DC	13
Full Program	15
Day 1 - Sunday August 30	17
Day 2 - Monday August 31	23
Day 3 - Tuesday September 1	33
Day 4 - Wednesday September 2	44
Plenary and Symposium Speakers	49
Plenary Speakers	49
Symposium Speakers	52
Industry Sponsored Symposia	80
Oral Presentations Listings	81
Poster Session	89
Exhibitors	113
Sponsor and Exhibitor Profiles	113
Exhibition Floor Plan	117

Thank you to our Sponsors and Supporters

Platinum Sponsors



Gold Sponsors



Bronze Sponsors



Vaccines at Pfizer

Partners



Organizing Committee



Justin Ortiz
(CHAIR), University of Maryland



Amanda Williams
ISRV CEO



Andy Pekosz
(CHAIR), Johns Hopkins University



Maria Zambon
ISRV Chair



Michael Ison
(Advisor), NIH/NIAID



Ultan Power
ISRV Treasurer

Scientific Track Committees

Clinical Science

Jake Dunning	Co-Chair, University of Oxford
Alicia Fry	Co-Chair, Task Force for Global Health
James Antoon	Vanderbilt University Medical Center
Tor Biering-Sorensen	University of Copenhagen
Brooke Bozick	NIAID
Angela Campbell	Emory University School of Medicine (Adjunct)
Sue Huang	New Zealand Institute of Public Health and Forensic Science
David Hui	The Chinese University of Hong Kong
Deepali Kumar	University of Toronto
Nelson Lee	University of Toronto
Srinivas Murthy	University of British Columbia

Implementation

John Ryan McLane	Chair, Asia-Pacific Alliance for Control of Influenza
Raja Dhar	Calcutta Medical Research Institute
Shoshanna Goldin	WHO
Jude Jayamaha	Medical Research Institute
Leesa Lin	London School of Hygiene & Tropical Medicine
Alisa Pedrana	Burnet Institute
Lois Privor-Dumm	Consultant
Nikki Turner	University of Auckland
Jevin West	University of Washington
Ian Chi-Kei Wong	University of Hong Kong

Scientific Track Committees (continued)

Public Health

Marc-Alain Widdowson	Co-Chair, WHO
Cheryl Cohen	Co-Chair, National Center for Communicable Disease
Joseph Bresee	Task Force for Global Health
Ben Cowling	Hong Kong University
Fiona Havers	Emory University
Jean-Michel Heraud	Institute Pasteur
Kathy Neuzil	Gates Foundation
Sheena Sullivan	Doherty Institute
Cecile Viboud	Fogarty International Center

Virology & Pathogenesis

Erik Karlsson	Co-Chair, NIC Cambodia
Kanta Subbarao	Co-Chair, Laval University
Wendy Barclay	Imperial College London
Jennifer Gordon	NIAID
Daniel Perez	University of Georgia
Kaori Sano	National Institute of Infectious Diseases
Stacey Schultz-Cherry	St. Jude Children's Research Hospital
Martin Schwemmle	Albert-Ludwigs Universitat Freiburg
Sophie Valkenburg	Doherty Institute, University of Melbourne
Marietjie Venter	University of Witwatersrand

Congratulations to our Travel Awardees

Omid Arhami , Iran	Aisha Hegab Souquette , United States	Justin McClendon , United States	Qiqi Yang , China
Brown Bulloch , United States	Xiaotong Huang , China	Martin Muigano , Kenya	Jiamu Yang , China
Michael Chan , China	Saira Hussain , Australia	Tanya Novak , United States	Xuan Yu , China
Linyi Chen , China	Anna Jaeger , United States	Eric Osoro , Kenya	Limin Zhang , China
Hualan, Chen , China	Mamadou Jallow , Gambia	Maclaine Parish , United States	Chengyao Zhang , China
Mercy Cheptoo , Kenya	Jakob Jonnerby , Sweden	Liping Peng , China	Jennifer Zhong , Canada
Lucas Ferreri , Argentina	Dikeledi Kekana , South Africa	Gracie Quirk , United States	Mia Zhu , United States
Lilach Friedman , Israel	Takuma Kobayashi , Japan	Justin Shepard , United States	
Matt Friedman , United States	Mariana Leguia , Peru	Deryn St. James , United States	
Tamara Garcia-Salum , Chile	Min Li , China	Smrithi Sugumaran Menon , India	
Reanna Gregory , United Kingdom	Xinyi Li , China	Natalie Tarbuck , United States	
Seran Hakki , United Kingdom	Angel Ma , United Kingdom	Yani Wu , China	
Kayla Hanson , United States	Heather Machkovech , United States	Hualei Xin , China	
Walter Harrington , United States	Clara Malekshahi , United States	Jade Yangyupei Yang , China	
Nneoma Harris , Guyana		Bingyi Yang , China	

Welcome Message from the ISRV Chair

The International Society for Respiratory Viruses (ISRV) is a professional scientific society and registered charity in the United Kingdom. Formally launched in 2005, ISRV's constant mission over the last two decades has been to provide a forum for international scientists from government, academia, and the private sector to exchange information, stimulate collaboration, and provide education for the promotion, prevention, detection, treatment, and control of influenza and other respiratory virus diseases throughout the world.

To achieve our charitable and educational aims, ISRV co-ordinates a variety of conferences, meetings, and events, aimed at scientists at all stages of their career, to disseminate information on cutting-edge research and scientific advances and to help in nurturing future generations of respiratory virus experts.

Options for the Control of Influenza, one of ISRV's flagship meeting series, is a global scientific meeting with a dedicated focus on influenza. Currently held every 2 years, this conference brings together the global scientific community across several days for a varied scientific program tackling a range of real-world issues pertinent to the respiratory virus community. In recent years, the scope of these meetings has expanded to spotlight other emerging respiratory infections, such as SARS-CoV-2, integrated into four parallel tracks.

Running each Options meeting is a complex process with a multitude of moving parts. The success of the series is rooted in the society's approach to rotating the meeting location across the world with each cycle, taking into consideration and adapting to the relevant issues faced by the host's geographic region, and ensuring our expert speakers reflect the diversity of our international colleagues and their fields of practice. Each program at Options is unique, though underpinned by a commitment to showcase strong and innovative scientific work that generates discussion and pushes the study and treatment of respiratory viruses ever forward.

On behalf of the society, I very much hope that you enjoy the Options XIII meeting.

Maria Zambon
ISRV Chair

Welcome Message from the Options XIII Meeting Chairs

On behalf of the Options for the Control of Influenza XIII organizing and scientific committees, we would like to welcome you to Washington, DC, and to the conference. The two years since Options XII in Brisbane, Australia, have brought significant change to the landscape of respiratory virus diseases, clinical care, and the implementation of vaccine policies. To capture the multifaceted nature of influenza as a human disease threat, we have organized the meeting into four tracks: Virology and Pathogenesis, Clinical Science, Public Health, and Implementation. While this type of organization is necessary to ensure we cover all the relevant areas of influenza research and response, we hope that the morning plenary sessions will help emphasize the interrelationships between these areas. With over 1,000 attendees and over 700 oral and poster presentations, attendees will find a wealth of important work relevant to their specific field in addition to gaining a broader perspective of how influenza and other respiratory viruses can be effectively controlled and their effects on human health minimized.

Options XIII brings the meeting back to the United States for the first time since Options X was held in Chicago, Illinois, in 2016. While this presents some challenges, it is also an opportunity to engage the broader scientific, corporate, and government communities on the seasonal and pandemic threats of influenza and other respiratory virus infections. We need to find new and effective means of translating science into policy, and we hope this meeting provides an effective venue for that.

We would also like to acknowledge the contributions of the Scientific Committee members, ISRV leadership, and our conference management team at Conference Solutions – all of whom contributed greatly to the planning and implementation of the conference.

Again, welcome to Options XIII!

Justin Ortiz
Andrew Pekosz

General Information

Venue Information

Washington DC Convention Center

Address: 801 Allen Y. Lew Place NW, Washington, DC 20001

Phone: (202) 249-3000

Website: <https://eventsdc.com/venue/walter-e-washington-convention-center>

WiFi

Free basic wireless access is available across public spaces in the facility. Select the network named "FreeConventionCenterWiFi", create an account, and verify your email address to connect.

Lactation Space

The Walter E. Washington Convention Center provides private nursing and pumping spaces via Mamava lactation pods located near room 140A and room 103B.

Parking

Multiple parking garages are located around the Convention Center with hourly and daily rates.

Program Information

Online Resources

Visit the ISRV website for additional information and resources, including:

- A PDF of the Abstract Book
- Attendee Roster
- Certificate of Attendance

Available at: www.isrv.global/options-xiii-onsite/

Mobile App

How to download the App

Download the WHOVA App from the Apple App Store or Google Play (or scan the QR code). Once the WHOVA App is installed, sign in or create an account with the email you used to register for the event.



Event Code (if needed): InfluenzaDC

Connect With Your Peers

- Use the mobile app to connect with your peers and showcase your experiences.
- **Direct Connections:** Use the "Attendees" section to connect with your fellow attendees via direct messaging.
- **Community:** Participate in the polls, forums and share your thoughts on a variety of topics. You can also see how your peers feel!

Meals

A daily morning and afternoon refreshment break will be offered every day of the conference, as well as a poster reception on Sunday, Monday and Tuesday, and is included in the registration fee. There are several sponsor-hosted lunch and breakfast seminars available on a first-come, first-served basis; refer to the program for details on those sessions. The conference banquet on Tuesday, September 1 is available for a separate fee.

Smoking

Smoking is prohibited in most public places and workplaces under the Clear Air Act. Smokers must stay at least 20 feet away from entrances, exits, or windows of public buildings to comply with the law.

Exhibit Hall

The exhibit hall is located within Ballroom C at the Convention Center.

The exhibit hall will be open at the following times:

Sunday, August 30	8:30 am – 7:00 pm
Monday, August 31	8:30 am – 7:00 pm
Tuesday, September 1	8:30 am – 7:00 pm

Registration & Information Desk

The Registration & Information Desk is located in Salon G on the first floor of the Walter Washington Convention Center. The desk will be open during the following times:

Saturday, August 29	4:30 pm – 6:30 pm
Sunday August 30	7:00 am – 7:00 pm
Monday August 31	8:00 am – 7:00 pm
Tuesday September 1	8:00 am – 7:00 pm
Wednesday September 2	7:30 am – 4:00 pm

Speaker Check-In

All oral presenters must provide their final presentation (16:9 format) by using the provided Dropbox link or on a USB drive at the Presentation Upload Room Salon G during the designated times. PC laptops will be used and equipped with the latest

General Information

software. Presentations should be provided in PowerPoint. Personal laptops may not be used.

The presentation upload process is in place to ensure that all sessions run smoothly. Failure to submit your presentation as indicated may result in technical errors or missing graphics for your presentation.

Presenter Guidelines

- Oral abstract presentations are 10-minutes plus 5-minutes for questions and answers.
- Arrive to your presentation room 15-minutes prior to the session start time to familiarize yourself with the microphone, slide advancer, and stage set-up.
- Plan to stay for your whole session.
- Please be seated at the front of the presentation room in the row reserved for speakers.
- The Session Chair(s) will introduce you and monitor the length of the presentation.
- A speaker timer will be visible from the podium.
- A laser pointer and slide advancer will be available at the podium for your use.
- All mobile phones must be turned off while you are presenting.

Presentation Upload Information

Presenters are highly encouraged to upload their presentations in advance to bypass the Presentation Upload Room lines. A Dropbox link was sent to all presenters via email and will remain active until the night before your scheduled talk.

If you elect not to upload your talk in advance, bring it on a USB drive to the Presentation Upload Room during the designated times listed below.

Please note:

- Presentations must be submitted in PowerPoint 16:9 format.
- PC laptops will be used for presentations and will be equipped with the latest software.
- Personal laptops may not be used for presentations.
- Failure to submit your presentation as instructed may result in technical issues or missing content during your talk.

Presentation Upload Room - Salon G, 1st Floor

Presentation Date	Check-In Date	Hours
Sunday, 30 August	Sunday, 30 August	08:00 am – 1:00 pm
Monday, 31 August	Sunday, 30 August	08:00 am – 1:00 pm
Tuesday, 1 September	Monday, 31 August	08:00 am – 1:00 pm
Wednesday, 2 September	Tuesday, 1 September	08:00 am – 1:00 pm

Conference Policies

Name Badges

As a registered attendee, you will be issued an Options XIII name badge when you pick up your registration materials. You will be required to display your name badge for admission to all official functions. In the event of a lost badge, please visit the Registration Desk for a replacement.

Liability

The Conference organizers cannot accept liability for injuries or losses arising from accidents or other situations during or as a consequence of the Conference.

Scientific Data

Information communicated by presenters should be considered “personal communication.” Please seek permission from the presenter before quoting unpublished research results or using data as a basis for further investigations.

Photography

Photographs or recording (audio or visual) of data, whether displayed on screens, in posters, or elsewhere is strictly forbidden.

Mobile Phones

As a courtesy to all conference attendees, please make sure all cell phones are turned off when sessions are in progress. Charging stations are available within the Tradeshow.

Local Information

Time Zone

Eastern Time Zone (UTC-05:00)

Currency

The official currency of USA is the United States Dollar (USD), commonly shown as “\$”. You can check the latest exchange rates at [xe.com](https://www.xe.com).

Getting Around

Getting around DC is easy and convenient. The city offers a reliable public transportation system, including buses and the metro, making it simple to navigate between conference venues, hotels, and local attractions. Ride-sharing apps are also widely available, providing a flexible option for direct travel throughout the city.

Tipping

Service charges are not typically included into the bills by hotels and restaurants. You may tip taxi drivers, hotel porters and restaurant wait-staff (up to about 18% of the bill) if you wish to acknowledge their service. At any time, tipping is your choice.

Weather


The weather in DC is hot and humid. We encourage you to dress in layers to accommodate the warm days and air-conditioned meeting spaces.

Venue Floor Plans


Walter E. Washington Convention Center

Meeting Room	Description
Ballrom AB	Plenary and Concurrent Sessions
Rooms 202, 206, 207	Concurrent Sessions and Sponsored Seminars
Ballrom C and South Pre-Function Area	Posters and Exhibits

LEVEL 2



LEVEL 3



About Washington DC

<https://washington.org/>

Washington, DC, is a dynamic destination where iconic landmarks, world-class museums, vibrant neighborhoods, and a thriving culinary scene come together to create an unforgettable experience. As the nation's capital, visitors can explore historic sites like the White House, U.S. Capitol, and National Mall while enjoying free admission to many renowned Smithsonian museums. Beyond the monuments, neighborhoods such as Georgetown, Capitol Hill, The Wharf, and Adams Morgan offer unique shopping, local restaurants, waterfront views, and lively nightlife. Whether you're interested in history, arts and culture, outdoor recreation, or exceptional dining, Washington, DC offers something for every traveler in a walkable, welcoming city filled with year-round events and only-in-DC experiences.



About Washington DC

Explore the Smithsonian Museums (Free!)

The Smithsonian museums are one of DC's biggest draws, and most are completely free. Explore and learn about everything from the origins of man and the future of flight to the history of art across multiple continents with more than 150 million objects, works of art and specimens to discover. The Smithsonian's collection of knowledge centers serve as a treasure chest for visitors and a guide to the most fascinating aspects of our world.

Walk the National Mall & Visit the Monuments

The National Mall is the heart of Washington, DC, and one of the most iconic destinations in the United States. Stretching from the U.S. Capitol to the Lincoln Memorial, this two-mile park is home to world-famous monuments, memorials, and Smithsonian museums. Whether you're admiring the Washington Monument, reflecting at the Martin Luther King, Jr. Memorial, exploring free museums, or simply strolling the tree-lined paths, the National Mall offers an unforgettable experience that brings American history, culture, and civic life together in one place.

Explore Capitol Hill & Historic Government Sites

The U.S. Capitol and Historic Government Sites offer a fascinating look at the nation's history and the workings of American democracy. Tour the iconic U.S. Capitol, admire the breathtaking architecture of the Library of Congress, visit the Supreme Court, and explore the surrounding Capitol Hill neighborhood filled with historic landmarks, museums, and charming streets. Many attractions are free to visit, and guided tours provide an inside look at some of the country's most important institutions.

The Wharf & DC Waterfront

The Wharf & DC Waterfront is one of Washington, DC's most vibrant destinations, offering a lively mix of waterfront dining, live music, shopping, and outdoor recreation along the Potomac River. Visitors can stroll the scenic promenade, catch a concert at The Anthem, take a water taxi or river cruise, browse the historic Municipal Fish Market, or simply relax while enjoying beautiful views of the water. Just a short walk from the National Mall, The Wharf is the perfect place to experience DC's modern waterfront atmosphere.



About Washington DC

Dining in Washington DC

Washington, DC is more than monuments and museums—it's one of the country's most exciting food destinations. From neighborhood gems and international cuisine to acclaimed fine dining and bustling waterfront restaurants, there's something for every palate. We've highlighted a few of our favorite dining districts and local recommendations to help you make the most of your time in the city.



Shaw

Just north of the Walter E. Washington Convention Center, Shaw is one of DC's hottest food neighborhoods. You'll find Michelin-starred restaurants, lively cocktail bars, Ethiopian cuisine, wood-fired pizza, bakeries, and trendy cafés all within a few blocks. It's the best choice if attendees only have one evening to explore.

The Wharf (10-minute rideshare)

The Wharf DC is DC's premier waterfront dining destination. With seafood restaurants, rooftop bars, cocktail lounges, and outdoor patios overlooking the Potomac River, it's perfect for an evening out or client dinner.



Looking for one comprehensive guide?

Eater's Visitor's Guide to Dining in Washington, DC is an excellent resource that includes the city's top restaurant neighborhoods, signature dishes, and curated restaurant maps.

Saturday, August 29

8:00am - 5:00pm	ISRV Mini School	Marriott Marquis
-----------------	------------------	------------------

Maximize your time at Options XIII by joining the ISRV Mini-School on Saturday, 29 August 2026 – a focused, one-day learning experience designed especially for early-career researchers (ECRs) and those looking to deepen their understanding of respiratory viruses.

This exclusive add-on offers a comprehensive program covering the epidemiology, virology, prevention, and control of influenza and other respiratory viruses, delivered by leading international experts. Sessions span key topics including global disease impact, One Health approaches, SARS-CoV-2 and RSV, immunity, antivirals, and next-generation vaccines, alongside a practical session on succeeding in biomedical research.

Pre-registration was required (and is now full).

8:00am - 8:30am	Registration	
8:30am - 8:35am	Welcome to the School	Dr Carolien van de Sandt
8:35am - 9:15am	Global Impact of Respiratory Viruses	Professor Maria Zambon
9:15am - 10:00am	Influenza and One Health	Dr Erik Karlsson
10:00am - 10:30am	Refreshment break	
10:30am - 11:15am	SARS-CoV-2: Unexpected Challenges, Achievements and Unknowns	Professor Kanta Subbarao
11:15am - 12:00pm	RSV: Old Foe, New Solutions	Professor Janet Englund
12:30pm - 12:45pm	Immunity to Respiratory Viruses	Dr Carolien van de Sandt
12:45pm - 1:30pm	Lunch	
1:30pm - 2:15pm	Antivirals and Antiviral Resistance	Dr Cameron Wolfe
2:15pm - 3:00pm	Influenza Vaccines, Effectiveness and Study Design	Dr Emily Martin
3:00pm - 3:45pm	Next Generation “Universal” Vaccines and Future Perspectives for Respiratory Viruses	Professor Rebecca Cox
3:45pm - 4:00pm	Refreshment break	
4:00pm - 4:45pm	A Practical Guide to Succeeding in Biomedical Research	Professor Jon Yewdell
4:45pm - 4:55pm	Closing Remarks	Professor Rebecca Cox
4:55pm - 5:45pm	Drinks and Nibbles: Past and Present ECRs	
4:30pm - 6:30pm	Options XIII Registration and Information Desk Open	Salon G, Level 1

5:45pm - 7:00pm	This Week in Virology (TWiV) Podcast: Live Recording	Marriott Marquis
-----------------	--	------------------

Open to all Options XIII Attendees. Spaces are limited and are on a first-come, first-served basis.

Please join us for an AstraZeneca-sponsored symposium
at Options for the Control of Influenza XIII Conference!

Moving the Needle: Expanding the Reach of Influenza Vaccination



Sunday, August 30, 2026 | 12:45–1:45 PM ET

Room 207 AB, Walter E. Washington Convention Center, Washington, DC

Join our expert faculty for an exploration of the evolving landscape of seasonal influenza and considerations for future vaccine access. This session will examine the ongoing variability of influenza risk, the role of school-based vaccination programs, and emerging approaches to expanding access beyond traditional clinical settings, with the potential to improve vaccine uptake.

Time (ET)	Title	Speaker
12:45–12:50 PM	Welcome and Introduction	Dr Richard Zimmerman
12:50–1:05 PM	The Changing Face of Influenza: A Shifting Threat We Cannot Afford to Underestimate	Dr Ravi Jhaveri
1:05–1:20 PM	Championing Vaccination Programs: The Impact of School-Based Influenza Vaccination	Dr George Kassianos
1:20–1:35 PM	From Clinic to Doorstep: The Future of Influenza Vaccine Access Is Here	Dr Richard Zimmerman
1:35–1:45 PM	Panel Discussion and Q&A	All



Dr Richard Zimmerman
(Chairperson)

Vice Chair of Research, Professor of Family Medicine and Clinical Epidemiology
University of Pittsburgh School of Medicine
Pittsburgh, PA, USA



Dr George Kassianos

National Immunisation Lead
Royal College of General Practitioners
United Kingdom



Dr Ravi Jhaveri

Division Head, Pediatric Infectious Diseases
Ann & Robert H. Lurie Children's Hospital of Chicago
Chicago, IL, USA

This industry symposium is organized and sponsored by AstraZeneca.

You are encouraged to report negative side effects of AstraZeneca prescription drugs by calling 1-800-236-9933. If you prefer to report these to the FDA, call 1-800-FDA-1088.

AstraZeneca fully supports and abides by the PhRMA Code on Interactions with Health Care Professionals. AstraZeneca cannot accommodate or pay for the cost of a spouse or other guests of a health care professional. As such, this program is open to invitees only. If you are a prescriber and/or a federal, state, or institution employee, you may be subject to laws, regulations, or rules which prohibit or limit gifts, meals, or items of value you may receive. We ask that you comply with any restrictions that govern your receipt of gifts, meals, or items of value. Subject to federal and state regulations, AstraZeneca will disclose information related to meals provided to attendees, which will be made public. To ensure accurate transparency reporting of meals, AstraZeneca requires program attendees to sign in upon arrival and indicate if a meal was accepted.

This is a presentation sponsored directly by AstraZeneca and there are no continuing medical education (CME), continuing nursing education (CNE), or continuing education (CE) credits associated with this activity.

©2026 AstraZeneca. All rights reserved. US-113265 Last Updated 6/26



Sunday, August 30

7:00am - 7:00pm	Options XIII Registration and Information Desk Open	Salon C, Level 1
ROOM:	Ballroom AB	
8:00am - 8:30am	Opening Remarks	
8:30am - 10:30am	Implementation and Communication Plenary: Understanding and Addressing Vaccine Hesitancy and Misinformation CHAired BY: John Ryan McLane , Asia-Pacific Alliance for Control of Influenza Michael Ison , NIH 8:30am - 9:10am – How to Decrease Hesitancy Rupali Limaye , Johns Hopkins 9:10am - 9:50am – Misinformation to Fuel Vaccine Hesitancy Jevin West , University of Washington, Seattle, Washington 9:50am - 10:30am – Evidence-based approaches to increasing maternal vaccine uptake Saad Omer , Dean and Professor, O'Donnell School of Public Health UT Southwestern	
Implementation		
ROOM:	Ballroom C	
10:30am - 11:00am	Refreshment Break	Ballroom C
ROOM:	Ballroom AB	
11:00am - 12:30pm	ISRV Award Presentations CHAired BY: Ultan Power , Queen's University Belfast Fred Hayden , University of Virginia School of Medicine Ian Barr , Deputy Director, WHO Collaborating Centre for Reference and Research on Influenza, VIDRL, Doherty Institute Maria Zambon , Chair, ISRV	
ROOM:	207	
12:30pm - 1:45pm	AstraZeneca invites you to a special lunch symposium: Moving the Needle: Expanding the Reach of Influenza Vaccination Join our expert faculty for an exploration of the evolving landscape of seasonal influenza and considerations for future vaccine access. This session will examine the ongoing variability of influenza risk, the role of school-based vaccination programs and emerging approaches to expanding access beyond traditional clinical settings, with the potential to improve vaccine uptake. <i>Sponsored by</i> AstraZeneca 	

Sunday, August 30

ROOM:	207
2:00pm - 4:00pm	Next Generation Technology to Study Influenza
Virology & Pathogenesis	CHAired BY: Wendy Barclay , Imperial College London
	2:00pm - 2:30pm – Integrating Immune Response
	Adriana Tomic , Assistant Professor, Boston University, Boston, Massachusetts
	2:30pm - 3:00pm – Human Organoids in Respiratory Virus Research and Vaccine Development
	Rebecca Cox , Professor of Medical Virology and Head of the influenza Centre, University of Bergen, Norway
	3:00pm - 3:30pm – Crispr/Cas Detection of Viruses
	AJ te Velhuis , Princeton University, Princeton, New Jersey
	3:30pm - 4:00pm – Novel Viral Sequencing
	Peter Thielen , Principal Scientist, Johns Hopkins University Applied Physics Laboratory, Baltimore, Maryland
ROOM:	206
2:00pm - 4:00pm	Implementation Science to Drive Influenza Vaccine Uptake in LMICs
Implementation	CHAired BY: Jean-Michel Heraud , Institute Pasteur
	2:00pm - 2:30pm – Current challenges and opportunities for implementation-driven influenza vaccine uptake in LMICs
	Silvia Bino , Professor of Infectious Diseases, Institute of Public Health, Albania
	2:30pm - 3:00pm Evidence-based approaches to strengthening vaccine clinical trials in Africa
	Charles Shey Wiysonge , Professor, South African Medical Research Council, South Africa
	3:00pm - 3:30pm – From Policy to Protection: Implementing Influenza Vaccination in Guyana - Overcoming System Barriers to Achieve Uptake in a New Adult Programme
	Oneka Scott
	3:30pm - 4:00pm – From National Guidelines to Real-World Implementation: Influenza Vaccination in Thailand
	Pinyo Rattanaumpawan , Professor, Faculty of Medicine Siriraj Hospital, Mahidol University
ROOM:	202
2:00pm - 4:00pm	Optimizing Antiviral Utilization for Influenza
Clinical Science	CHAired BY: Michael Ison , NIH
	2:00pm - 2:30pm – Antiviral Resistance
	Larisa Gubareva , Research Biologist, Centers for Disease Control and Prevention
	2:30pm - 3:00pm – Antiviral Use in the Future
	Andy Pavia , George and Esther Gross Presidential Professor, Division of Pediatric Infectious Diseases, University of Utah, Provo, Utah
	3:00pm - 3:30pm – Understanding the Gaps of Evidence for the Use of Antivirals
	Cameron Wolfe , Professor of Medicine, Transplant Infectious Disease, Duke University Medical Center, Durham, North Carolina
	3:00pm - 4:00pm – How to Improve Antiviral Use
	James Antoon , Assistant Professor of Pediatrics, Vanderbilt University Medical Center, Nashville, Tennessee

Sunday, August 30

ROOM:	Ballroom AB	
2:00pm - 4:00pm	Innovative Tools and Their Contributions to Public Health Strategies CHAired BY: Vivian Dugan , CDC 2:00pm - 2:30pm – Leveraging Big Data and AI for Vaccine Strain Selection Regina Barzilay , Massachusetts Institute of Technology, Cambridge, Massachusetts 2:30pm - 3:00pm – Near-real time mapping of the human neutralizing antibody landscape to influenza to inform vaccine selection Jesse Bloom , Fred Hutch, Seattle, Washington 3:00pm - 3:30pm – Landscape of Influenza and COVID Vaccines Ruben Donis , Centers for Disease Control and Prevention 3:30pm - 4:00pm – Key Tips to Improve Public Communication on Infectious Diseases and Vaccination Cynthia Baur	
4:00pm – 4:30pm	Refreshment Break	Ballroom C
ROOM:	Ballroom AB	
4:30pm – 6:00pm	Burden of Disease and Risk Factors CHAired BY: Alicia Budd , CDC Emi Takashita , National Institute of Animal Health 4:30pm - 4:45pm – Incidence and Risk Factors of Influenza, Respiratory Syncytial Virus, and COVID-19 within the SHIVERS-III Community Child Cohort Study Sue Huang , The New Zealand Institute for Public Health and Forensic Science 4:45pm - 5:00pm – Recent SARS-CoV-2 Infection and Risk of Asymptomatic Influenza Illness Mia Zhu , University of Michigan 5:00pm - 5:15pm – Comparison of the Annual Disease Burden of Acute COVID-19 and Seasonal Influenza in the Netherlands, 2020-2024, in Disability-Adjusted Life Years Pieter de Boer , National Institute for Public Health and the Environment (RIVM) 5:15pm - 5:30pm – Reporting Fractions of Laboratory-Confirmed SARS-CoV-2, Influenza, and RSV in ICD-10 Coding: Estimates of Correction Factors for Underreporting Zhe Zheng , Moderna Inc 5:30pm - 5:45pm – Targeted metagenomic analysis of causes of influenza-like and respiratory illness in healthcare workers in the UK, winter 2025/26: the SIREN study Sarah Foulkes , UKHSA 5:45pm - 6:00pm – Human Behavior and Built Environments Drive Influenza Seasonality in the United States Giulia Pullano , Georgetown University	

Sunday, August 30

4:30pm – 6:00pm	Abstract Sessions
ROOM:	Room 207
4:30pm – 6:00pm	Virulence and Transmission of H5N1 CHAired BY: Erik Stemmy, NIH Carolien van de Sandt, Murdoch Children's Research Institute 4:30pm - 4:45pm – Characterization of an avian precursor of bovine HPAI H5N1 viruses Yoshihiro Kawaoka, University of Wisconsin - Madison 4:45pm - 5:00pm – From Nose to Neuron: Evaluating H5 Clade 2.3.4.4b and Australian H7 HPAIV Replication in Human and Chicken ex vivo Models Jasmina Luczo, Commonwealth Scientific and Industrial Research Organisation 5:00pm - 5:15pm – Determinants of Mammalian Transmission of H5N1 D1.1 Viruses in Ferret Model Gracie Quirk, Emory University 5:15pm - 5:30pm – Population Immunity to Highly Pathogenic Avian Influenza 2.3.4.4b A(H5N1) Viruses in the United States Min Levine, US Centers for Disease Control and Prevention 5:30pm - 5:45pm – Enhanced Pathogenicity and Transmissibility of Human-Origin Avian Influenza H5N1 Clade 2.3.4.4b Genotype B3.13 Compared to D1.1 in mice and ferrets Ahmed Elsayed, Texas Biomedical Research Institute 5:45pm - 6:10pm – Key Determinants in PB2-mediated Mammalian Adaptation of Clade 2.3.4.4b A (H5N1) Virus Shuofeng Yuan, The University of Hong Kong
Virology & Pathogenesis	
ROOM:	Room 202
4:30pm – 6:00pm	Immune Response in Special Populations CHAired BY: Brooke Bozick, NIAID John Beigel 4:30pm - 4:45pm – Divergent Immunity in Early Life: Using High-Resolution Dynamics of Infant Influenza Vaccine Responses to Predict Future Immunity Tal Einav, La Jolla Institute for Immunology 4:45pm - 5:00pm – The Effect of Influenza Vaccination Timing on Antibody and T-cell Responses in Older Adults: the Chrono-Vax trial Koen Vink, RIVM 5:00pm - 5:15pm – Association of Pre-existing Antibodies with H3N2 Viral Shedding Duration and Clinical Outcomes in Household Transmission Study in Nicaragua Justin McClendon, University of Michigan 5:15pm - 5:30pm – Previous Influenza Exposure and Vaccine Platform Impact CD4+ T cell Responses Following Vaccination with H2 Hemagglutinin Kristin Boswell, Vaccine Research Center, NIAID, NIH 5:30pm - 5:45pm – T cell Responses in Children with Influenza-related Critical Illness. Srnithi Sugumaran Menon, Fred Hutchinson Cancer Center/CEIRR-CIDER 5:45pm - 6:10pm – Comparison of Maternal Influenza-specific Antibody Concentrations over Time in Consecutive Pregnancies With and Without Maternal Influenza Vaccination Alisa Kachikis, University of Washington, Department of Obstetrics & Gynecology
Clinical Science	

Sunday, August 30

ROOM:	Room 206	
4:30pm – 6:00pm	Implementation Approaches to Respiratory Virus Epidemiology and Interventions CHAired BY: Aaron Bandremer, HHS Ben Cowling, Hong Kong University 4:30pm - 4:45pm – Optimal Dilution Points for Reliable Antibody Titer Prediction: Four-Parameter Logistic Model for SARS-CoV-2 Xinyi LI, The University of Hong Kong 4:45pm - 5:00pm – Alternatives to venepuncture for assessment of SARS-CoV-2 and influenza antibodies in care homes Maria Zambon, UKHSA 5:00pm - 5:15pm – Resolving SARS-CoV-2 Aerosol and Fomite Transmission and Implications for Public Health Interventions Jakob Jonnerby, Imperial College London 5:15pm - 5:30pm – HOPPER: a scalable household transmission platform for rapid evidence generation in respiratory virus pandemics Seran Hakki, Imperial College London 5:30pm - 5:45pm – A Universal Influenza Nucleic Acid Vaccine Affords Broad Protection in Nonhuman Primates via Induction of Systemic and Mucosal Immune Responses Deborah Fuller, University of Washington 5:45pm - 6:10pm – Recombinant influenza vaccines induce antibodies with broader A(H3N2) virus reactivity among repeat vaccinees compared to egg- or cell-based vaccines Annette Fox, WHO Collaborating Centre for Reference and Research on Influenza, Melbourne	
Implementation		
6:00pm – 7:00pm	Exhibitor Viewing and Poster Session I	Ballroom C
7:00pm – 10:00pm	ECR Event – Join your fellow ECRs for a night of trivia and fun!	BeerLab, Marriot Marquis



A CSL Seqirus-sponsored symposium at the
Options XIII Conference for the Control of Influenza

FLU VACCINATION: FROM EVIDENCE TO IMPACT

Monday, August 31st, 2026 | 07:15–08:15 EDT | Breakfast available from 06:45 EDT
Room 202, Walter E. Washington Convention Center, Washington, DC, USA

**Why Vaccination Rates Matter:
The Foundation of Influenza Prevention**
Professor Colin Russell, Amsterdam, Netherlands

**Reducing Influenza Burden:
The Role of Innovative Technologies
and Real-World Evidence**
Dr Ravi Jhaveri, Chicago, IL, USA

**Pandemic Influenza: Responding Rapidly
to this Public Health Threat**
Dr Matthew Hepburn, Washington, DC, USA

Final Remarks and Q&A
All, facilitated by Professor Colin Russell

**Visit the CSL Seqirus
exhibition stand (103)**

This meeting is sponsored and organized by CSL Seqirus and may include discussion of policy and products. Prescribing information is available from CSL Seqirus staff and on the CSL Seqirus stand. This meeting is intended for medical and scientific professionals attending Options XIII.

US-FLU-26-0004 | August 2026

Monday, August 31

7:00am – 7:00pm	Options XIII Registration and Information Desk Open	Salon G, Level 1
ROOM:	Room 202	
7:15pm – 8:15pm	CSL Seqirus invites you to a special breakfast symposium: Flu Vaccination: From Evidence to Impact Join this symposium to discover how improving influenza vaccination uptake, together with innovative seasonal influenza vaccines and real-world evidence, can help protect populations against seasonal disease burden. The symposium will also examine how lessons learned today can strengthen preparedness and resilience against future influenza pandemics. <i>Sponsored by</i> CSL Seqirus	
ROOM:	Ballroom AB	
8:30am – 10:30am	Public Health Plenary Session: Role of Innovation in Respiratory Virus Prevention Policies CHAired BY: Cheryl Cohen, National Center for Communicable Disease Marc-Alain Widdowson, WHO 8:30am - 9:00am – Viral Evolution and Public Health Sarah Cobey, Professor, Ecology & Evolution, University of Chicago, Chicago, Illinois 9:10am - 9:50am – CEPI’s 100 Days Mission for and Influenza Pandemic Nicki Lurie, CEPI 9:50am - 10:30am – Advances and Challenges in Assessing Vaccine Composition over the last 20 Years Ian Barr, Deputy Director, WHO Collaborating Centre for Reference and Research on Influenza, VIDRL, Doherty Institute	
Public Health		
10:30am – 11:00am	Refreshment Break	Ballroom C

Monday, August 31

ROOM:	Room 202
11:00pm – 12:30pm	Prevention of Avian Influenza Viruses CHAIRED BY: Sue Huang, New Zealand Institute of Public Health and Forensic Science Kim Armstrong, HHS 11:00am - 11:15am – Primary Safety and Immunogenicity Assessment of A/H5N8 Inactivated Monovalent Influenza Vaccines at Different Antigen Dose Levels Adjuvanted with AS03 Kristina Lu, Center for the Biomedical Advanced Research and Development Authority (BARDA), Administration for Strategic Pandemic Preparedness and Response (ASPR), U.S. Department of Health and Human Services 11:15am - 11:30am – Comparative systems biology analysis of nasal mucosa and peripheral blood from H1N1pdm09, H3N2, and avian H10N7 influenza A human challenge studies John Kash, NIAID/NIH 11:30am - 11:45am – Homologous and Heterologous Humoral Immunogenicity of AS03-Adjuvanted H5N1 A/Indonesia/2005 and H5N8 A/Astrakhan/2020 vaccines Frank Struyf, GSK 11:45am - 12:00pm – Contribution of Influenza H5 Head and Stalk Domains to Functional Non-Neutralizing Antibodies After Intranasal rH5-NE Vaccination in Humans Franklin Toapanta, University of Maryland School of Medicine 12:00pm - 12:15pm – Dose-Escalation Study of a Low Pathogenicity Avian H10N7 Influenza Virus in a Healthy Human Challenge Model Luca Giurgea, NIH/NIAID 12:15pm - 12:30pm – Protective effect of A(H5N8) stockpiled vaccine against a human isolate of bovine A(H5N1) influenza virus Ryuta Uraki, Japan
Clinical Science	
ROOM:	Room 206
11:00pm – 12:30pm	Use of Implementation Science to Assess Motivation and Barriers to Vaccination at the Global, Country, and Sub-Population Levels CHAIRED BY: Tom Shimabukuro, CDC John Ryan McLane, Asia-Pacific Alliance for Control of Influenza 11:00am - 11:15am – Vaccine Availability for Past Pandemics: Implications for Future Responses Haley Farrie, Johns Hopkins University Bloomberg School of Public Health 11:15am - 11:30am – Geospatial Distribution and Determinants of Laboratory-Confirmed Influenza and Vaccination Coverage in Guyana (2023-2026) Nneoma Harris, Ministry of Health, Guyana 11:30am - 11:45am – Timing of Influenza Vaccination Decisions During Pregnancy: Evidence from a North American Prospective Preconception Cohort Annette Regan, Kaiser Permanente Southern California 11:45am - 12:00pm – Leveraging U.S. President’s Emergency Plan for AIDS Relief to Increase Influenza Vaccination among People Living with HIV: South Africa, 2024 Julia Petras, U.S. Centers for Disease Control and Prevention 12:00pm - 12:15pm – Healthcare Worker Influenza Vaccination at Scale in Kenya: Two-Phase Implementation Evidence from Four Counties, 2023-2025 Eric Osoro, Washington State University Global Health Kenya 12:15pm - 12:30pm – Using “Pop-Up” Clinics and Live-Attenuated Influenza Vaccine to Promote Flu Vaccination Among College Students Over Multiple Seasons Ravi Jhaveri
Implementation	

Monday, August 31

ROOM:	Ballroom AB
11:00pm – 12:30pm	Antibody Landscapes and Immune Responses Session 1 CHAIRED BY: Maria de la Montana Iglesias Caballero, Instituto de Salud Carlos III Emily Martin, University of Michigan School of Public Health 11:00am - 11:15am – Antibody landscape following multiple COVID-19 vaccinations and Omicron infections Jade Yangyupei Yang, University of Michigan School of Public Health 11:15am - 11:30am – Investigating the Antibody Ceiling Effect and Antibody Diversification Following Repeated Influenza Vaccination in Older Adults Min LI, The University of Hong Kong 11:30am - 11:45am – Integrated Drivers of Basal and Acute Immunity in Diverse Human Populations Aisha Hegab Souquette, University of Maryland School of Medicine 11:45am - 12:00pm – Nobody is naïve: the role of imprinting and demography in shaping future A/H5N1 pandemic risk Cecile Viboud, Fogarty International Center, National Institutes of Health, USA 12:00pm - 12:15pm – Quantifying individual and population-level effects of influenza vaccines in the face of imprinting and antigenic evolution Rahul Subramanian, NIH-NIAID 12:15pm - 12:30pm – Influenza neutralising antibody responses and protection in vaccinated healthcare workers: the 2023-24 SIREN study Ana Atti, UKHSA
Public Health	
ROOM:	Room 207
11:00pm – 12:30pm	Novel Vaccines to Enhance Immunity CHAIRED BY: Sabra Klein, Johns Hopkins University Michelle Arnold, NIH 11:00am - 11:15am – Robust live attenuated influenza vaccine virus replication drives protection against antigenically distinct challenges Oliver Dibben, AstraZeneca 11:15am - 11:30am – Optimizing an avian influenza vaccine using a novel Bacterial Enzymatic Combinatorial Chemistry (BECC) TLR4 adjuvant Matthew Frieman, University of Maryland Baltimore, School of Medicine United States 11:30am - 11:45am – Protective neutralizing and non-neutralizing antibody networks against human and avian influenza virus are influenced by compartment Ryan McNamary, Harvard T.H. Chan School of Public Health 11:45am - 12:00pm – A nanobody-based proteolysis-targeting chimera offers broad-spectrum protection against diverse influenza virus infections Hualan Cheng, Harbin Veterinary Research Institute 12:00pm - 12:15pm – Trivalent M2SR Intranasal Vaccine Provides Greater Mucosal Immunity than an Inactivated Influenza Vaccine in a Preclinical Model Shiho Chiba, The Japan Institute for Health Security 12:15pm - 12:30pm – Engineering the Established Live-Attenuated Influenza Vaccine as a Mucosal Vaccination Platform for Diverse Respiratory Pathogens David Bauer, The Francis Crick Institute
Virology & Pathogenesis	

Monday, August 31

ROOM:	Room 207
12:30pm – 1:45pm	Sanofi invites you to a special lunch symposium: Elevating the Patient Experience in Influenza & COVID-19 Vaccination This symposium will examine the role of patient experience in seasonal influenza and COVID-19 vaccination, focusing on factors that influence vaccination behavior and confidence. Through the review of clinical evidence, real-world outcomes, and patient-centered research, the discussion will address how these insights can inform vaccination recommendations and guidelines for high-risk and age-specific populations and support public health decision-making. <i>Sponsored by</i> 
ROOM:	Room 202
12:30pm – 1:45pm	Moderna invites you to a special lunch symposium: Influenza Vaccines: Current Evidence and Future Directions This symposium will examine the persistent challenges in influenza prevention, particularly the disproportionate burden in older adults. It will explore key drivers of reduced vaccine effectiveness—including immunosenescence, antigenic drift, and egg adaptation—and how these factors contribute to variable vaccine effectiveness. By reviewing historical vaccine performance and strain selection limitations, the session will explore how antigen fidelity and strain matching may influence variability in vaccine effectiveness across influenza seasons. Speaker will also present other vaccine technologies considered for flu vaccines. <i>Sponsored by</i> 
ROOM:	Room 207
2:00pm – 4:00pm Virology & Pathogenesis	Influenza Virology CHAired BY: Richard Webby, St. Jude Children's Research Hospital 2:00pm - 2:30pm - MHC-II mediated host cell entry of H2 and H5 influenza A viruses Silke Stertz, Prof. Dr., Institute of Medical Virology, University of Zurich, Zurich, Switzerland 2:30pm - 3:00pm - In-Cell Structural Systems Biology of Influenza A Virus Replication Jan Kosinski, Group Leader, European Molecular Biology Laboratory Hamburg, Hamburg, Germany 3:00pm - 3:30pm - Innate Immune Activation and Evasion During Influenza Virus infection Andrew Mehle, Professor, University of Wisconsin, Madison, Wisconsin

FLUZONE® HIGH-DOSE (INFLUENZA VACCINE) PROVIDES SUPERIOR PROTECTION VS A STANDARD DOSE FLU VACCINE¹ EVEN FOR YOUR PATIENTS WHO FEEL INVINCIBLE^{1*}

THE ONLY HIGH-DOSE FLU VACCINE SHOWN TO PROTECT AGAINST FLU AND ITS COMPLICATIONS^{1,2,4†}

Fluzone High-Dose is a vaccine indicated for active immunization for the prevention of disease caused by influenza A subtype viruses and type B virus contained in the vaccine. Fluzone High-Dose is approved for use in persons 65 years of age and older.

- RCT** The first and only high-dose flu vaccine to deliver **superior flu protection vs standard dose** in a randomized controlled trial that included a matched and a mismatched season¹
- 4x** Contains **4x the antigen** compared to standard-dose flu vaccine^{2†}
- ↓** Laboratory-confirmed cases of flu **reduced by 24%** vs a standard-dose flu vaccine in a randomized controlled trial^{1,2,*}
- #1** **The #1-administered flu vaccine** for people aged 65+^{3‡}
- RWE** **More than a decade of real-world evidence** in flu and its complications.^{1,4,5§}



Fluzone High-Dose is among the flu vaccines preferentially recommended by ACIP for those aged 65+ vs unadjuvanted standard-dose flu vaccines.⁶

¹In a clinical study conducted in 2011-2012 and 2012-2013 in approximately 32,000 adults 65+, Fluzone High-Dose was 24% (95% CI: 10, 37) more effective (rVE) against influenza due to ANY lab-confirmed circulating strains than standard-dose Fluzone® (Influenza Vaccine). The prespecified statistical superiority criterion for the primary endpoint (lower limit of 2-sided 95% CI of the vaccine efficacy of Fluzone High-Dose relative to Fluzone >91%) was met.^{1,2}

²Fluzone High-Dose contains 60 micrograms (mcg) of hemagglutinin (HA) per strain vs 15 mcg of HA per strain in a standard-dose influenza vaccine.²

³Internal calculations by Sanofi based on IQVIA database of total flu vaccines administered from July 2024 to April 2025 in people 65+. Not inclusive of all federal payers. Study details and information maintained by Sanofi.³

⁴Analysis included studies conducted over 12 influenza seasons (2009-2010 to 2019-2020, and 2021-2022).⁴

ACIP=Advisory Committee on Immunization Practices; CI=confidence interval.

Available on the Federal Supply Schedule. Available as sole source on the Defense Logistics Agency Contract in support of the Department of Defense.

IMPORTANT SAFETY INFORMATION

Do not administer Fluzone High-Dose to anyone with a history of a severe allergic reaction (e.g., anaphylaxis) to any component of the vaccine, including egg protein, or after previous dose of any influenza vaccine.

Appropriate medical treatment must be immediately available to manage potential anaphylactic reactions following administration of Fluzone High-Dose.

If Guillain-Barré syndrome has occurred within 6 weeks following previous influenza vaccination, the decision to give Fluzone High-Dose should be based on careful consideration of the potential benefits and risks.

If Fluzone High-Dose is administered to immunocompromised persons, including those receiving immunosuppressive therapy, the expected immune response may not be obtained.

Vaccination with Fluzone High-Dose may not protect all recipients.

Syncope (fainting) has been reported following vaccination with Fluzone High-Dose. Procedures should be in place to avoid injury from fainting.

In adults 65 years of age and older, the most common injection-site reaction was pain; the most common solicited systemic adverse reactions were myalgia, malaise, and headache. Other adverse reactions may occur.

Please see Brief Summary of full Prescribing Information on the following pages.

References: 1. Fluzone High-Dose. Prescribing Information. Sanofi Pasteur Inc. 2. DiazGranados CA, Dunning AJ, Kimmel M, et al. Efficacy of high-dose versus standard-dose influenza vaccine in older adults. *N Engl J Med*. 2014;371(7):635-645. doi:10.1056/NEJMOa1315727. 3. Sanofi Pasteur Inc. Data on file. 4. Lee JKH, Lam GKL, Yin JK, et al. High-dose influenza vaccine in older adults by age and seasonal characteristics: systematic review and meta-analysis update. *Vaccine X*. 2023;14:100327. doi:10.1016/j.jvax.2023.100327. 5. Falsey AR, Treanor JJ, Tornieporth N, et al. Randomized, double-blind controlled phase 3 trial comparing the immunogenicity of high-dose and standard-dose influenza vaccine in adults 65 years of age and older. *J Infect Dis*. 2009;200(2):172-180. doi:10.1086/599790. 6. Grohskopf LA, Ferdinands JM, Blanton LH, et al. Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices - United States, 2024-25 influenza season. *MMWR Recomm Rep*. 2024;73(5):1-25. doi:10.15585/mmwr.rr7305a1.

sanofi

MAT-US-2508620-v1.0-08/2025 © 2025 Sanofi
Sanofi 1 Discovery Drive, Swiftwater, Pennsylvania 18370 www.sanofi.us

 **Fluzone® High-Dose**
Influenza Vaccine



**Fluzone® High-Dose (Influenza Vaccine)
injectable suspension, for intramuscular use
2025-2026 Formula**

Rx Only

Brief Summary of Prescribing Information

1 INDICATIONS AND USAGE

Fluzone® High-Dose is a vaccine indicated for active immunization for the prevention of disease caused by influenza A subtype viruses and type B virus contained in the vaccine. Fluzone High-Dose is approved for use in persons 65 years of age and older.

2 DOSAGE AND ADMINISTRATION

For intramuscular use

2.1 Dose and Schedule

Administer Fluzone High-Dose as a single 0.5 mL dose from one prefilled syringe.

2.2 Administration

Fluzone High-Dose is a colorless opalescent liquid. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. If either of these conditions exist, the vaccine should not be administered.

Before administering a dose of vaccine, shake the prefilled syringe.

Administer Fluzone High-Dose intramuscularly.

4 CONTRAINDICATIONS

Do not administer Fluzone High-Dose to anyone with a history of severe allergic reaction (e.g., anaphylaxis) to any component of the vaccine [see *Description (11) in the full prescribing information*], including egg protein, or to a previous dose of any influenza vaccine.

5 WARNINGS AND PRECAUTIONS

5.1 Guillain-Barré Syndrome

If Guillain-Barré Syndrome (GBS) has occurred within 6 weeks following previous influenza vaccination, the decision to give Fluzone High-Dose should be based on careful consideration of the potential benefits and risks. The 1976 swine influenza vaccine was associated with an elevated risk of GBS. Evidence for a causal relation of GBS with other influenza vaccines is

inconclusive; if an excess risk exists, it is probably slightly more than 1 additional case per 1 million persons vaccinated. (See reference 1.)

5.2 Preventing and Managing Allergic Reactions

Appropriate medical treatment must be immediately available to manage potential anaphylactic reactions following administration of Fluzone High-Dose.

5.3 Altered Immunocompetence

If Fluzone High-Dose is administered to immunocompromised persons, including those receiving immunosuppressive therapy, the expected immune response may not be obtained.

5.4 Limitations of Vaccine Effectiveness

Vaccination with Fluzone High-Dose may not protect all recipients.

5.5 Syncope

Syncope (fainting) has been reported following vaccination with Fluzone High-Dose. Procedures should be in place to avoid injury from fainting.

6 ADVERSE REACTIONS

In adults ≥ 65 years of age, the most common (>10%) injection-site adverse reaction was pain (>35.6%); the most common solicited systemic adverse reactions were myalgia (21.4%), malaise (18.0%), and headache (16.8%).

6.1 Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse event rates observed in the clinical trial(s) of a vaccine cannot be directly compared to rates in the clinical trial(s) of another vaccine and may not reflect the rates observed in practice. Two clinical studies have evaluated the safety of Fluzone High-Dose.

Study 1 (NCT00391053) was a multi-center, double-blind trial conducted in the US. In this study, adults 65 years of age and older were randomized to receive either Fluzone High-Dose or Fluzone (2006–2007 formulation). The study compared the safety and immunogenicity of Fluzone High-Dose to those of Fluzone. The safety analysis set included 2573 Fluzone High-Dose recipients and 1260 Fluzone recipients.

Table 1 summarizes solicited injection-site reactions and systemic adverse reactions reported within 7 days post-vaccination via diary cards. Onset was usually within the first 3 days after vaccination and a majority of the reactions resolved within 3 days. Solicited injection-site reactions and systemic adverse reactions were more frequent after vaccination with Fluzone High-Dose compared to Fluzone.

Table 1: Frequency of Solicited Injection-Site Reactions and Systemic Adverse Reactions Within 7 Days After Vaccination with Fluzone High-Dose or Fluzone, Adults 65 Years of Age and Older (Study 1)^{*}

	Fluzone High-Dose (N [†] =2569–2572) Percentage			Fluzone (N [†] =1258–1260) Percentage		
	Any	Moderate [‡]	Severe [§]	Any	Moderate [‡]	Severe [§]
Injection-Site Pain	35.6	3.7	0.3	24.3	1.7	0.2
Injection-Site Erythema	14.9	1.9	1.8	10.8	0.8	0.6
Injection-Site Swelling	8.9	1.6	1.5	5.8	1.3	0.6
Myalgia	21.4	4.2	1.6	18.3	3.2	0.2
Malaise	18.0	4.7	1.6	14.0	3.7	0.6
Headache	16.8	3.1	1.1	14.4	2.5	0.3
Fever[¶] (≥99.5°F)	3.6	1.1	0.0	2.3	0.2	0.1

^{*}NCT00391053

[†]N is the number of vaccinated participants with available data for the reactions listed

[‡]Moderate - Injection-site pain: sufficiently discomforting to interfere with normal behavior or activities; Injection-site erythema and Injection-site swelling: ≥2.5 cm to <5 cm; Fever: >100.4°F to ≤102.2°F; Myalgia, Malaise, and Headache: interferes with daily activities

[§]Severe - Injection-site pain: incapacitating, unable to perform usual activities; Injection-site erythema and Injection-site swelling: ≥5 cm; Fever: >102.2°F; Myalgia, Malaise, and Headache: prevents daily activities

[¶]Fever - The percentage of temperature measurements that were taken by oral route or not recorded were 97.9% and 2.1%, respectively, for Fluzone High-Dose; and 98.6% and 1.4%, respectively, for Fluzone

Within 6 months post-vaccination, 156 (6.1%) Fluzone High-Dose recipients and 93 (7.4%) Fluzone recipients experienced a serious adverse event (SAE). No deaths were reported within 28 days post-vaccination. A total of 23 deaths were reported during Days 29 – 180 post-vaccination:

16 (0.6%) among Fluzone High-Dose recipients and 7 (0.6%) among Fluzone recipients. The majority of these participants had a medical history of cardiac, hepatic, neoplastic, renal, and/or respiratory diseases. These data do not provide evidence for a causal relationship between deaths and vaccination with Fluzone High-Dose.

Study 2 (NCT01427309) was a multi-center, double-blind post-licensure efficacy trial conducted in the US and Canada over two influenza seasons. In this study, adults 65 years of age and older were randomized to receive either Fluzone High-Dose or Fluzone (2011–2012 and 2012–2013 formulations). The study compared the efficacy and safety of Fluzone High-Dose to those of Fluzone. The safety analysis set included 15,992 Fluzone High-Dose recipients and 15,991 Fluzone recipients.

Within the study surveillance period (approximately 6 to 8 months post-vaccination), 1323 (8.3%) Fluzone High-Dose recipients and 1442 (9.0%) Fluzone recipients experienced an SAE. Within 30 days post-vaccination, 204 (1.3%) Fluzone High-Dose recipients and 200 (1.3%) Fluzone recipients experienced an SAE. The majority of these participants had one or more chronic comorbid illnesses. A total of 167 deaths were reported within 6 to 8 months post-vaccination: 83 (0.5%) among Fluzone High-Dose recipients and 84 (0.5%) among Fluzone recipients. A total of 6 deaths were reported within 30 days post-vaccination: 6 (0.04%) among Fluzone High-Dose recipients and 0 (0%) among Fluzone recipients. These data do not provide evidence for a causal relationship between deaths and vaccination with Fluzone High-Dose.

6.2 Postmarketing Experience

The following events have been spontaneously reported during the postmarketing use of Fluzone, Fluzone High-Dose, Fluzone Quadrivalent, or Fluzone High-Dose Quadrivalent. Because these events are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to vaccine exposure. Adverse events were included based on one or more of the following factors: severity, frequency of reporting, or strength of evidence for a causal relationship to the vaccine.

- **Blood and Lymphatic System Disorders:** Thrombocytopenia, lymphadenopathy
- **Immune System Disorders:** Anaphylaxis, other allergic/hypersensitivity reactions (including urticaria, angioedema)
- **Eye Disorders:** Ocular hyperemia
- **Nervous System Disorders:** Guillain-Barré syndrome (GBS), convulsions, febrile convulsions, myelitis (including encephalomyelitis and transverse myelitis), facial palsy (Bell's palsy), optic neuritis/neuropathy, brachial neuritis, syncope (shortly after vaccination), dizziness, paresthesia
- **Vascular Disorders:** Vasculitis, vasodilatation/flushing
- **Respiratory, Thoracic and Mediastinal Disorders:** Dyspnea, oropharyngeal pain, rhinorrhea, cough, wheezing, throat tightness
- **Skin and Subcutaneous Tissue Disorders:** Stevens-Johnson syndrome
- **General Disorders and Administration Site Conditions:** Pruritus, asthenia/fatigue, pain in extremities, chest pain, chills
- **Gastrointestinal Disorders:** Vomiting, nausea, diarrhea
- **Musculoskeletal and Connective Tissue Disorders:** Arthralgia

Fluzone® High-Dose (Influenza Vaccine)
injectable suspension, for intramuscular use
2025-2026 Formula

8 USE IN SPECIFIC POPULATIONS

8.1 Pregnancy

Fluzone High-Dose is not approved for use in persons <65 years of age. There are limited human data and no animal data available to establish whether there is a vaccine-associated risk with use of Fluzone High-Dose in pregnancy.

8.2 Lactation

Fluzone High-Dose is not approved for use in persons <65 years of age. No human or animal data are available to assess the effects of Fluzone High-Dose on the breastfed infant or on milk production/excretion.

8.4 Pediatric Use

Safety and effectiveness of Fluzone High-Dose in persons <65 years of age have not been established.

8.5 Geriatric Use

Safety, immunogenicity, and efficacy of Fluzone High-Dose have been evaluated in adults 65 years of age and older. [See *Adverse Reactions (6.1)* and *Clinical Studies (14)* in the full prescribing information]

Fluzone is a registered trademark of Sanofi Pasteur Inc.

Manufactured by:
Sanofi Pasteur Inc.
Swiftwater, PA 18370 USA

INFZHD-BPLR-SL-JUL25

Revised: July 2025

Monday, August 31

ROOM:	Room 202	
2:00pm – 4:00pm	Diagnostics and Biomarkers of Influenza Infection	
Clinical Science	CHAIRED BY: David Hui , The Chinese University of Hong Kong	
	2:00pm - 2:30pm – Next Generation Sequencing for Clinical Care of Patients	
	Judy Breuer , Professor of Virology, Institute Child Health, University College London, London, United Kingdom	
	2:30pm - 3:00pm – Biomarkers to Predict Severe Disease Outcomes	
	Adrienne Randolph , Professor of Anaesthesia and Pediatrics, Harvard Medical School, Cambridge, Massachusetts	
	3:00pm - 3:30pm – Diagnostics to Optimize Antimicrobial Use	
	Brendan Flannery , Epidemiologist, Centers for Disease Control and Prevention (CDC)	
	3:30pm - 4:00pm – Rapid Influenza Diagnostic Testing for Clinician Decision Making	
	Jonathan Temte , Associate Dean for Public Health and Community Engagement, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin	
ROOM:	Room 206	
2:00pm – 4:00pm	Manufacturing Strategies to Ensure Adequate Global Supply and Capacity of Influenza Vaccine	
Implementation	CHAIRED BY: Bruce Gellin , Georgetown University	
	2:00pm - 2:30pm – The role of implementation science approaches in the Gates Foundation influenza vaccine strategy	
	Usman Nakakana , Senior Program Officer Clinical Vaccine Development and Impact, Gates Foundation	
	2:30pm - 3:00pm – Implementation science and the Global Action Plans for Influenza Vaccines	
	Claudia Nannei , WHO, Geneva, Switzerland	
	3:00pm - 3:30pm – Driving Vaccine Access in a Chaotic Global Context	
	Martin Friede , Medicines Patent Pool, Geneva, Switzerland	
ROOM:	Ballroom AB	
2:00pm – 4:00pm	Pandemic Preparedness	
Public Health	CHAIRED BY: Emily Erbelding , Qigley BioPharma	
	2:00pm - 2:30pm – Seasonal influenza prevention and control – a foundation for pandemic preparedness	
	Shoshanna Goldin , Technical Officer, WHO, Geneva, Switzerland	
	2:30pm - 3:00pm – Virus evolution in informing pandemic preparedness	
	Katia Koelle , Emory University, Atlanta, Georgia	
	3:00pm - 3:30pm – H5N1 Vaccination in Europe	
	Hanna Nohynek , Finnish Institute for Health and Welfare, Helsinki, Finland	
	3:30pm - 4:00pm – Pandemic Preparedness - past, present and future	
	Richard Pebody , Dr, The UK Health Security Agency, United Kingdom	
4:00pm - 4:30pm	Refreshment Break	Ballroom C

Monday, August 31

4:30pm - 6:00pm	Abstract Sessions
ROOM:	Room 207
4:30pm - 6:00pm	Assessment of Immunity against Influenza Vaccines CHAired BY: Tim Uyeki, CDC Cameron Wolfe, Duke University Medical Center 4:30pm - 4:45pm - A Booster Dose of OVX836 - a Broad-Spectrum Nucleoprotein Based Influenza Vaccine - is Safe and Immunogenic in Healthy Adults Alexandre Levert, Osivax 4:45pm - 5:00pm - Immunogenicity and Safety of Higher-Dose MF59-Adjuvanted Quadrivalent Cell-Derived Influenza Vaccine (aQIVc): A Phase 3 Randomised Controlled Trial Frank Albano 5:00pm - 5:15pm - Evaluating Immunogenicity by ELLA of Formulations of an Adjuvanted Cell Culture-derived A/H2N3 Subunit Influenza Virus Vaccine in Healthy Adults Eve Versage, CSL Seqirus 5:15pm - 5:30pm - Humoral Correlates of Protection Against Influenza B Virus Infection Kayla Hanson, University of Michigan 5:30pm - 5:45pm - Increased Antibody Breadth with Two A/H3N2 Antigens in a Human Influenza Vaccine Trial Lorena Preciado Llanes, Sanofi 5:45pm - 6:00pm - A Phase 2 Trial Assessing Immunogenicity and Safety of an mRNA-Based Seasonal Influenza Vaccine Candidate Encoding Hemagglutinin and Neuraminidase Isabel Leroux-Roels
ROOM:	Room 207
4:30pm - 6:00pm	Understanding Influenza Vaccine Immunity CHAired BY: Catherine Bozio, CDC Lynda Coughlan, University of Maryland 4:30pm - 4:45pm - Local B-cell immunity and durable memory following live-attenuated influenza intranasal vaccination of humans Shane Crotty, La Jolla Institute for Immunology (LJI) 4:45pm - 5:00pm - Systematic profiling reveals breadth of antibody responses to avian influenza neuraminidases elicited by past influenza pandemics Sook-San Wong, The University of Hong Kong 5:00pm - 5:15pm - H3N2 antigenic cartography identifies viral population geometry, together with antigenic distance determine seasonal vaccine effectiveness Omid Arhami, Inst. of Bioinformatics, University of Georgia 5:15pm - 5:30pm - TLR Agonist-linked, Stabilized N1 Neuraminidase Tetramers Confer Homologous and Heterologous Protection Against Influenza A Justin Shepard, University of Georgia 5:30pm - 5:45pm - Neuraminidase immunity complements hemagglutinin to reduce influenza viral burden across challenge and transmission models Raveen Rathnasinghe, Seqirus Inc 5:45pm - 6:00pm - C1q Expands Anti-Stem Influenza Antibody Function and Broadens Viral Escape Ivan Kosik, NIAID

Clinical Science

Virology & Pathogenesis

Monday, August 31

ROOM:	Ballroom AB	
4:30pm - 6:00pm	Transmission	
Public Health	CHAIRED BY: Balasubramani Goundappa Angela Campbell, Emory University School of Medicine (Adjunct)	
	4:30pm - 4:45pm – Comparative transmissibility of SARS-CoV-2, influenza virus, and common human coronaviruses in the post-pandemic era: a prospective cohort study	
	Hualei Xin , School of Population Medicine and Public Health, Chinese Academy of Medical Sciences & Peking Union Medical College	
	4:45pm - 5:00pm – Correlated Infectiousness Between Index and Secondary Cases Shapes Transmission Heterogeneity and Epidemic Control of Respiratory Viruses	
	Liping Peng	
	5:00pm - 5:15pm – Influenza in the Fields: Incidence and Household Transmission in the AGRI-CASA Study, Southwest Guatemala, 2023-2024	
Virology & Pathogenesis	Danny Carreon , Influenza Division / US CDC	
	5:15pm - 5:30pm – Host Genetic Variants Shape Influenza A Susceptibility and Transmission in Households	
	Chengyao Zhang , The University of Hong Kong	
	5:30pm - 5:45pm – Indirect Protection from Antibody Titers Against Influenza A Virus Infection in Households	
	Yani Wu , The University of Hong Kong	
	5:45pm - 6:00pm – Epidemiological and evolutionary drivers behind the probable extinction of influenza B/Yamagata	
Wenjie Han , Sun Yat-sen University		
ROOM:	Room 206	
4:30pm - 6:00pm	Ecology and Immunologic Responses to H5N1	
Virology & Pathogenesis	CHAIRED BY: Diane Post, NIH Emanuele Montomoli, University of Siena	
	4:30pm - 4:45pm – The Epizootic Continues: Natural Immunity Limits Disease but Permits Breakthrough Replication of Divergent H5N1 Strains in Dairy Cattle	
	Natalie Tarbuck , The Ohio State University	
	4:45pm - 5:00pm – Evolutionary Constraints Limit Additional Mammalian Adaptation Of Bovine-Derived H5N1 Influenza Viruses In Ferrets	
	Heather Machkovech , University of Wisconsin-Madison	
	5:00pm - 5:15pm – Wild Bird Ecology is Driving the Transmission and Dissemination of HPAI H5N1 in North America	
Virology & Pathogenesis	Clara Malekshahi , University of Pennsylvania	
	5:15pm - 5:30pm – More than mallards: Experimental infection with HPAI A(H5N1) D1.1 reveals species-specific outcomes in dabbling, diving, and sea ducks	
	Walter Harrington , St. Jude Children's Research Hospital	
	5:30pm - 5:45pm – Successive Genotype Turnover and Multi-Host Involvement Shape Consecutive High-Pathogenicity Avian Influenza A(H5) Epizootic Waves in Germany	
	Anne Pohlmann , Friedrich-Loeffler-Institut, Federal Research Institute for Animal Health (FLI)	
	5:45pm - 6:00pm – Divergent Antibody-Mediated Population Immunity to H5, H7 and H9 Subtype Potential Pandemic Influenza Viruses	
Reanna Gregory , Warwick Medical School, University of Warwick		
6:00pm – 7:00pm	Exhibitor Viewing and Poster Session II	Ballroom C
6:30pm - 7:45 pm	NIV SIG Meeting (open to all)	Room 306

Tuesday, September 1

8:00am - 7:00pm	Options XIII Registration and Information Desk Open	Salon G, Level 1
7:30am - 8:30am	AVG SIG Meeting (open to all)	Room 304
ROOM:	Ballroom AB	
8:30am - 10:30am	Clinical Science Plenary Session: Contemporary Diagnosis and Management of Seasonal and Pandemic Influenza CHAired BY: Jake Dunning, University of Oxford Alicia Fry, Task Force for Global Health 8:30am - 9:10am - Rapid diagnostic tests for respiratory viruses: What's new Tristan Clark , NIHR Research Professor and Honorary Consultant in Infectious diseases, School of Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton and University Hospital Southampton NHS Foundation Trust, United Kingdom 9:10am - 9:50am - Antivirals and Other Therapies for Respiratory Viruses Janet Englund , Professor of Pediatrics, University of Washington, Seattle Children's Hospital, Seattle, Washington 9:50am - 10:30am - Clinical Characteristics and Management of Patients with Highly Pathogenic Avian Influenza A(H5N1) Virus Infections Tim Uyeki , CDC	
10:30am - 11:00am	Refreshment Break	Ballroom C
11:00pm - 12:30pm	Abstract Sessions	
ROOM:	Room 202	
11:00am - 12:30pm	Clinical Science Exploring Influenza Immunity CHAired BY: Kristen Coleman, University of Maryland Justin Ortiz, University of Maryland 11:00am - 11:15am - Antibody landscapes help explain influenza A(H3N2) infection and vaccine responses Bingyi Yang , University of Macau 11:15am - 11:30am - Advancing Protection against Influenza Through Neuraminidase-Targeted Immunity David Wentworth , GSK 11:30am - 11:45am - Deep Immune Characterization Following Controlled Human A/Texas/71/2017 (H3N2) Infection of Healthy Australian Adults Annette Fox , WHO Collaborating Centre for Reference and Research on Influenza, Melbourne 11:45am - 12:00pm - Impact of Obesity on Antigen-specific T cell Response to 2023-24 Seasonal Influenza Vaccination Shivaprakash Gangappa , CDC 12:00pm - 12:15pm - Immune Profiling at Hospital Admission is Associated with Influenza Disease Severity Lilach Friedman , Ben Gurion University of the Negev 12:15pm - 12:30pm - Dysregulated host responses are associated with severe influenza A virus disease in individuals with arterial hypertension Tamara Garcia-Salum , Emory University, Department of Pathology and Laboratory Medicine	

Tuesday, September 1

ROOM:	Room 207
11:00am - 12:30pm Clinical Science	Improving Care of Influenza Infections CHAIRED BY: Nita Basu, NIH Michael Ison, NIH 11:00am - 11:15am – Diagnostic accuracy of nasal versus capillary MxA for respiratory virus detection in symptomatic adults Tristan Clark, University of Southampton 11:15am - 11:30am – Bacterial Coinfection is Associated with Life-threatening Influenza Lower Respiratory Tract Infection in Children Takuma Kobayashi, Boston Children's Hospital 11:30am - 11:45am – Early Prediction of Intensive Care Unit Admission in COVID-19: Development and Retrospective Validation of a Novel Risk Score Xin Pan, Shandong Provincial Hospital 11:45am - 12:00pm – NK Cell Count as a Universal and Non-linear Predictor of Severity in Influenza and COVID-19 Chunyan Xiang, China-Japan Friendship Hospital 12:00pm - 12:15pm – Post Pandemic, but not Post Impact: Respiratory viruses in transplanted patients Beatrice Sim, University of Queensland 12:15pm - 12:30pm – Oseltamivir for Critically Ill Patients with Influenza Christopher Horvat, University of Pittsburgh Medical Center
ROOM:	Room 202
11:00am - 12:30pm Public Health	Vaccine Effectiveness CHAIRED BY: Nancy Otieno, Kenya Medical Research Institute Cristina Cassetti, WHO CEPI 11:00am - 11:15am – Within-season waning of influenza vaccine effectiveness against hospitalisation among children in Hong Kong, 2015-2025: a test-negative study Xuan YU, The University of Hong Kong 11:15am - 11:30am – Influenza vaccine effectiveness against medically attended influenza, US Flu VE Network, 2025-26 influenza season Carrie Reed, CDC 11:30am - 11:45am – Impact of Vaccine Strain Changes, Sequence Mismatch, and Prior Season Incidence on Repeated Seasonal Influenza Vaccination Effectiveness Xiaotong Huang 11:45am - 12:00pm – Influenza Vaccine Effectiveness Across Seven Latin American Countries: REVELAC i 2025 Results Francisco Nogareda, Pan American Health Organization 12:00pm - 12:15pm – Heterogeneity in Influenza Vaccine Effectiveness in Pediatric Acute Respiratory Illness in Hospital and Outpatient Settings: A Latent Class Analysis Linyi Chen, University of Pittsburgh 12:15pm - 12:30pm – Reassessing Expectations for Indirect Effects of Influenza Vaccination: A Systematic Review and Meta-Analysis of Randomized Controlled Trials Meagan Fitzpatrick, University of Maryland School of Medicine

Reframing RSV in adults: Uncovering the hidden burden of RSV in adults and advancing evidence for prevention strategies

A Pfizer-sponsored lunchtime symposium

Tuesday, September 1, 2026

12:45–13:45 EDT | Room: 207AB

Please join us to uncover the often under-recognized burden of RSV in adults, including complications beyond acute infection. Hear from leading experts as they review key clinical and real-world evidence supporting vaccination, with a focus on individuals at high risk of severe outcomes, including those with cardiovascular comorbidities.

Expert faculty



Professor Ann Falsey

*Chair, Professor of Medicine
at the University of Rochester
School of Medicine, Rochester,
NY, USA*



Giovanni Checcucci Lisi

*Senior Medical Director,
Global Medical Affairs,
Pfizer Inc.,
Italy*



**Associate Professor
Joseph Lewnard**

*Associate Professor
of Epidemiology, University
of California, Berkeley,
CA, USA*

Tuesday, September 1

ROOM:	Room 206
11:00am - 12:30pm Virology & Pathogenesis	Animal and Non-Animal Models of Influenza CHAIRED BY: Mark Tompkins, University of Georgia Daniel Perez, University of Georgia 11:00am - 11:15am – The guinea pig as a survival model to study the evolution of H5 highly pathogenic avian influenza viruses in mammals Lucas Ferreri, Emory University 11:15am - 11:30am – Enhanced Therapeutic Potential of Hypoxia-Preconditioned Mesenchymal Stromal Cell-Derived Extracellular Vesicles for Influenza A/H5N1 Lung Injury Angel Ma, Centre for Immunology & Infection Limited 11:30am - 11:45am – Interspecies Replication Kinetics of Avian Influenza Viruses in Chicken, Quail, and Duck Cell Lines Mariana Andrioli Pinheiro, Auburn University 11:45am - 12:00pm – Comparison of B4.7.4 and B4.7.2 Influenza H9N2 Viruses in Human Respiratory Explants and Organoids Michael Chan, The University of Hong Kong 12:00pm - 12:15pm – Control of highly pathogenic avian influenza through vaccination Hualan Chen 12:15pm - 12:30pm – Precision-cut lung slices: Development of a high-throughput ex-vivo model to study influenza virus infections Saira Hussain, WHO Collaborating Centre for Reference and Research on Influenza, Melbourne
ROOM:	Room 202
12:30pm - 1:45pm	Pfizer invites you to a special lunch symposium: Reframing RSV in adults: Uncovering the hidden burden of RSV in adults and advancing evidence for prevention strategies • Explore the burden and clinical impact of RSV disease in adults, including consequences beyond acute infection and in the context of other respiratory viruses. • Critically evaluate global RSV surveillance systems and their ability to capture the year-round burden as well as acute and long-term RSV related outcomes in adults. • Review key clinical trial evidence supporting RSV vaccination in adults, including efficacy, safety, and immunogenicity • Review emerging real-world evidence on the effectiveness of RSV vaccination in adults and its implications for vaccination policy and program implementation • Highlight the impact of RSV vaccination in high-risk subgroups <i>Sponsored by</i> 

JOIN US FOR AN EXPERT-LED
LUNCH SYMPOSIUM



Beyond the 48-Hour Window:

Redefining Success in Influenza



TUESDAY,
SEPTEMBER 1

TIME
12:30PM

LOCATION
ROOM 202

*Lunch provided - seating
may be limited*

MEET THE PANEL

Experts advancing the influenza conversation



DR. DEEPALI KUMAR

Director, Ajmera Transplant Centre, UHN
Professor of Medicine, University of Toronto

Dr. Deepali Kumar is an attending transplant infectious diseases physician whose research focuses on viral infections, vaccines, and immunologic responses in immunocompromised patients. Her work advances understanding of infection prevention and vaccine strategies for transplant recipients and other vulnerable populations.



DR. MARK HEISE

Professor, University of North Carolina at Chapel Hill

Dr. Mark Heise studies how viral and host factors shape virus-induced disease. His lab integrates molecular virology, viral immunology, quantitative genetics, and antiviral drug discovery to advance therapeutics against emerging threats including influenza A and chikungunya viruses. He also co-founded the Rapidly Emerging Antiviral Drug Development Initiative (READDI), a nonprofit dedicated to developing broad-spectrum antiviral drugs for current and future pandemic threats.



DR. COLIN RUSSELL

Professor at Amsterdam UMC
Chair of ESWI

Dr. Colin Russell studies respiratory virus evolution, influenza vaccine strategy, and mathematical modelling of infectious disease dynamics. He chairs ESWI and the EU Steering Group on Prevention of Respiratory Infections, and regularly advises WHO, governments, and international organizations on vaccination strategy and pandemic preparedness.

Tuesday, September 1

ROOM:	Room 202
12:30pm – 1:45pm	Eradivir invites you to a special lunch symposium: Beyond the 48-Hour Window: Redefining Success in Influenza Therapeutics Join an expert panel lunch symposium examining current clinical realities, persistent unmet needs, and the clinical considerations for treatment beyond the traditional window. <i>Sponsored by</i> 
ROOM:	Room 202
2:00pm – 4:00pm Clinical Science	Respiratory Viruses in the Immunocompromised CHAired BY: Deepali Kumar, University of Toronto 2:00pm - 2:30pm – Clinical Presentation and Challenges of Respiratory Viruses in Immunocompromised Alpana Waghmare, Associate Professor, Department of Pediatrics, University of Washington, Seattle, Washington 2:30pm - 3:00pm – Prolonged Shedding of Respiratory Viruses and Risks of Resistance Adam Lauring, University of Michigan, Ann Arbor, Michigan 3:00pm - 3:30pm – Prevention of Respiratory Viruses in Immunocompromised Hosts Natasha Halasa, Craig Weaver Professor of Pediatrics, Pediatric Infectious Diseases, Vanderbilt University Medical Center, Nashville, Tennessee 3:30pm - 4:00pm – Management of Respiratory Viruses in Immunocompromised Markus Buchfellner, Assistant Professor, Pediatric Infectious Diseases, MUSC Shawn Jenkins Children's Hospital, Charleston, South Carolina
ROOM:	Room 206
2:00pm – 4:00pm Implementation	Closing the Gap Between Clinical Discovery and Practice CHAired BY: Shanti Narayanasamy, Austin Health/Burnet Institute 2:00pm - 2:30pm – Implementation Challenges and Potential with Respiratory Illness Nikki Turner, Professor, University of Auckland, Auckland, New Zealand 2:30pm - 3:00pm – Applying Implementation within the GII and Summit LJ Tan, Chief Policy and Partnerships Officer, Immunize.org 3:00pm - 3:30pm – High-Dose Influenza Vaccines; Implementation of Enhanced Protection for the Elderly Emanuele Montomoli, Full Professor on Hygiene and Public Health, University of Siena, Siena, Italy

Tuesday, September 1

ROOM:	Room 207	
2:00pm – 4:00pm	H5 Influenza	
Virology & Pathogenesis	CHAired BY: Erik Karlsson , NIC Cambodia	
	2:00pm - 2:30pm - Evaluation of the replication fitness and virulence of evolutionary precursor strains to avian and bovine B3.13 genotype H5N1 viruses	
	Troy Sutton , Vaccine and Infectious Disease Organization, University of Saskatchewan, State College, Pennsylvania	
	2:30pm - 3:00pm - Understanding determinants and impacts of interspecies transmission	
	Michelle Wille , University of Melbourne, Melbourne, Australia	
	3:00pm - 3:30pm - Host determinants of influenza disease (human and avian)	
	Stacey Schultz-Cherry , Full Member, St. Jude Children's Research Hospital, Memphis	
ROOM:	Ballroom AB	
2:00pm – 4:00pm	Evidence for Vaccine Policy	
Public Health	CHAired BY: Fiona Havers , Emory University	
	2:00pm - 2:30pm - Changing Regulatory Landscape for Future Vaccines	
	Marco Cavaleri , Head of Anti-infectives and Vaccines, European Medicine Agency	
	2:30pm - 3:00pm - Vaccine Confidence in Today's Environment	
	Lois Privor-Dumm , Johns Hopkins University, Baltimore, Maryland	
	3:00pm - 3:30pm - Mathematical Methods for Evaluating Immune Correlates of Protection Against Transmission: From Individual-Level Observational Studies to Population-Level Impact	
	Kaiyuan Sun , Westlake University, Hangzhou, China	
	3:30pm - 4:00pm - Advances in Modeling and Impact on Public Health Response to Influenza	
	Cecile Viboud , Fogarty International Center, Bethesda, MD	
4:00pm - 4:30pm	Refreshment Break	Ballroom C

Tuesday, September 1

4:30pm - 6:00pm	Abstract Sessions
ROOM:	Ballroom AB
4:30pm - 6:00pm	Assessment of New Influenza Vaccines CHAired BY: Jeremy Crawford , St Jude and Chris Roberts , NIH 4:30pm - 4:45pm – Phase 1 randomized, double-blind, placebo-controlled study of the safety and immunogenicity of an adjuvanted Group 1/2 INFV A HA stem vaccine Spencer Stonier , Emergent BioSolutions 4:45pm - 5:00pm – Increased Anti-N2 Neuraminidase Immune Responses With MF59-Adjuvanted aQIVc vs aQIV and QIVr and Implications for A/H3N2 Protection in Older Adults Mansoor Ashraf 5:00pm - 5:15pm – A Phase 1 Trial of the Safety, Tolerability, and Immunogenicity of a Quadrivalent Mosaic Influenza Nanoparticle Vaccine in Healthy Adults LaSonji Holman , National Institutes of Health, NIAID 5:15pm - 5:30pm – Safety and Immunogenicity of Intranasal M2SR H3N2 Influenza Vaccine in Healthy Children: A Phase 1b Randomized Controlled Trial James Campbell , UMSOM 5:30pm - 5:45pm – MF59-Enhanced Cell Based Influenza Vaccination Elicits Superior H3 Specific T Cell Immunity in Adults ≥50 Years: Results from Phase 3 Immunogenicity S Arik Elfassy , CSL Seqirus 5:45pm - 6:00pm – Immunization with novel H1 hemagglutinin-mini stem antigens elicits broadly cross-reactive, antibody responses and heterosubtypic influenza protection Laiba Uroog , University of Georgia

Clinical Science

Tuesday, September 1

4:30pm - 6:00pm	Abstract Sessions
ROOM:	Room 206
4:30pm - 6:00pm	Forecasting CHAIRED BY: Cecile Viboud, Fogarty International Center Sascha Ellington, CDC 4:30pm - 4:45pm - Linking prior immunity, vaccination, and subtype circulation to long-term projection accuracy: an evaluation of the U.S. Flu Scenario Modeling Hub Amanda Perofsky, Northeastern University 4:45pm - 5:00pm - Advancing Influenza Forecasting Models for Improved Real-Time Predictions Simon Cauchemez, Institut Pasteur 5:00pm - 5:15pm - A comprehensive way forward for control of influenza: from antigenic prediction, vaccine recommendation to epidemic forecasting Xiangjun Du, School of Public Health (Shenzhen), Sun Yat-Sen University 5:15pm - 5:30pm - Beyond Test Positivity: Monitoring Influenza-Attributable Illness Signals Earlier Epidemic Activity Melissa Rolfes, U.S. Centers for Disease Control and Prevention 5:30pm - 5:45pm - Measuring Fitness of Imported Influenza A Lineages Through Phylodynamic Analysis of Repeated Introductions Emily Bendall, University of Michigan 5:45pm - 6:00pm - A Bayesian Framework for Population Level Influenza Immunity Measurement using Routine Serology Jennifer Zhong, World Health Organization Collaborating Centre for Infectious Disease Epidemiology and Control, School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong
ROOM:	Room 202
4:30pm - 6:00pm	Zoonotic Influenza CHAIRED BY: Sonja Olsen, CDC Vijaykrishna Dhanasekaran, The University of Hong Kong 4:30pm - 4:45pm - Within- and Between-Host Dynamics of Highly Pathogenic Avian Influenza in Domestic Birds from Pennsylvania Farms and Live Bird Markets Anna Jaeger 4:45pm - 5:00pm - Factors Impacting Spread of A/H5N1 D1.3 in Ohio and Indiana Poultry Jennifer Havens 5:00pm - 5:15pm - Rapid expansion of HPAI H5 clade 2.3.4.4b genotype D1.1 across North American flyways during fall 2024 avian migration Matthew Scotch, Arizona State University 5:15pm - 5:30pm - Dynamics and Control of Highly Pathogenic H5 Avian Influenza in a Threatened Pelican Population Qiqi Yang, University of Pennsylvania 5:30pm - 5:45pm - Emergence of D1.1 reassortant H5N1 avian influenza viruses in North America Martha Nelson 5:45pm - 6:00pm - Developing On-Farm Management Strategies for Reducing H5N1 Transmission in Dairy Cattle Oliver Eales, University of Melbourne

Public Health

Public Health

Tuesday, September 1

ROOM:	Room 207	
4:30pm - 6:00pm	Global Threat of Influenza Viruses CHAIRED BY: Andy Pekosz, Johns Hopkins Lauren Byrd-Leotis, NIAID 4:30pm - 4:45pm – Cohort-Specific Antigenic Evolution of Influenza A/H3N2 in Tropical Regions Reveals Recurrent Immune Escape Hotspots Martin Muigano, Bio One Scientific 4:45pm - 5:00pm – Outbreak of H9N2 Avian Influenza Viruses in Lesser Rhea in the Andean Highlands of Peru, June-July 2025 Mariana Leguia, Pontificia Universidad Catolica del Peru 5:00pm - 5:15pm – Evolutionary dynamics and hub-driven dissemination of seasonal influenza viruses in Madagascar, 2019-2025 Norosoa Razanajatovo, Institut Pasteur de Madagascar 5:15pm - 5:30pm – Decoding antigenic evolution of influenza H3N2 virus by genomics and deep learning Lin Wang, University of Cambridge 5:30pm - 5:45pm – Phylogenetic analysis and phenotypic evaluation of zoonotic influenza A/H9N2 viruses from Cambodia Brown Bulloch, Université Laval 5:45pm - 6:00pm – Antigenic drift in the receptor binding site of H1N1 balances antibody evasion and receptor binding Jenna Guthmiller, University of Colorado Anschutz Med	
6:00pm - 7:00pm	Exhibitor Viewing and Poster Session III	Ballroom C

Closing Banquet: A Night Out at the Puttery (7:15 pm - 10:15 pm)

Celebrate Options XIII with an unforgettable evening at Puttery DC! Join us for a fun and casual after-hours event featuring great food, interactive mini golf, and plenty of time to connect with fellow attendees in a relaxed setting. Whether you're celebrating new friendships, reflecting on the week's experiences, or simply enjoying a night out, this is the perfect way to close out the program. Add the closing banquet to your registration for an additional cost of \$125 (or \$95 for students) by visiting the Registration Desk

GSK at Options XIII 2026

31

Aug

Monday



11:00 a.m. - 12:00 p.m.



Room 202

Homologous and heterologous humoral immunogenicity of ASO3-Adjuvanted H5N1 A/Indonesia/2005 and H5N8 A/Astrakhan/2020 vaccines

Vishal Jain, Vinay Gupta, Huajun Wang, Sonia Schoonbroodt, Giresse Tima, Mikael Le Bouter, Damien Friel, Frank Struyf

31

Aug

Monday



4:30 p.m. - 6:00 p.m.



Room 202

A phase 2 trial assessing immunogenicity and safety of an mRNA-based seasonal influenza vaccine candidate encoding hemagglutinin and neuraminidase

Kyu-Bin Oh, Rafael A. Ubeda, Jose F. Cardona, Isabel Leroux-Roels, Helen Stacey, Danaé Steinbrecher, Mireille Venken, Pierre Piro, Jane Temple, Clarisse Lorin, François P. Roman

01

Sep

Tuesday



11:00 a.m. - 12:30 p.m.



Room 202

Advancing protection against influenza through neuraminidase-targeted immunity

Krystal J. Evans, Rafik Bekkat-Berkani, Luis Romano-Mazzotti, Clarisse Lorin, Nadia Ouaked, David E. Wentworth, Tomas Mrkvan

Poster Session I

30

Aug

Sunday



6:00 p.m. - 7:00 p.m.



Ballroom C & Foyer

Immunogenicity and safety of an mRNA-based seasonal influenza vaccine candidate encoding hemagglutinin and neuraminidase: a phase 2 randomized trial

Marcus Nordgren, Kyu-Bin Oh, Rafael A. Ubeda, Jose F. Cardona, Donald Brandon, Lambert Uwimana, Mireille Venken, Sabine de Prins, Tapiwa Ganyani, Clarisse Lorin, François P. Roman

Understanding variability in influenza-associated hospitalization rates and influenza virus genetic characteristics

Yoo-Ah Kim, Weisong Liu, Zijian Zhang, David E. Wentworth, Jane Temple, Sarah Welby

First-time-in-human study to assess safety and immunogenicity of a 2-dose mRNA-based H5 influenza vaccine candidate in younger and older adults

Pegah Rouhikhorasani, Mira Baron, Huajun Wang, Vinay Gupta, Frank Struyf

Poster Session II

31

Aug

Monday



6:00 p.m. - 7:00 p.m.



Ballroom C & Foyer

Seasonal influenza in U.S. adults: Economic and humanistic burden highlighting the importance of influenza protection

Shahina Begum, Joost Simons, Eliana Biundo

What drives acceptance of mRNA influenza vaccines? US preferences from two discrete-choice experiments

Joost Simons, Eliana Biundo, Laith Yakob, Freddie Hall, Luis Val-Maranes

Poster Session III

01

Sep

Tuesday



6:00 p.m. - 7:00 p.m.



Ballroom C & Foyer

Vaccine effectiveness and the impact of genetic and antigenic distances of circulating viruses with the potential stabilizing role of neuraminidase

Yoo-Ah Kim, Weisong Liu, Zijian Zhang, David E. Wentworth, Jane Temple, Sarah Welby

Wednesday, September 2

7:30am - 4:00pm	Options XIII Registration and Information Desk Open	Salon C, Level 1
ROOM:	Ballroom AB	
8:00am - 10:30am	Virology & Pathogenesis Plenary Session: Respiratory Viruses in Transition: Evolution, Adaptation, and Function CHAired BY: Stacey Schultz-Cherry , St. Jude Children's Research Hospital Sophie Valkenburg , Doherty Institute, University of Melbourne	
Virology & Pathogenesis	8:00am - 8:40am - In Situ Cryo-Electron Tomography Reveals Assembly Mechanisms of Influenza A Virus and SARS-CoV-2 Petr Chlanda , Professor, BioQuant - Center for Quantitative Analysis of Molecular and Cellular Biosystems, Germany	
	8:40am - 9:20am - How HPAI Viruses Get the Multibasic Cleavage Site for HA Mathilde Richard , Associate Professor, Dept of Viroscience, Erasmus MC, Netherlands	
	9:20am - 10:00am - Ecology, evolution, and spread of highly pathogenic avian influenza viruses in North America Louise Moncla , University of Pennsylvania, Philadelphia, Pennsylvania	
10:00am - 10:30am	Refreshment Break	Ballroom C
ROOM:	Room 202	
10:30am - 12:00pm	Exploring Human Responses to Influenza Infection CHAired BY: Lieve Naesens , Rega Institute, KU Leuven Peter Adams , HHS	
Clinical Science	10:30am - 10:45am - High Resolution Temporal Physiological Signatures of Respiratory Virus Infection in Human Viral Challenge Jiamu Yang , Duke University	
	10:45am - 11:00am - First clinical validation of bispecific antigenic immunotherapy (BAiT): single-dose EV25 achieves 98% viral reduction in human influenza A challenge Ashley Wozinak , Eradivir Inc	
	11:00am - 11:15am - High febrile illness rates in dose-ranging characterisation of a contemporary influenza B human challenge model in healthy adults Alex Mann , hVIVO Services Ltd.	
	11:15am - 11:30am - Household Dynamics of Influenza Transmission and Susceptibility Deryn St. James , Fred Hutch Cancer Center	
	11:30am - 11:45am - A Multicenter, Adaptive, Dose-Ranging Human Challenge Study of a Recombinant Influenza A (A/Texas/71/2017 (H3N2)) Christopher Woods , Duke University School of Medicine	
	11:45am - 12:00pm - LATE-BREAKER: Single-cell analysis revealed differential immune responses against clade 2.3.4.4b H5N1 virus and seasonal influenza virus in respiratory organoids Rachel Chun Yee Tam , The University of Hong Kong	

Wednesday, September 2

10:30am - 12:00pm	Abstract Sessions
ROOM:	Ballroom AB
10:30am - 12:00pm	Late Breaking Abstract Session CHAired BY: Matt Friedman, University of Maryland Brian Wasik, Cornell University 10:30am - 10:45am – Influenza COVID-19 and RSV Vaccine Effectiveness Against Hospitalization Among Adults During the 2025-2026 Season in the United States Amanda Payne, Centers for Disease Control and Prevention 10:45am - 11:00am – BPL-1357 Vaccination Protects Mice Against Lethal Challenge With H5N1 Highly Pathogenic Avian Influenza Virus Clade 2.3.4.4b Sebastian Gygli, NIH 11:00am - 11:15am – Ongoing Phase 1/2 Evaluation of Subcutaneous EV25a Novel Antibody-Recruiting Small Molecule for Influenza Including a Late-Treatment (>48hr) Cohort Aaron Blouin, Eradivir Inc. 11:15am - 11:30am – Immunogenicity of Two Doses of a Novel Influenza A/H5 Antigenically Central (AC)-Anhui mRNA-LNP Vaccine in Healthy Adults C. Buddy Creech, Vanderbilt University School of Medicine 11:30am - 11:45am – Advancing Pandemic Preparedness: Phase 1/2 Safety and Immunogenicity of an H5 mRNA Influenza Vaccine Candidate Srinivas Acharya Nanduri, Sanofi Pasteur 11:45am - 12:00pm – Phase 2b ASUNIVA topline results on efficacy safety and immunogenicity of OVX836 a broad-spectrum influenza A vaccine Isabel Leroux-Roels, Center for Vaccinology (CEVAC) - Ghent University Hospital
ROOM:	Room 206
10:30am - 12:00pm	Surveillance CHAired BY: Christine Oshansky, HHS Carrie Reed, CDC 10:30am - 10:45am – Strengthening respiratory pandemic surveillance in the UK using the WHO MOSAIC approach Mary Sinnathamby, UK Health Security Agency 10:45am - 11:00am – Right-Sizing Influenza Genomic Surveillance: Detection Capacity and Subclade Diversity Across Six African Countries (2023-2025) Dikeledi Kekana, National Institute for Communicable diseases, Division of the National Health Laboratory Service 11:00am - 11:15am – Operationalizing collaborative surveillance: the Mosaic framework as an innovative tool for strengthening public health strategies Marc Marc, Pan-American Health Organization 11:15am - 11:30am – Leveraging Routine Mortality Data to Detect Respiratory and Influenza Like Mortality Signals in Kenya, 2025 Mercy Cheptoo, Kenya National Public Health Institute 11:30am - 11:45am – Clinical Outcomes Among Preterm Infants Hospitalized with Severe Acute Respiratory Illness: A Kenyan Sentinel Surveillance Study, 2021-2025. Juma Maleve, HJF Medical Research International, Inc. 11:45am - 12:00pm – Filling the Gap in Influenza Surveillance: Integrating Swine and Live bird market Surveillance into a One Health Early Warning System in Senegal Mamadou Malado Jallow, Institut Pasteur De Dakar

Public Health

Wednesday, September 2

10:30am - 12:00pm	Abstract Sessions
ROOM:	Room 207
10:30am - 12:00pm	Clinical Applications of Basic Influenza Research CHAIREDBY: Bin Zhou, CDC Jenna Guthmiller, University of Colorado Anschutz Medical Campus 10:30am - 10:45am – Baloxavir susceptibility of seasonal influenza viruses in Japan since its introduction, 2017/18-2025/26 Emi Takashita, Japan Institute for Health Security 10:45am - 11:00am – Development of a novel long-acting pan antiviral to influenza Saira Hussain, WHO Collaborating Centre for Reference and Research on Influenza, Melbourne 11:00am - 11:15am – Combined Antiviral and NSAID Therapy Mitigates Placental Inflammation and Fetal Complications Triggered by Maternal H1N1 Infection Maclaine Parish, Johns Hopkins 11:15am - 11:30am – Elevated sRAGE is a Peripheral Blood Biomarker of Life-Threatening Influenza Lower Respiratory Tract Infection in Children Tanya Novak, Boston Children's Hospital 11:30am - 11:45am – AM-derived IL-1β activates IL1R1-high fibroblasts to drive CXCL1-dependent pathogenic neutrophil recruitment and lung injury in early severe influenza Limin Zhang, China-Japan Friendship Hospital 11:45am - 12:00pm – Meta-analysis of Relative Vaccine Effectiveness of Adjuvanted (aTIV/aQIV) vs Standard-dose Influenza Vaccines (TIV/QIV) for Prevention of Influenza Ian McGovern, CSL Seqirus

Virology & Pathogenesis

Wednesday, September 2

ROOM:	Room 202
12:15pm – 1:15pm	Early Career Researcher Panel: How to Get Published CHAired BY: Carolien van de Sandt, Murdoch Children's Research Institute Ian Barr, Deputy Director, WHO Collaborating Centre for Reference and Research on Influenza, VIDRL, Doherty Institute Seema Lakdawala, Emory University Ben Cowling, Hong Kong University, Hong Kong SAR, China Amanda Williams, CEO, ISRV
ROOM:	Room 206
1:30pm – 3:30pm	Measuring the Impact of Interventions CHAired BY: Sheena Sullivan, Doherty Institute 1:30pm - 2:00pm – From Genomic Surveillance to Clinical Impact: Understanding Influenza Severity Marta Nunes, Hospices Civils de Lyon, France 2:00pm - 2:30pm – Vaccination and prevention of influenza transmission in households Carlos Grijalva, Professor, Vanderbilt University Medical Center, Nashville, Tennessee 2:30pm - 3:00pm – Measuring the Effectiveness and Impact of Vaccines through pragmatic randomized trials Tor Biering-Sørensen, MD, MSc, MPH, PhD, University of Copenhagen, Copenhagen, Denmark 3:00pm - 3:30pm – Protection Before Day One: Building Pandemic Preparedness into Seasonal Influenza Vaccines Samson Lee
ROOM:	Room 207
1:30pm – 3:30pm	Influenza Pathogenesis CHAired BY: Kanta Subbarao, Laval University 1:30pm - 2:00pm – The expulsion of infectious influenza virus from humans Anice Lowen, Professor of Microbiology and Immunology, Emory University School of Medicine, Atlanta, Georgia 2:00pm - 2:30pm – From birds to mammals: HPAI H5N1 infection dynamics and pathogenesis Diego Diel, Director, Virology Laboratory, College of Veterinary Medicine, Cornell University, Ithaca, New York 2:30pm - 3:00pm – Virus-host interactions and virulence Sam Wilson, GSK Professor of Microbial Pathogenesis, Cambridge Institute of Therapeutic Immunology and Infectious Disease, United Kingdom

Public Health

Virology & Pathogenesis

Wednesday, September 2

ROOM:	Ballroom AB	
1:30pm – 3:30pm Implementation	Emerging Methodology for Next Generation Influenza Vaccines CHAired BY: Jennifer Gordon, NIAID	
	1:30pm - 2:00pm – From Systems Vaccinology to Universal Vaccines Bali Pulendran , Professor, Stanford University, Palo Alto, California	
	2:00pm - 2:30pm – Novel Technologies for Controlled Release Vaccines for Influenza Szu-Wen Wang , University of California, Irvine, Irvine, California	
	2:30pm - 3:00pm – Beyond Variants: Engineering Broad T Cell Immunity for Viral Families Alba Grifoni , La Jolla Institute, La Jolla, California	
	3:00pm - 3:30pm – Innate Immunity and Training to Subvert Original Antigenic Sin Daniel Lingwood , Associate Professor of Medicine, Ragon Institute of MGH, MIT and Harvard, Cambridge, Massachusetts	
ROOM:	Room 202	
1:30pm – 3:30pm Clinical Science	Trial Methodology to Address Public Health and Clinical Issues CHAired BY: Angela Campbell , Emory University School of Medicine (Adjunct)	
	1:30pm - 2:00pm – Novel Clinical Trial Methodology Leon Peto , University of Oxford, Oxford, United Kingdom	
	2:00pm - 2:30pm – Measuring Non-Pharmaceutical Interventions Joshua Weitz , Professor, University of Maryland, College Park, Maryland	
	2:30pm - 3:00pm – Human Challenge Studies to Understand Influenza Infection Meagan Deming , University of Maryland, Baltimore, College Park, Maryland	
	3:00pm - 3:30pm – Fit for Purpose: Aligning Study Outcomes with Public Health Goals Kathy Neuzil , Gates Foundation	
3:30pm - 4:00pm	Refreshment Break	
		Ballroom C
ROOM:	Ballroom AB	
4:00pm – 5:00pm	Plenary Session V and Closing Remarks CHAired BY: Justin Ortiz , University of Maryland Andrew Pekosz , Johns Hopkins University	
	4:00pm - 4:30pm – Fighting influenza: from evolutionary prediction to prospective vaccination Michael Lässig	
	4:30pm - 5:00pm – Looking Back and Looking Forward: pandemic Readiness in a New Era Daniel Jernigan , Contributing Scholar, Johns Hopkins Bloomberg School of Public Health	
5:00pm – 5:30pm	Best Poster Awards and Closing Remarks Maria Zambon , ISRV	
	Andrew Pekosz , Johns Hopkins University	
	Justin Ortiz , University of Maryland	

Plenary Speakers



Ian Barr, WHO Collaborating Centre for Reference and Research on Influenza, VIDRL, Doherty Institute

Professor Ian Barr is currently the Deputy Director of the WHO Collaborating Centre for Reference and Research on Influenza which was designated in 1992 (one of 5 globally). The Centre plays a key role in the national and regional surveillance of human and zoonotic influenza viruses as well as having an active research program. Ian has over 35 years' experience with academic and commercial organisations, including over 26 years at the Centre. He has authored or co-authored over 350 scientific publications including more than 300 peer reviewed journal articles, reviews and editorials on various aspects of influenza and RSV.



Petr Chlanda, BioQuant - Center for Quantitative Analysis of Molecular and Cellular Biosystems

Petr Chlanda studied Biochemistry at Charles University in Prague, Czech Republic. He earned his PhD at Heidelberg University, focusing on the assembly of poxviruses using electron microscopy (EM) methods. During his postdoctoral research at EMBL Heidelberg and the NIH in Bethesda and at RML (Hamilton), he investigated the structural mechanisms of influenza A virus membrane fusion and assembly. In 2017, he became a Chica and Heinz Schaller group leader at the Department of Infectious Diseases – Virology at Heidelberg University and BioQuant. Since 2025, he has held the position of W3-Heisenberg Professor for Cryo-EM of Viral Infection at the Department of Infectious Diseases-Virology, Medical Faculty of Heidelberg University. He is a founding member of the Heidelberg University Cryo-EM Network (HDcryoNet). In 2025, he was awarded the Sanofi ideaTech Award to contribute to influenza A virus vaccine development. His research group combines in situ cryo-EM and imaging methods to unravel molecular details on viral infection and restriction bottlenecks.



Tristan Clark, School of Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton and University Hospital Southampton NHS Foundation Trust

Tristan Clark is a Professor of Infectious Diseases at the University of Southampton and an Honorary Consultant at University Hospitals Southampton NHS trust. His research involves the assessment of accuracy, usability, and clinical impact of novel rapid diagnostic tests for infections. He has been awarded grant funding from NIHR, Research Councils, EU, and Industry and is the current holder of a prestigious NIHR Research Professorship. He has published the results of his trials in The New England Journal of Medicine and Lancet series journals and has introduced new point-of-care tests into clinical pathways locally and nationally. He is an editor for the Journal of Infection, a panel member the NIHR Doctoral Fellowship scheme, a council member for the International Society for Respiratory Viruses and a member of the Scientific Affairs committee of the British Infection Association. During the COVID-19 pandemic he was as an advisor to the UK Department of Health and Social Care. The aim of his research is to improve patient care and experience through the evidence-based use of rapid diagnostic tests for infection.

Plenary Speakers



Sarah Cobey, University of Chicago



Janet Englund, University of Washington, Seattle Children's Hospital

Janet Englund, MD, Professor of Pediatrics at University of Washington/Seattle Children's Hospital, is involved in the study of the diagnosis, prevention, and treatment of respiratory viruses. She has studied new vaccines against respiratory diseases in children, pregnant persons, and immunocompromised patients. She has studied antivirals for influenza and respiratory syncytial virus (RSV) in healthy and immunocompromised patients, and worked with Dr. Helen Chu and the CDC on large community-wide surveillance studies assessing community and household spread of respiratory viruses. Her research group has studied new types of influenza vaccines in healthy and immunocompromised children as well as new methods of preventing respiratory syncytial virus (RSV) disease in infants using passive monoclonal antibody or maternal immunization. This work has resulted in licensure and use of these treatments for all babies less than 8 months of age in the US, and a substantial decrease approaching 70% in RSV-related hospitalizations in infants both here in Seattle as well as the USA, and select countries worldwide. In addition, she partners with Dr. Eileen Klein in the Emergency Department (ED) in CDC-sponsored studies as part of the New Vaccine Surveillance Network to assess the effectiveness of current vaccines in children living in King and Snohomish Counties. These studies, ongoing since 2015, use active surveillance and testing for viral causes of respiratory and gastrointestinal infection in children presenting for care in the ED, urgent care, outpatient clinics, and/or admitted to the hospital.

Plenary Speakers



Daniel Jernigan, Johns Hopkins Bloomberg School of Public Health

Daniel Jernigan, MD MPH, is an internationally recognized public health leader with over three decades of experience in medical epidemiology, complex outbreak response, and infectious disease prevention. During his career at the Centers for Disease Control and Prevention (CDC), he served in multiple leadership roles, most recently as Director of the National Center for Emerging and Zoonotic Infectious Diseases, overseeing the agency's largest portfolio of high-consequence pathogens, vectorborne, fungal, parasitic, and foodborne illnesses, antimicrobial resistance, and healthcare-associated infections. He also directed the Influenza Division for six years. He has been instrumental in innovations advancing genomic sequencing, diagnostics, public health informatics, and supporting state health departments to strengthen their capacity to respond to infectious threats.

Dr. Jernigan began his CDC career in the Epidemic Intelligence Service in 1994 and went on to lead investigations and responses to major public health emergencies, including anthrax, SARS, H1N1, Ebola, MERS, and COVID-19. He has authored more than 160 scientific publications and chapters, earned multiple awards such as the Service to America Medal, the George Washington Award for Patriotic Achievement, and the Distinguished Service Medal, and retired as a Captain (O-6) in the U.S. Public Health Service before continuing at CDC in civil service until 2025. He is a graduate of Duke University, Baylor College of Medicine, and the University of Texas School of Public Health and has completed residencies in Internal Medicine and Preventive Medicine. Dr. Jernigan is currently a contributing scholar at Johns Hopkins Bloomberg School of Public Health.



Nikki Lurie, CEPI

Nicole Lurie, M.D., M.S.P.H. is Director of CEPI-US and Executive Director for Preparedness and Response at the Coalition for Epidemic Preparedness Innovations (CEPI) and Director of CEPI-US. She is also a Senior Lecturer at Harvard Medical School and Professor of Medicine at George Washington University School of Medicine. She served an 8-year term as Assistant Secretary for Preparedness and Response at the US Department of Health and Human Services from 2009-2017. In that role she led the HHS response to numerous public health emergencies, ranging from infectious disease to natural and man-made disasters and is responsible for many innovations in emergency preparedness and response. She also chaired the Public Health Emergency Medical Countermeasures Enterprise, a government wide organization ultimately responsible for the development of medical countermeasures, including vaccines against pandemics and emerging threats. Dr. Lurie has a long history in health policy and in health services research, leading seminal work on access to and quality of care, mental health and health equity. Prior to federal service, she was the Paul O'Neill Professor of Policy Analysis at RAND, where she started and led the public health preparedness program and RAND's Center for Population Health and Health Disparities. She has had leadership roles in academia, as Professor of Medicine and Public Health at the University of Minnesota, as Medical Advisor to the Commissioner, Minnesota Department of Health, and as Principal Deputy Assistant Secretary for Health at the US Department of Health and Human Services. Dr. Lurie received her BA and MD degrees from the University of Pennsylvania and completed her residency and public health training at UCLA. She is recipient of numerous awards and is a member of the National Academy of Medicine. She continues to practice medicine in a community clinic in Washington DC.

Plenary Speakers



Louise Moncla, University of Pennsylvania

Dr. Moncla's research lab focuses on using genomic approaches to understand RNA virus emergence, evolution, and transmission, with a particular focus on highly pathogenic avian influenza viruses. Her lab draws on approaches from virology, phylodynamics, and population genetics to study how emerging and re-emerging RNA viruses cross species barriers, evolve within individuals, and transmit across population, with the ultimate goal of improving surveillance and public health responses.



Saad Omer, O'Donnell School of Public Health UT Southwestern

Dr. Saad B. Omer is the founding Dean of Peter O'Donnell Jr. School of Public Health at UT Southwestern in Dallas. He was previously the inaugural Director of Yale Institute for Global Health. Dr. Omer has conducted studies in the United States, Guatemala, Kenya, Uganda, Ethiopia, India, Pakistan, Bangladesh, South Africa, and Australia. Dr Omer's research portfolio includes epidemiology of respiratory viruses such as influenza, RSV, and SARS-Cov-2; clinical trials to estimate efficacy of maternal and/or infant influenza, pertussis, polio, measles and pneumococcal vaccines; and trials to evaluate drug regimens to reduce mother-to-child transmission of HIV. His work has also included public health preparedness strategies to effectively respond to large emerging and re-emerging infectious disease outbreaks. Dr Omer's work has been cited in global and country-specific policy recommendations and has informed clinical practice and health legislation in several countries.

Dr. Omer has published widely in peer reviewed journals including the New England Journal of Medicine, JAMA, Lancet, Cell, Science, and Nature. Moreover, he has written op-eds for publications such as the New York Times, Politico, and the Washington Post.

Dr Omer was elected to the National Academy of Medicine and has received multiple awards – including the Maurice Hilleman Award by the National Foundation of Infectious Diseases for his work on the impact of maternal influenza immunization on respiratory illness in infants younger than 6 months- for whom there is no vaccine. He has served on the boards of trustees of Gavi the Vaccine Alliance and Sabin Vaccine Institute and advisory panels including the World Health Organization Strategic Advisory Group of Experts (SAGE) on Vaccines, U.S. National Vaccine Advisory Committee, the Presidential Advisory Council on Combating Antibiotic-Resistant Bacteria-Vaccine Innovation Working Group, and multiple National Academy of Medicine panels. Moreover, he served as an academic affiliate of the Office of Evaluation Sciences –formerly known as the White House Social and Behavioral Sciences Team.

Plenary Speakers



Mathilde Richard, Dept of Viroscience, Erasmus MC

Mathilde Richard is a biochemical engineer and molecular virologist. She completed her PhD in 2010 in France under the supervision of Prof. Bruno Lina, focusing on the resistance of influenza A viruses to neuraminidase inhibitors. She subsequently joined the Viroscience Department for her postdoctoral research, where she investigated the pathogenesis, virulence, and transmissibility of influenza A viruses, with particular emphasis on the genetic and phenotypic viral determinants that contribute to pandemic emergence.

Since 2018, she serves as a principal investigator in the Viroscience Department. Her team's research centers on understanding the emergence and pathogenesis of highly pathogenic avian influenza viruses (HPAIV) and developing innovative vaccination strategies to address antigenic diversity, all within the broader framework of pandemic preparedness.



Tim Uyeki, CDC

Tim Uyeki is the Chief Medical Officer in the Influenza Division at the U.S. CDC, with interests in antiviral treatment and clinical management of influenza and respiratory viral infections, human infections with avian influenza A viruses, and emerging viral infectious diseases. He served as the Chief Medical Officer for the CDC Response to the multi-state outbreak of H5N1 virus infections in dairy cattle and sporadic human infections in the U.S. during 2024-2025. He has contributed to recommendations and guidelines on clinical management of influenza in the U.S. and worldwide.



Jevin West, University of Washington

Jevin West is a Professor and the Associate Dean for Research in the Information School at the University of Washington. He is the co-founder and the inaugural director of the Center for an Informed Public at UW, aimed at resisting strategic misinformation, promoting an informed society and strengthening democratic discourse. His research and teaching focus on the impact of data and technology on science, with a focus on slowing the spread of misinformation in and about science. He has published in computer science, human computer interaction, information science, biology, philosophy, law, and sociology. He is the co-author with Carl Bergstrom of the book, "Calling Bullshit: The Art of Skepticism in a Data-Driven World," which helps non-experts question numbers, data, and statistics without an advanced degree in data science. He has given keynotes around the world and his work featured in The New Yorker, The Economist, Washington Post, NPR, BBC, Nature, Science, and many others.

Symposia Speakers



James Antoon, Vanderbilt University Medical Center

Dr. Antoon is a clinical and health services researcher at Vanderbilt University Medical Center. His research program focuses on pharmacoepidemiology and medication safety in the pediatric population and is supported by funding from the NIH, CDC and PCORI. As a physician-scientist, Dr. Antoon designs and conducts clinical trials and population-based observational studies of medications, with a focus on the treatment of respiratory illness (e.g. influenza, COVID-19, RSV, pneumonia,) in children. He evaluates the relationship between serious adverse events and medication exposures, as well as determining the role of drug-drug interactions and underlying infections in the development of serious adverse events in children. Dr. Antoon's studies have investigated medication-related neurologic and psychiatric adverse events, severe cutaneous adverse reactions (e.g, Stevens Johnson Syndrome), cardiac events, and anaphylactic allergic reactions, among others.

An expert on the safety and effectiveness of antivirals in the treatment of influenza and other respiratory viruses, Dr. Antoon is the recipient of a NIH Career Development Award focused on determining the association between influenza, oseltamivir, and serious neuropsychiatric events, such as suicide or self-harm, encephalopathy, and psychosis.

He has published more than 100 peer-reviewed articles and book chapters in the fields of pediatrics, pharmacology, and drug safety. He is a member of the Society for Pediatric Research, the International Society for Influenza and Other Respiratory Virus Diseases, and the International Society for Pharmacoepidemiology. Dr. Antoon was a 2021 recipient of the Young Investigator Award from the Academic Pediatric Association.

Dr. Antoon is a practicing pediatric hospitalist at Monroe Carell Jr. Children's Hospital at Vanderbilt. He is board certified in both General Pediatrics and Pediatric Hospital Medicine.



Ian Barr, WHO Collaborating Centre for Reference and Research on Influenza, VIDRL, Doherty Institute

Professor Ian Barr is currently the Deputy Director of the WHO Collaborating Centre for Reference and Research on Influenza which was designated in 1992 (one of 5 globally). The Centre plays a key role in the national and regional surveillance of human and zoonotic influenza viruses as well as having an active research program. Ian has over 35 years' experience with academic and commercial organisations, including over 26 years at the Centre. He has authored or co-authored over 350 scientific publications including more than 300 peer reviewed journal articles, reviews and editorials on various aspects of influenza and RSV.



Regina Barzilay, Massachusetts Institute of Technology

Symposia Speakers



Cynthia Baur, University of Maryland

Cynthia Baur, PhD, is a health literacy and health communication expert focused on improving health literacy at the individual, family, community and organizational levels. She is the Endowed Chair and Director of the University of Maryland Horowitz Center for Health Literacy, the nation's first academic health literacy center, and is a professor in the Department of Behavioral and Community Health. In 2022, the Maryland General Assembly designated the Horowitz Center as the state's consumer health information hub. During the COVID-19 pandemic, the Center provided communications support to Maryland local health departments and coalitions, and since 2023, Dr. Baur co-led the UMD Grand Challenges Pandemic Readiness Initiative. Dr. Baur is the Principal Investigator on multiple federal and state funded projects on health literacy, clear communication, digital health, diabetes prevention and organizational health literacy improvement. Before coming to UMD, she served for almost 20 years in the federal Office of Disease Prevention and Health Promotion and the Centers for Disease Control and Prevention (CDC), U.S. Department of Health and Human Services. She was CDC's Plain Language and Health Literacy Lead from 2011 to 2016.



Tor Biering-Sørensen, University of Copenhagen

Dr. Biering-Sørensen holds a distinguished academic background, having obtained his medical degree in 2011 and his Ph.D. degree in 2015 from the University of Copenhagen. He furthered his education with a Master of Public Health from Harvard University in 2018 and a Master of Science in Clinical Trials from the University of Oxford in 2023.

He is the Founding Head of the Center for Translational Cardiology and Pragmatic Randomized Trials (CTCPR), a collaboration between Copenhagen University Hospital Herlev-Gentofte and the Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen. Furthermore, he is the Founding Head of the Cardiovascular Non-Invasive Imaging Research Laboratory (CIRL), which is world-renowned for its innovative research in cardiac imaging.

Together with his research group at CTCPR and CIRL which consists of more than 50 affiliated researchers, Dr. Biering-Sørensen conducts extensive investigations into the efficacy of cardiovascular imaging techniques to enhance individualized risk prediction. Moreover, he has initiated several large-scale pragmatic randomized trials utilizing the resources of the nationwide Danish registries, thereby contributing significantly to the advancement of pragmatic trial methodologies.

Additionally, in his capacity as an academic leader, he has been awarded some of the most prestigious research awards in Denmark but also internationally, he has published more than 500 scientific publications and he provides mentorship to numerous medical students, PhD students, and postdoctoral researchers, offering guidance in various aspects of clinical research, with a particular focus on cardiovascular imaging, randomized trials, heart failure, and the effects of infections on cardiovascular outcomes.

Symposia Speakers



Silvia Bino, Institute of Public Health

Dr. Silva Bino is Head of the Control of Infectious Diseases Department at the Institute of Public Health in Tirana, Albania, and Professor of Infectious Diseases at the Faculty of Medicine, University of Tirana.

Dr. Bino has dedicated her career to strengthening infectious disease control and surveillance systems, particularly in resource-limited settings. She coordinated Albania's response to pandemic influenza A (H1N1) in 2009 and has played a key role in strengthening influenza and other respiratory virus surveillance across Southeastern Europe. She has also led regional initiatives to improve early warning systems, preparedness, and response to pandemics.

Since 2000, she has coordinated Albania's national immunization program and contributed extensively to public health research, guidelines, and policy development. She has served as a consultant to several agencies and held positions on several international advisory groups, including those focused on immunization, pandemic influenza, and global health emergencies.

During the COVID-19 pandemic, Dr. Bino led epidemiological surveillance and coordinated vaccination efforts in Albania, while contributing to regional work on vaccine initiatives laboratory capacities and surveillance.

She obtained her medical and doctoral degrees from the University of Tirana and completed postgraduate training in infectious diseases, microbiology, epidemiology, and public health in several European countries, United Kingdom and the United States.

Dr. Bino has dedicated her career to strengthening infectious disease control and surveillance systems, particularly in resource-limited settings. She coordinated Albania's response to pandemic influenza A (H1N1) in 2009 and has played a key role in strengthening influenza and other respiratory virus surveillance across Southeastern Europe. She has also led regional initiatives to improve early warning systems, preparedness, and response to pandemics.

Since 2000, she has coordinated Albania's national immunization program and contributed extensively to public health research, guidelines, and policy development. She has served as a consultant to several agencies and held positions on several international advisory groups, including those focused on immunization, pandemic influenza, and global health emergencies.

During the COVID-19 pandemic, Dr. Bino led epidemiological surveillance and coordinated vaccination efforts in Albania, while contributing to regional work on vaccine initiatives laboratory capacities and surveillance.

She obtained her medical and doctoral degrees from the University of Tirana and completed postgraduate training in infectious diseases, microbiology, epidemiology, and public health in several European countries, United Kingdom and the United States.

Symposia Speakers



Jesse Bloom, Fred Hutch

Jesse Bloom studies the evolution of viruses, including influenza, coronaviruses, and RSV. His group has developed high-throughput experimental techniques to measure the neutralization of different viral strains or variants by antibodies, and computational methods to leverage the resulting data to inform vaccine design. Jesse has been a faculty member at the Fred Hutchinson Cancer Center since 2011, and an Investigator of the Howard Hughes Medical Institute since 2018.



Judy Bruer, Institute Child Health, University College London

Judith Breuer is Professor of Virology at UCL and Clinical lead for Virology at Great Ormond Street Hospital for Children. Professor Breuer established a UKAS accredited diagnostic metagenomics at GOSH for the detection of pathogens in suspected cases of encephalitis. She leads work on metagenomics of sterile sites within the Serious Presentation of Infectious Disease (SPID) Genomic Network of Excellence (GNoE) and the Genomics to Enhance Microbial Screening (GEMS) Blood Transfusion Research Unit (BTRU), identifying metagenomically adeno-associated virus 2 (AAV2) as the unexplained paediatric hepatitis occurring in children in 2022. Professor Breuer's group were the first to show that the Guys and St Thomas Trust the ONT respiratory metagenomics pipeline could be successfully implemented in a second centre. More recently Professor Breuer's laboratory has developed a new method to improve the sensitivity of ONT sequencing for sterile sites. This will be trialled against the current UKAS accredited pipeline. Professor Breuer chairs and is a member of several national government and UKHSA committees on vaccines and infection.



Markus Buchfellner, MUSC Shawn Jenkins Children's Hospital

Dr. Markus Buchfellner is an assistant professor of pediatric infectious diseases at the Medical University of South Carolina (MUSC) Shawn Jenkins Children's Hospital in Charleston, SC. He completed his pediatric residency at the University of South Florida where he trained at Tampa General Hospital and Johns Hopkins All Children's Hospital. He then completed his fellowship in Pediatric Infectious Diseases at the University of Alabama at Birmingham and following that completed an additional year of advanced subspecialty training through the Infectious Diseases in Immunocompromised Children Fellowship Program at St. Jude Children's Research Hospital. Dr. Buchfellner's clinical interests include viral infections in pediatric solid organ transplant recipients, bone marrow transplant recipients and oncology patients. He is interested in long term care following transplant including vaccine readiness and co. His research centers on cytomegalovirus (CMV) and T cell immunity and reconstitution after hematopoietic cell transplant and outcomes in RSV and influenza infection in the early post-transplant period. He is also deeply committed to medical education and has developed transplant medicine curricula for learners across all stages of medical training. He has delivered invited lectures nationally on topics including pediatric hepatitis, long COVID in children, and severe neonatal infections.

Symposia Speakers




Marco Cavaleri, European Medicine Agency



Ben Cowling, Hong Kong University

Ben Cowling is currently Chair of Epidemiology, Doris and Francis Zimmern Professor in Population Health, head of the Division of Epidemiology and Biostatistics in the School of Public Health at the University of Hong Kong, and co-Director of the WHO Collaborating Centre for Infectious Disease Epidemiology and Control. He conducts research into the epidemiology of respiratory virus infections, with a focus on transmission dynamics and the effectiveness of control measures including vaccination. Since early 2020 he has conducted research on the epidemiology and control of COVID-19 including highly cited publications in NEJM, Science and Nature Medicine. He holds major research grants to study how individual measures of immunity translate to population immunity, and to estimate the impact of public health measures for influenza and COVID-19. He has authored more than 800 peer-reviewed journal publications to date.



Rebecca Cox, University of Bergen

Rebecca Cox leads the Influenza Centre at the University of Bergen and Haukeland University Hospital, Norway, leading a team of 18 scientists. Rebecca Cox completed her PhD in 1995 at the London Hospital Medical College, University of London, UK before post doc positions at Guys Hospital, UK and the University of Bergen, Norway. She has over 30 years of experience of influenza work particularly in development and evaluation of influenza vaccines. Her research focuses on influenza and respiratory virus vaccine development and evaluation, correlates of protection and pandemic preparedness, with particular emphasis on clinical trials, longitudinal human cohort studies and translational immunology.

Rebecca has extensive experience in international collaborative projects addressing influenza and emerging pathogens. Rebecca has advisory roles with international health organisations (WHO, EU and European Medicines Agency).

Rebecca is a trustee of ISRV and Chair of the Education committee, where her passion is education of the next generation of young scientists. She is a senior editor for the journal Influenza and Other Respiratory Viruses. She is author of more than 180 peer-reviewed papers and regularly contributes to the public debate on Influenza, COVID and vaccines through multi-media channels.

Symposia Speakers



Meagan Deming, University of Maryland, Baltimore

Dr. Deming is a board-certified Infectious Disease specialist with a primary research interest in respiratory viruses, including coronaviruses and influenza. She earned her MD & PhD at the University of North Carolina studying SARS-coronavirus vaccine strategies and antibody neutralization. Currently an Assistant Professor at the University of Maryland School of Medicine Center for Vaccine Development and Global Health, she is working to bring improved influenza and coronavirus vaccines to the clinic, ideally with the assistance of respiratory virus controlled human infection models.



Diego Diel, College of Veterinary Medicine, Cornell University

Dr. Diego Diel, DVM, MS, PhD is a Professor of Virology in the Department of Population Medicine and Diagnostic Sciences and Director of the Virology Laboratory at the Cornell Animal Health Diagnostic Center (AHDC), College of Veterinary Medicine, Cornell University. Dr. Diel's research focuses on emerging viruses at the human–animal interface. His work encompasses viral pathogenesis, virus–host interactions, and the development of vaccines and improved diagnostic assays for several high-consequence pathogens affecting both humans and animals.

In 2024, Dr. Diel led the Cornell team that first detected the spillover of influenza A H5N1 virus into dairy cattle. Since then, his laboratory has been at the forefront of characterizing this unprecedented event, investigating mechanisms of disease pathogenesis and species susceptibility, developing vaccines and improved diagnostics, and evaluating the public health and food safety risks associated with H5N1 circulation in multiple host species.



Ruben Donis, Centers for Disease Control and Prevention

Ruben Donis received his PhD in virology from Cornell University and his postdoctoral training with Robert G. Webster at St. Jude Children's Research Hospital. He served as professor at the University of Nebraska-Lincoln before joining the CDC Influenza Division in 2003, where he led the Molecular Virology and Vaccines Branch. In those roles he provided scientific leadership during the 2005 H5N1 avian influenza emergency, the 2009 H1N1 pandemic, and the 2014–2017 H7N9 outbreaks. From 2015 to 2025 he served as Deputy Director of the Influenza and Emerging Infectious Diseases Division at BARDA/HHS, guiding advanced development of pandemic influenza vaccines and other countermeasures, and leading the scientific response to the 2015 Zika outbreak and the COVID-19 pandemic correlates of protection program. His research contributions include the discovery of canine influenza virus, broadly neutralizing anti-hemagglutinin stem antibodies, and bat influenza viruses in collaboration with other scientists. He is a two-time recipient of the CDC Charles C. Shepard Science Award (2009, 2013) and the 2023 ASPR Pinnacle Award. Dr. Donis currently serves as an independent consultant in influenza vaccines.

Symposia Speakers



Brendan Flannery, Centers for Disease Control and Prevention (CDC)

Dr. Deming is a board-certified Infectious Disease specialist with a primary research interest in respiratory viruses, including coronaviruses and influenza. She earned her MD & PhD at the University of North Carolina studying SARS-coronavirus vaccine strategies and antibody neutralization. Currently an Assistant Professor at the University of Maryland School of Medicine Center for Vaccine Development and Global Health, she is working to bring improved influenza and coronavirus vaccines to the clinic, ideally with the assistance of respiratory virus controlled human infection models.



Martin Friede, Medicines Patent Pool

Martin Friede served at the World Health Organization (WHO) from 2003 to 2025, most recently as Head of the Vaccine Research Unit, where he led global programmes to define global vaccine R&D priorities and expand access to vaccine technologies. He established and oversaw the WHO mRNA Technology Transfer Programme, enabling the development of sustainable mRNA manufacturing capacity across multiple regions, and led the WHO pandemic influenza vaccine research and capacity building activities. Prior to joining WHO Martin held senior roles in pharma and biotech industries.

Since September 2025, he has been a Senior Advisor to the Medicines Patent Pool (MPP). Dr. Friede holds a PhD in Biochemistry from the University of Cape Town.



Shoshanna Goldin, World Health Organization

Dr. Shoshanna Goldin leads the portfolio on influenza medical countermeasures at the World Health Organization headquarters in Geneva, Switzerland. Within this role, Dr Goldin develops guidance and technical resources on product pipelines, global production capacity, policy and program development, and product use for influenza vaccines and antivirals. Her experience spans influenza and COVID-19 medical countermeasures, capacity building for respiratory pathogen pandemic preparedness and response, antimicrobial resistance and behavior change, and improving access to pediatric care. Dr Goldin has a Doctorate of Public Health from Johns Hopkins University and a Master of Public Health in Health Policy and Management from Yale University.

Symposia Speakers



Alba Grifoni, La Jolla Institute

Dr. Alba Grifoni is a Research Assistant Professor at the La Jolla Institute for Immunology (LJI), where she leads cutting-edge research in Human Viral Immunology and T cell responses at the Center for Vaccine Innovation.

Dr. Grifoni is recognized as a Clarivate Highly Cited Scientist since 2022, a distinction that underscores her exceptional global influence. Her scholarly impact is profound, evidenced by her profile reflecting an H Index of 56 and over 28,653 total citations, establishing her as a foremost authority in the field.

Her career has been defined by breakthrough contributions to pandemic preparedness. In 2025, she co-authored a seminal paper in the journal *Cell*, "Highly conserved Betacoronavirus sequences are broadly recognized by human T cells," which is currently shaping the direction of multi-antigen vaccine strategies. This follows her foundational work on SARS-CoV-2, including publications in *Cell* and *Science* that were cited in congressional hearings and were critical to understanding the immune response to COVID-19.

Since 2020, Dr. Grifoni has directed her lab at LJI, where she leads NIH and CEPI funded projects focused on pan-coronavirus vaccine design and the study of T cell immunity to pathogens like Mpox and Dengue. She holds a Ph.D. in Immunology from the University of Rome "Tor Vergata" and has been recognized with multiple honors, including the ISSNAF/Embassy of Italy Award and the Bouille-SEI International Award



Carlos Grijalva, Vanderbilt University Medical Center

Dr. Grijalva is Professor of Health Policy and Biomedical Informatics at Vanderbilt University Medical Center. He has led or Co-led several single site and multicenter household-based and cohort studies of influenza, SARS-CoV-2 and RSV infections. Dr. Grijalva has expertise in the design of observational studies of acute respiratory infections and their transmission, and the evaluation of the effectiveness of vaccination and other preventive programs. Dr. Grijalva is also an experienced mentor and over the last several years, he has provided mentorship to a number of master and doctoral students as well as early stage faculty members. He has received several recognitions for excellence in teaching and mentoring.

Symposia Speakers



Larisa Gubareva, Centers for Disease Control and Prevention

Larisa Gubareva, M.D., Ph.D. is the Lead for the Molecular Epidemiology Team at the Influenza Division, CDC.

Her team conducts research on broad aspects of influenza virology with emphasis on molecular mechanisms of drug resistance, zoonotic virus risk assessment, antigenic analysis, response to vaccination, and related topics. Dr. Gubareva's interests also lie in the development of new laboratory methods for influenza viruses. Dr. Gubareva is a recipient of the CDC's Charles C. Shepard Science Awards for outstanding research papers.

Dr. Gubareva is a member of the ISRV Antiviral Group executive committee (ISRV-AVG) and of the WHO GISRS expert group on antiviral surveillance (WHO-AVWG). Over the years, Dr. Gubareva has served on editorial boards of several scientific journals. She has conducted research on influenza since 1990 and has authored over 200 research articles, reviews, commentaries, and book chapters.



Natasha Halasa, Pediatric Infectious Diseases, Vanderbilt University Medical Center

Dr. Halasa is the Craig Weaver Professor of Pediatric Infectious Diseases at Vanderbilt University Medical Center. She earned her BS in biology from the University of Akron, her MD from the Medical College of Ohio, completed pediatric residency at Columbus Children's Hospital, and fellowship training at Vanderbilt, where she also earned an MPH. A faculty member since 2004, her research focuses on reducing the burden of diarrheal and respiratory illnesses through vaccines and therapeutics. She has led and participated in numerous pediatric vaccine trials and currently serves as PI for multiple CDC- and NIH-funded surveillance and vaccine studies.



Katia Koelle, Emory University

My research program investigates the underlying evolutionary and population dynamic factors contributing to the spread of viral infectious diseases at the within-host and host population levels. I have studied the evolutionary dynamics of RNA viruses for the past 20 years, starting as a postdoctoral researcher at the Center for Infectious Disease Dynamics at The Pennsylvania State University, and since then as an Assistant and then Associate Professor at Duke University (2007-2017), and more recently as an Associate Professor (2017-2022) and now Full Professor (2022-present) at Emory University. My research focuses on designing and applying quantitative approaches to better understand patterns of viral evolution and spread. These approaches include mathematical and computational modeling, as well as phylogenetic and statistical analysis of viral sequence data. One main research question that I have targeted over the last decade focuses on the role that rapid evolutionary changes of infectious pathogens play in generating and maintaining strain diversity, and the consequences of this diversity on patterns of disease incidence. More recent work has focused on identifying what processes shape viral evolution and adaptation within hosts, between transmission pairs, and at the population level. Prior to the SARS-CoV-2 pandemic, my work focused primarily on understanding patterns of immune escape and antigenic variation in human influenza viruses. My group's efforts currently include the study of influenza virus evolution, SARS-CoV-2 evolution, and norovirus evolution at the within-host, between-host, and population-level scales.

Symposia Speakers



Jan Kosinski, European Molecular Biology Laboratory Hamburg

Dr. Jan Kosinski is a Group Leader at the European Molecular Biology Laboratory (EMBL) Hamburg and the Centre for Structural Systems Biology (CSSB) in Hamburg, Germany, with a joint appointment in the Molecular Systems Biology Unit at EMBL Heidelberg. He also co-chairs EMBL's Infection Biology Transversal Theme. His group studies macromolecular assemblies, viruses, and parasites using integrative structural and systems biology. The group develops computational methods that combine AI-based structure prediction, cryo-electron tomography, crosslinking mass spectrometry, proteomics, and fluorescence microscopy to model biological structures and mechanisms in their native cellular context. This work helped establish integrative modeling of large complexes, including a near-atomic model of the human nuclear pore complex, and now extends to mapping the influenza A virus infection cycle and host-pathogen interactions inside cells. Dr. Kosinski received his PhD from the International Institute of Molecular and Cell Biology in Warsaw, Poland, and carried out postdoctoral research at Sapienza University of Rome and at EMBL Heidelberg, with a visiting period at the University of California, San Francisco. He has led his group at EMBL Hamburg since 2017. He is a co-investigator of the ERC Synergy grant TransFORM, which builds near-atomic models of translation in whole cells, and leads or co-leads projects funded by the DFG, including the Graduate School VISION (VISualization and imaging of virus infectiON). His honors include EMBO Long-Term and Short-Term Fellowships and the Polish Prime Minister Award for his PhD thesis.



Seema Lakdawala, European Molecular Biology Laboratory Hamburg

Dr. Lakdawala trained as a molecular virologist at the Salk Institute and at the NIH began studying airborne transmission of influenza viruses. During her postdoc she made important discoveries regarding the presence of 2009 H1N1 influenza pandemic virus in expelled aerosols (Lakdawala et al PLoS Pathogens 2011), and she defined the soft palate as an important site for viral adaptation and transmission (Lakdawala et al Nature 2015). Dr. Lakdawala started an independent laboratory in 2015 studying influenza virus transmission, pathogenesis, and assembly across scales. The Lakdawala Lab uses sophisticated microscopy and biochemistry to examine viral replication, animal models to study airborne transmission of influenza viruses, and engineering to examine persistence of viruses in the air. This work has resulted in 11 peer-reviewed publications in top-tier journals (such as Nature Communications, eLife, Journal of Infectious Diseases, etc) and has required the updating of virology textbooks on the architecture of influenza genome and policy changes on the persistence of viruses in the environment. Their research has been featured in the popular press including on NPR, Gizmodo, and Nature News. Recently their research has expanded into universal influenza vaccines using multivalent mRNA technology in collaboration with Drew Weissman, this work was recently published in Science (Arevalo et al Science 2022). Dr. Lakdawala was also successful at grant funding, currently receiving over a million dollars of direct funding through the following awards: two NIH-R01 grants co-PI of a Project in Penn-CEIRR, and co-I Foundation award. Dr. Lakdawala was the recipient of the 2020 ASV Ann Palmenberg Junior Investigator Award and co-organized the NASEM workshop on SARS-CoV-2 Airborne Transmission in 2020.

Symposia Speakers



Michael Lassig, University of Cologne



Adam Luring, University of Michigan

Dr. Lakdawala trained as a molecular virologist at the Salk Institute and at the NIH began studying airborne transmission of influenza viruses. During her postdoc she made important discoveries regarding the presence of 2009 H1N1 influenza pandemic virus in expelled aerosols (Lakdawala et al PLoS Pathogens 2011), and she defined the soft palate as an important site for viral adaptation and transmission (Lakdawala et al Nature 2015). Dr. Lakdawala started an independent laboratory in 2015 studying influenza virus transmission, pathogenesis, and assembly across scales. The Lakdawala Lab uses sophisticated microscopy and biochemistry to examine viral replication, animal models to study airborne transmission of influenza viruses, and engineering to examine persistence of viruses in the air. This work has resulted in 11 peer-reviewed publications in top-tier journals (such as Nature Communications, eLife, Journal of Infectious Diseases, etc) and has required the updating of virology textbooks on the architecture of influenza genome and policy changes on the persistence of viruses in the environment. Their research has been featured in the popular press including on NPR, Gizmodo, and Nature News. Recently their research has expanded into universal influenza vaccines using multivalent mRNA technology in collaboration with Drew Weissman, this work was recently published in Science (Arevalo et al Science 2022). Dr. Lakdawala was also successful at grant funding, currently receiving over a million dollars of direct funding through the following awards: two NIH-R01 grants co-PI of a Project in Penn-CEIRR, and co-I Foundation award. Dr. Lakdawala was the recipient of the 2020 ASV Ann Palmenberg Junior Investigator Award and co-organized the NASEM workshop on SARS-CoV-2 Airborne Transmission in 2020.

Plenary and Keynote Speakers

Symposia Speakers



Samson Lee, Influenza and Emerging Infectious Diseases, BARDA

Sam Lee, PhD, is the Director of Vaccine Development in the Influenza and Emerging Infectious Disease Division at the Biomedical Advanced Research and Development Authority (BARDA). He leads a dedicated team focused on advancing pandemic influenza vaccine strategies and preparedness. Since joining BARDA in 2023, he established the Protection Before Day One initiative, which aims to enhance readiness and safeguard public health prior to the onset of an influenza pandemic by building pandemic preparedness into seasonal influenza vaccines. Before joining BARDA, Dr. Lee spent 28 years at Sanofi, where he specialized in vaccine manufacturing, development, and strategy. Notably, he served as principal investigator for the several BARDA contracts in 2004-2009 to establish year-round egg supply and avian influenza vaccine stockpiles. He worked closely with BARDA to deliver over 75 million doses of pandemic influenza vaccine during the 2009 H1N1 pandemic response.



Daniel Lingwood, Ragon Institute of MGH, MIT and Harvard

The Lingwood Lab's research centers on defining how fundamental principles of B cell antigen recognition control epitope-targeting by the antibodies elicited by vaccines. We have defined how gene-encoded antigen 'pattern' recognition motifs exist within the human antibody repertoire and can, within purpose-built humanized mouse systems, serve as natural substrates for refocusing humoral immunity upon 'universal' vaccine targets on influenza virus, HIV, and gram-negative bacteria. We have also recently described a biological buffer system which sets the circulating level of interleukin-6 (IL-6) to regulate the output of these antibody responses and more broadly, innate immune reactions.



Anice Lowen, Emory University School of Medicine

Anice Lowen is the William P. Timmie Professor of Microbiology and Immunology at Emory University, Principal Investigator of the Emory Center of Excellence for Influenza Research and Response (Emory-CEIRR) and Co-Director of the Emory Center for Transmission of Airborne Pathogens (Emory CTAP). Her research uses molecular tools, classical virology, and both human and animal models of infection to study the biology of influenza A virus. Major focus areas include the features of viral biology that shape evolutionary dynamics and the mechanisms governing transmission between individuals.

Symposia Speakers



Andrew Mehle, University of Wisconsin

Dr. Mehle is a Professor at the University of Wisconsin-Madison where his group began in 2011. He is currently the Vice-Director of the Microbiology Doctoral Training Program and will become Director in July 2026. He received his PhD in the Harvard Virology Program and performed postdoctoral training in the Doudna lab at the University of California Berkeley. The Mehle Lab studies the influenza virus replication machinery and the host factors that regulate expression of viral genes and replication of the viral genome. The lab is especially interested in how influenza virus usurps cellular processes to support viral replication, including those classically associated with responses thought to inhibit infection.



Emanuele Montomoli, University of Siena

Emanuele Montomoli was graduated in Life Sciences at University of Siena. Since November 2002 he was appointed by the University of Siena as Professor on Public Health, where he has carried out epidemiological research, surveillance networks for infectious diseases and serological assays for vaccines clinical trials. He has participated in more than 300 vaccines clinical trials as responsible for laboratory testing. Since 2010, he is fully concentrated in the assessment of new assays for vaccines evaluation and correlates of protection. In 2015 he was appointed as scientific coordinator for a project funded by EU-IMI (Innovative Medicine Initiative) titled "Standardization and development of assays for assessment of influenza vaccine correlates of protection"; He is member of International Society for Influenza and other Respiratory Viral Diseases (ISIRV) since 2005 and he was elected in the Scientific Board from 2014. With ISIRV, he organized 2 editions of the "Summer School on Influenza" and a meeting on "correlates of protection for respiratory diseases"; He is President of the Board for the "Master in vaccinology and drug development"; at University of Siena. He is founder and President of VisMederi srl, a company involved in laboratory activities for vaccines and antiviral drugs clinical trials. He is the author of more than 300 papers, as well as numerous abstracts and letters, published in international scientific journals.



Usman Nakakana, Gates Foundation

Claudia Nannei, WHO Claudia Nannei is Team Lead for Product Development and Manufacturing at the World Health Organization (WHO). A health economist with a doctorate in health, she has more than 25 years of experience in public health, including over 15 years at WHO advancing equitable access to health products through sustainable and geographically diversified manufacturing in low- and middle-income countries (LMICs). Her work focuses on strengthening pandemic preparedness and response by building sustainable capacities for the research, development, manufacturing, and equitable access to medical countermeasures. At WHO, she has led and contributed to major global initiatives, including the Global Action Plan for Influenza Vaccines, the R&D Blueprint, and the Allocation Workstream during the COVID-19 response through COVAX. She currently leads the WHO Health Technology Access Programme (HTAP) and the mRNA Technology Transfer Programme.

Symposia Speakers



Claudia Nannei, WHO

Claudia Nannei is Team Lead for Product Development and Manufacturing at the World Health Organization (WHO). A health economist with a doctorate in health, she has more than 25 years of experience in public health, including over 15 years at WHO advancing equitable access to health products through sustainable and geographically diversified manufacturing in low- and middle-income countries (LMICs). Her work focuses on strengthening pandemic preparedness and response by building sustainable capacities for the research, development, manufacturing, and equitable access to medical countermeasures. At WHO, she has led and contributed to major global initiatives, including the Global Action Plan for Influenza Vaccines, the R&D Blueprint, and the Allocation Workstream during the COVID-19 response through COVAX. She currently leads the WHO Health Technology Access Programme (HTAP) and the mRNA Technology Transfer Programme.



Kathy Neuzil, Gates Foundation

Dr. Kathleen Neuzil is a global health leader and vaccinologist who leads the Gates Foundation's efforts to eradicate polio and strengthen the health systems that support immunization and disease surveillance.

With more than 25 years of leadership in vaccine research, development, implementation, and policy, Kathleen joined the Gates Foundation in 2025 from the National Institutes of Health, where she served as associate director for international research and director of the Fogarty International Center, advancing global health research and training programs worldwide.

Throughout her career, Kathleen has helped develop, evaluate, and introduce vaccines for influenza, rotavirus, HPV, Japanese encephalitis, COVID-19, and other infectious diseases. She previously held leadership roles at the University of Maryland School of Medicine, including Myron M. Levine Professor in Vaccinology and director of the Center for Vaccine Development and Global Health. Earlier, she served on the faculty at the University of Washington and led vaccine development programs at PATH.

Kathleen has led large-scale clinical trials across diverse global settings and has helped shape international and national immunization policies through collaborations with the World Health Organization and the U.S. Centers for Disease Control and Prevention.

She is a member of the National Academy of Medicine, a fellow of the American College of Physicians and the Infectious Diseases Society of America, and has authored more than 375 publications.

Kathleen earned her B.S. in zoology from the University of Maryland and her M.D. from Johns Hopkins. She completed her residency, infectious disease fellowship, and MPH at Vanderbilt University.

Symposia Speakers



Hanna Nohynek, Finnish Institute for Health and Welfare



Marta Nunes, Hospices Civils de Lyon

Marta is the director of the Center of Excellence in Respiratory Pathogens (CERP) in Lyon, France, since September 2022. She did her PhD thesis work at the Weill Medical College of the Cornell University in New York, USA. Her post-doctoral training was at the Parasitology Department of the Institut Pasteur in Paris. In 2009 she moved to South Africa where the focus of her research was on vaccines and reducing under-5 childhood morbidity and mortality from leading causes of death. To approach the problem of infant morbidity and mortality related to infections she explored the potential of vaccination during pregnancy to protect the women and their babies against infections. Moreover, Marta led large hospital-based surveillance projects on RSV, Covid-19, influenza, pertussis; and Covid-19 vaccine effectiveness studies. At the CERP they current develop evidence generating research to support decision making related to respiratory pathogens.



Andrew T. Pavia M.D, FAAP, FACP, FIDSA

Andrew Pavia M.D. is the George and Esther Gross Presidential Professor in the Department of Pediatrics and adjunct Professor of Medicine at the University of Utah. From 2002-2024 he served as Chief of the Division of Pediatric Infectious Diseases. He also serves as Director of Hospital Epidemiology at Primary Children's Medical Center and Associate Director of the Antimicrobial Stewardship Program.

He received his MD from Brown University and was a resident and Chief resident in Medicine at Dartmouth. He served as an EIS officer and Preventive Medicine Resident at the Centers for Disease Control and Prevention (CDC) . He completed Pediatric and Adult ID fellowship at the University of Utah.

Dr. Pavia's research, public health, and policy work has focused on emerging infectious diseases, particularly respiratory infections and pandemic preparedness. He is the author of over 240 peer-reviewed papers and 50 invited reviews, editorials and textbook chapters. He served as an advisor to CDC and the Utah Department of Health on COVID-19, and is a member of the NIH COVID-19 Treatment Guidelines Panel where he was the Pediatric Team Lead. He is a member of the National Academy of Science, Engineering and Medicine's (formerly known as the IOM) Preparedness Forum. Dr. Pavia co-chairs the Influenza Guidelines Writing Committee for the Infectious Disease Society of America (IDSA). He was a member from 2012-2018 and the 2018 chair of the IDWeek Program Committee. He previously served on the Board of Scientific Counselors for CDC, was a board member of IDSA and chair of the IDSA Pandemic Influenza task force and the IDSA Public Health Committee. He has served on the National Biodefense Science Board (NBSB) where he chaired the influenza working group during the 2009 H1N1 influenza pandemic.

Symposia Speakers



Richard Pebody, The UK Health Security Agency

Richard is a public health epidemiologist and currently Director of Epidemic and Emerging Infections at the UK Health Security Agency and honorary Professor at University College London. Richard was previously High Threat Pathogen Team Lead at the WHO Regional Office for Europe working on a range of epidemic and pandemic infections notably SARS-CoV-2 and influenza. Prior to this, Richard led the Influenza Team at the UK National Surveillance Centre. Richard originally trained and worked in clinical medicine, before undertaking the EPIET field epidemiology programme and specialising in public health.



Leon Peto, University of Oxford

Leon Peto is an infectious diseases physician and clinical trialist at Oxford University. He is clinical coordinator for the RECOVERY trial, a global platform trial testing treatments for influenza and bacterial pneumonia, which previously evaluated therapies for COVID-19. He is also a co-investigator for the DEN-HOST platform trial of dengue treatment, and was clinical lead for the PLATINUM trial of tecovirimat for mpox. His research centres on the design and delivery of large, efficient randomised trials for infectious diseases, with a particular focus on adaptive platform trials that can generate reliable evidence rapidly during epidemics.



Lois Privor-Dumm, Johns Hopkins University

Lois Privor-Dumm is an independent global health consultant focusing on vaccines and vaccination. Ms. Privor-Dumm brings nearly 30 years of vaccine expertise, working in more than 70 countries supporting decision making for new vaccine introductions across the life course and efforts to improve uptake in countries of all income levels, particularly in low- and middle-income countries. During her career at Johns Hopkins Bloomberg School of Public Health, she built and oversaw numerous large-scale and community-based programs that have impacted the lives of underserved communities throughout the life course and founded a council of international experts to develop a global agenda for adult immunization. Prior to and during the COVID-19 pandemic, she partnered with multiple health departments, universities, community churches, local organizations, and the Maryland Vaccine Equity Task Force. She led the VALUE Baltimore program that significantly reduced vaccination disparities in Baltimore City. Post COVID, she evaluated efforts in Asian countries to document challenges and best practices during the pandemic, including the impact on vaccine confidence. She continues to work with community groups, national organizations, and local leaders in the US to build trust in vaccination and advance the health equity agenda. Prior to joining Hopkins, she worked in the pharmaceutical industry leading new product introductions in the US and regional operations in Latin America and Canada and Europe, Middle East and Africa. She holds a Master in International Business Studies from University of South Carolina and studied in Spain and Belgium.

Symposia Speakers



Bali Pulendran, Stanford University

Bali Pulendran, PhD Bali Pulendran is the Violetta L. Horton Professor at the Stanford University School of Medicine, and Director of the Institute for Immunology, Transplantation, and Infection, at Stanford University. He received his undergraduate degree from Cambridge University, and his Ph.D., from the Walter & Eliza Hall Institute in Melbourne, Australia, under the supervision of Sir Gustav Nossal. He then did his post-doctoral work at Immunex Corporation in Seattle. Dr. Pulendran has had a transformative impact on human immunology and vaccinology by pioneering the use of systems approaches to probe immunity to vaccination and infection in humans. In addition, Dr. Pulendran discovered that dendritic cells, one of the key cell types orchestrating the immune response, consist of multiple subtypes, which are functionally distinct. He also discovered the mechanisms by which microbial stimuli program DCs to modulate T-helper responses and helped establish Flt3-Ligand as the key growth factor for DCs in vivo. These groundbreaking findings helped define major paradigms in innate immunity. Dr. Pulendran's research is published in front line journals such as Nature, Science, Cell, Nature Medicine, and Nature Immunology. Dr. Pulendran serves on many advisory boards including that of Keystone Symposia and on the External Immunology Network of GSK. He is a fellow of the American Association for the Advancement of Science and the recipient of several honors and awards, including two concurrent MERIT awards from the NIH, the AAI Ralph Steinman Award for Human Immunology, the Albert Levy Prize, the ViE Award for the Best Research Team at the World Vaccine Congress, and is listed on Thomson Reuter's list of Highly Cited Researchers, which recognizes the world's most influential researchers of the past decade.



Adrienne Randolph, Harvard Medical School

Dr. Adrienne Randolph is a pediatric critical care physician at Boston Children's Hospital and Professor of Anaesthesia and Pediatrics at Harvard Medical School. She founded the Pediatric Acute Lung Injury and Sepsis Investigator's (PALISI) Network in 2002 that now has over 90 pediatric sites internationally. Her areas of expertise are pediatric sepsis, acute lung injury, and severe respiratory infections in children. She founded and directs the multicenter NIH-funded Pediatric Intensive Care Influenza Network (PICFLU) and the CDC-funded Overcoming COVID-19 Networks, both of which are focused on optimizing prevention and treatment of life-threatening viral respiratory complications in children. The PICFLU Network has enrolled over 1,000 hospitalized children into studies to understand the immunobiology of influenza-related critical illness. Working with the CDC, her research networks have used test-negative control designs to estimate influenza and COVID vaccine effectiveness and RSV monoclonal antibody effectiveness in preventing critical illness in children. She has over 250 peer reviewed publications with over half related to pediatric vaccine-preventable diseases that cause critical illness in children.

Symposia Speakers



Pinyo Rattanaumpawan, Faculty of Medicine Siriraj Hospital, Mahidol University

Professor Pinyo Rattanaumpawan, MD, MSCE, PhD, is a Professor of Medicine at Division of Infectious Diseases and Tropical Medicine, the Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand, and serves as Executive Director of the Clinical Trial Unit. She leads the Antimicrobial Stewardship Program at Siriraj Hospital and holds key roles nationally and internationally, including with the Infectious Disease Association of Thailand (IDAT), the Thailand Immunization Guideline Committee, the National AMR Working Group, the National List of Essential Medicines (Infectious Disease Subcommittee), the WHO Technical Advisory Group on AWARE, and the GARDP Scientific Advisory Committee.

Her research focuses on clinical infectious diseases, health policy research, antimicrobial resistance (AMR) and antimicrobial stewardship (AMS), with over 20 clinical trials and nearly 100 international peer-reviewed publications. Her work has been recognized by the 2026 SHEA International Ambassador Program, the 2019 SHEA William Jarvis Award, and the 2017 Institut Merieux Young Investigator Award.



Stacey Schultz-Cherry, St. Jude Children's Research Hospital

Stacey Schultz-Cherry, PhD, is a Member (Professor) in the Department of Host-Microbe Interactions at St Jude Children's Research Hospital in Memphis, TN as well as Senior Associate Dean for Academic Affairs in the St Jude Graduate School of the Biomedical Sciences. She serves as Co-Director of not only the Center for Excellence in Influenza Research and Response but also the Collaborative Influenza Vaccine Innovation Center, both research centers supported by the National Institute of Allergy and Infectious Diseases.

Dr. Schultz-Cherry received her PhD in Molecular and Cellular Pathology from the University of Alabama at Birmingham investigating extracellular matrix and growth factor interactions. After a short postdoctoral fellowship at the University of Wisconsin-Madison studying influenza virus-induced apoptosis and cellular responses, she served as a Lead Scientist at the U.S. Department of Agriculture Southeast Poultry Research Laboratory in Athens, GA, doing research on emerging highly pathogenic avian influenza viruses and astroviruses. She subsequently joined the faculty in the Department of Medical Microbiology and Immunology at the University of Wisconsin, Madison Medical School rising to become tenured Associate Professor before moving to St Jude Children's Research Hospital in 2009.

Dr. Schultz-Cherry is recognized internationally for her studies on the pathogenesis of influenza and enteric viruses, especially astroviruses, in high-risk populations, and on the interactions of influenza viruses among different avian species and other animals and humans. She is the author and co-author of over 250 research articles, reviews, and book chapters and has lectured internationally. She has been a member of the editorial boards of several prominent journals and is now the editor-in-chief of the Journal of Virology.

Dr. Schultz-Cherry has served on the National Institutes of Health study sections and other of its institutional committees. She was elected President of the American Society for Virology in 2017, is the current chair of the Public and Scientific Affairs Committee for the American Society for Microbiology and is an American Academy of Microbiology Fellow. Since 2012 she has been Deputy Director of the World Health Organization Collaborating Center for Studies on the Ecology of Influenza in Animals and Birds

Symposia Speakers



Oneka Scott, Ministry of Health

Dr. Oneka Scott is a leading public health specialist and national programme strategist with the Ministry of Health, Guyana, where she serves as Maternal and Child Health Officer and Immunisation Lead. With over nine years of leadership in policy and programme implementation, she has driven remarkable national impact achieving 98–100% immunization coverage in children under one and 90–95% in under fives over the past five years. A graduate of the University of Liverpool, she champions life course immunization, health equity, and system innovation, positioning Guyana as a regional leader in vaccine delivery and public health excellence.

She has led the introduction of new vaccines, including the national influenza programme, expanding immunization beyond childhood into adult populations. Her work reflects a strong commitment to translating policy into measurable outcomes, particularly in underserved and hinterland communities.



Silke Stertz, Institute of Medical Virology, University of Zurich

Silke Stertz studied biology in Freiburg, Germany. She conducted her PhD work on the antiviral mechanism of Mx proteins in the lab of Prof. Otto Haller at the University of Freiburg, Germany. She then trained as postdoctoral fellow in the lab of Prof. Peter Palese at Icahn School of Medicine at Mount Sinai in New York, U.S., where she studied influenza virus-host interactions. Since 2011 she leads her own research group at the Institute of Medical Virology (University of Zurich), where she was promoted to Full Professor in 2025. Her work focuses on influenza virus-host cell interactions, particularly at the stage of viral entry.



Kiiyuan Sun, Westlake University

Dr. Kaiyuan Sun leads the Laboratory of Multiscale Host–Pathogen Dynamics at Westlake University. His research uses mathematical and computational modeling to investigate how respiratory viruses spread, evolve, and interact with host immunity across biological scales. By integrating immunological and epidemiological data with population-dynamics modeling, his lab links within-host viral and immune processes to population-level transmission and viral evolution. A central goal is to identify immune correlates of protection and determine how host immune responses and pathogen adaptation shape host susceptibility, pathogen transmission, and epidemic dynamics. Current research focuses on major respiratory pathogens, including influenza, RSV, and SARS-CoV-2.

Plenary and Keynote Speakers

Symposia Speakers



Troy Sutton, Vaccine and Infectious Disease Organization, University of Saskatchewan

Dr. Troy Sutton, PhD, is an Associate Professor at Pennsylvania State University. He received his doctoral training at the University of British Columbia in Canada and subsequently completed postdoctoral research at the University of Maryland and the National Institutes of Health. He joined Pennsylvania State University as an Assistant Professor in 2017 and was promoted with tenure in 2024. Dr. Sutton's research program is focused on pandemic risk assessment of emerging influenza viruses, with particular emphasis on evaluating viral pathogenesis and transmission in the ferret model. In parallel, his laboratory works to advance the development of influenza vaccines that can reduce viral transmission. His research has been published in leading peer-reviewed journals, including Nature Communications, Science Translational Medicine, and Science Advances. In July of 2026, Dr. Sutton will join the Vaccine and Infectious Disease Organization (VIDO) at the University of Saskatchewan in Canada as a Principal Scientist.



LJ Tan, Immunize.org



Jonathan Temte, University of Wisconsin School of Medicine and Public Health

Jonathan L. Temte, MD/PhD is Associate Dean for Public Health and Community Engagement at the University of Wisconsin School of Medicine and Public Health where he also serves as professor of Family Medicine and Community Health. Dr. Temte served on the U.S. Advisory Committee on Immunization Practices from 2008-2015 and served as chair from 2012 to 2015. He currently chairs the Wisconsin Council on Immunization Practices. He is the principal investigator of the Wisconsin Influenza Incidence Surveillance Project and the Oregon Child Absenteeism due to Respiratory Disease Study (ORCHARDS). He has experience with surveillance and epidemiology of influenza and other respiratory viruses in community settings and has evaluated the role of rapid influenza diagnosis in schools, primary care clinics, urgent care centers, and long-term care facilities.



Peter Thielen, Johns Hopkins University Applied Physics Laboratory

Peter is a principal staff scientist at the Johns Hopkins Applied Physics Laboratory. With a background in molecular biology and genomics, his research focuses on advancing DNA and RNA sequencing to support rapid decision-making, including in the clinical, environmental, and national security domains. He currently leads multiple programs that focus on transitioning basic research approaches to operational environments, including agnostic pathogen detection and characterization of aquatic environmental DNA for ecological species monitoring.

Symposia Speakers



Adriana Tomic, Boston University

Dr. Adriana Tomic is an Assistant Professor at Boston University, with appointments in Virology, Immunology & Microbiology, and Biomedical Engineering. She leads a Systems Immunology group at the National Emerging Infectious Diseases Laboratories (NEIDL) and is the developer of SIMON, an open-source knowledge discovery platform. Her research focuses on defining immunological signatures of protective immunity and accelerating vaccine development through novel systems immunology and AI approaches. Dr. Tomic received her Ph.D. in Infection Biology from Hannover Medical School, Germany, for which she was awarded a Hannover Medical School Award, and completed her postdoctoral training at Stanford University School of Medicine.

A recipient of multiple honors, including the prestigious Marie Curie Fellowship, Dr. Tomic leads significant projects for international consortia such as the NIAID-funded Centers of Excellence for Influenza Research and Response (CEIRR), the Coalition for Epidemic Preparedness Innovations (CEPI), and the Medical Research Council HIC-Vac network. Dr. Tomic is also actively involved in science communication and outreach. Reflecting her commitment to open science, she established a community to further develop and apply machine-learning tools for biomedical data analysis.



Carolien Van de Sandt, Murdoch Children's Research Institute

Dr Carolien van de Sandt is a Team Leader at the Murdoch Children's Research Institute (MCRI) and an Honorary Senior Research Fellow at the University of Melbourne (UoM).

Carolien obtained her PhD at the ErasmusMC, Netherlands in 2016, where she investigated the longevity, cross-reactivity and immune evasion strategies of influenza-specific CD8+ T cells. Following two years of postdoctoral research, she started as a MSCA Research Fellow at the UoM, studying how influenza and SARS-CoV-2-specific immunity changes across the human lifespan. During the pandemic (2020-2021) she led a research team at Sanquin in the Netherlands, studying SARS-CoV-2 immunity in autoimmune patients. In 2025, Carolien became a Team Leader and NHMRC Investigator Senior Research Fellow at the MCRI, where she continues her research on virus-specific immunity across the human life and in high-risk populations.

Carolien is a member of the International Society for Respiratory Viruses (ISRV) council and co-chair of the ISRV Education Committee where she is passionate about creating supportive opportunities that help talented early-career researchers build networks, develop professionally, and reach their full potential.

Carolien has 76 peer-reviewed publications including in leading scientific journals like Nature Medicine, Immunity, Nature Immunology and Nature Communications. Her research has been recognized by 11 Awards including the Australian and New Zealand Society for Immunology (ASI)-Peter Doherty Medal (2024), the ESWi-Claude Hannoun Prize for Best Body of Work (2023) and the UoM-MDHS Selwyn-Smith Medical Research Prize (2024). In 2023, she received the Australian Institute of Policy and Science (AIPS)-Young Tall Poppy Award and ASI-Public Engagement Award for her contributions to public outreach and in 2024 she was shortlisted for the Nature Inspiring Women: Scientific Achievement Award.

Symposia Speakers



AJ te Velthuis, Princeton University

Dr Carolien van de Sandt is a Team Leader at the Murdoch Children's Research Institute (MCRI) and an Honorary Senior Research Fellow at the University of Melbourne (UoM).

Carolien obtained her PhD at the ErasmusMC, Netherlands in 2016, where she investigated the longevity, cross-reactivity and immune evasion strategies of influenza-specific CD8+ T cells. Following two years of postdoctoral research, she started as a MSCA Research Fellow at the UoM, studying how influenza and SARS-CoV-2-specific immunity changes across the human lifespan. During the pandemic (2020-2021) she led a research team at Sanquin in the Netherlands, studying SARS-CoV-2 immunity in autoimmune patients. In 2025, Carolien became a Team Leader and NHMRC Investigator Senior Research Fellow at the MCRI, where she continues her research on virus-specific immunity across the human life and in high-risk populations.

Carolien is a member of the International Society for Respiratory Viruses (ISRV) council and co-chair of the ISRV Education Committee where she is passionate about creating supportive opportunities that help talented early-career researchers build networks, develop professionally, and reach their full potential.



Alpana Waghmare, Department of Pediatrics, University of Washington

Dr. Alpana Waghmare is a pediatrician who specializes in the treatment and prevention of infectious diseases with a focus on respiratory infections and their impact on vulnerable populations. Her research investigates risk factors and pathogenesis of severe respiratory viral infections in immunocompetent and immunocompromised adults and children. Through clinical and translational studies, Dr. Waghmare aims to describe the epidemiology, virology and host responses of these infections in high-risk populations, including hematopoietic cell transplant and immunotherapy patients, to develop highly precise and optimally timed risk stratification tools.



Szu-Wen Wang, University of California, Irvine

Szu Wang is a Professor of Chemical and Biomolecular Engineering at the University of California, Irvine. Her research is in the areas of drug delivery and biomaterials, with an emphasis in designing biomimetic materials that modulate immune responses. Application areas have included infectious disease vaccines and cancer immunotherapy.

Symposia Speakers



Joshua Weitz, University of Maryland

Prof. Joshua S. Weitz holds the Clark Leadership Chair in Data Analytics and is Professor of Biology at the University of Maryland, College Park where he is a Faculty member of IHC and holds an affiliate appointment in the Department of Physics. Weitz received his PhD in Physics from MIT in 2003, was a NSF Postdoctoral Fellow in Ecology and Evolutionary Biology at Princeton University from 2003-6, and previously served as faculty in Biological Sciences at Georgia Tech from 2007-2023 where he founded the Interdisciplinary Graduate Program in Quantitative Biosciences. Weitz leads a multidisciplinary research team whose central goal is to understand how viruses transform human and environmental health. He is an author on more than 170 peer-reviewed publications and three books, including his most recent 'Asymptomatic: The Silent Spread of COVID-19 and the Future of Pandemics' (Johns Hopkins University Press, 2024). Weitz is a Simons Foundation Investigator, a Fellow of the American Association for the Advancement of Science, and a Fellow of the American Academy of Microbiology.



Michelle Wille, University of Melbourne

Symposia Speakers



Amanda Williams, ISRV

Amanda Williams is Chief Executive Officer of the International Society for Respiratory Viruses (ISRV), a global scientific society dedicated to advancing research, education, collaboration, and public health action across the field of respiratory viruses. She leads the Society's strategic development, international partnerships, scientific conferences, educational programmes, governance, membership growth, and financial sustainability initiatives.

Amanda brings more than two decades of experience in scientific communications, scholarly publishing, professional education, and international conference management. Prior to joining ISRV, she held senior leadership positions at Springer Nature, where she led global conference and professional education portfolios, including Nature Conferences and Nature Masterclasses. Earlier in her career, she worked within the scientific publishing sector at Thomson Reuters developing programmes that connected researchers, industry leaders, and policymakers worldwide.

As CEO of ISRV, Amanda has focused on strengthening the Society's global reach and long-term sustainability. Her work includes overseeing the Society's flagship scientific meetings, including Options XIII for the Control of Influenza and other Respiratory Viruses, the International RSV Symposium, and a growing portfolio of educational and special interest group activities. She has also led initiatives to expand membership engagement, diversify organisational income, secure strategic partnerships and grants, and develop evidence-based membership and growth strategies.

Amanda is a passionate advocate for global scientific collaboration and equitable access to education. She frequently represents ISRV at major international meetings and forums, promoting collaboration across disciplines and regions to address emerging respiratory virus threats. Based in London, United Kingdom, Amanda is committed to advancing ISRV's mission of improving global health through excellence in respiratory virus research, education, and international scientific exchange.



Sam Wilson, Cambridge Institute of Therapeutic Immunology and Infectious Disease

Sam J. Wilson is GSK Professor of Microbial Pathogenesis at the University of Cambridge, based at the Cambridge Institute of Therapeutic Immunology and Infectious Disease (CITIID), and an affiliate of the Hong Kong Jockey Club Global Health Institute.

Sam is a molecular virologist whose research examines how genome-encoded antiviral defences (restriction factors) and temperature-dependent constraints on viral replication shape viral host range and emergence in humans. His work also addresses how these defences influence viral pathogenicity and disease severity.

Symposia Speakers



Charles Shey Wiysonge, South African Medical Research Council

Professor Charles Shey Wiysonge is a globally recognised public health physician, vaccinologist, and implementation scientist with more than 25 years of experience advancing population health in Africa and globally. He currently serves as an Extraordinary Professor of Global Health at Stellenbosch University in South Africa, Honorary Professor at the South African Medical Research Council (SAMRC), and a Director at the Centre for Equitable Immunisation and Pandemic Preparedness (in Cape Town, South Africa). Professor Wiysonge previously served as Team Lead for Vaccine-Preventable Diseases at the WHO Regional Office for Africa, where he led regional efforts to strengthen immunisation systems, expand vaccine access, introduce new vaccines, and recover immunisation services following the COVID-19 pandemic. He has also held leadership positions at Cochrane South Africa, SAMRC, University of Cape Town (in South Africa), and Stellenbosch University. An internationally acclaimed researcher, Professor Wiysonge has authored more than 500 peer-reviewed publications with a h-index of more than 100. His research focuses on immunisation, vaccine confidence and hesitancy, implementation science, evidence-informed policymaking, and health systems strengthening. He is internationally recognised for his pioneering work on vaccine confidence and hesitancy and for helping shape global understanding of the behavioural and social drivers of vaccination. Professor Wiysonge has served on numerous global and continental advisory bodies, including (but not limited to) the Strategic Advisory Group of Experts on Immunization, Executive Board of the Global Research Collaboration for Infectious Disease Preparedness, African Advisory Committee on Health Research and Development, and the National Advisory Group on Immunisation of South Africa. He is widely recognised for strengthening immunisation programmes, advancing health equity, and mentoring the next generation of African public health leaders.



Cameron Wolfe, Duke University Medical Center

Cameron is a Professor of Medicine, in the Transplant Infectious Disease section at Duke University. His clinical work focusses on the care of immunocompromised patients, including those receiving transplants or chemotherapy. He maintains a clinical research interest, especially trying to better understand viral infections in transplant populations and respiratory viral outbreaks and their mitigation across college campuses.

Symposia Speakers



Maria Zambon, ISRV

Professor Maria Zambon has been the chair of the International Society for Respiratory Viruses (ISRV), an independent professional scientific society and registered charity, since 2020. She is a consultant virologist and head of the WHO National Influenza Centre (NIC) at the UK Health Security Agency (UKHSA) overseeing influenza, MERS, and respiratory viruses.

Her main research interests include the diagnosis of viral infections in humans, especially RNA viruses, the pathogenicity of influenza, and the development of new vaccines and diagnostics for respiratory viruses, particularly influenza. Her PhD on the mechanism of action of amantadine led directly to the identification of a novel class of viral proteins and viral ion channels (influenza M2 protein). This early work developed into a lifelong interest in antivirals for respiratory viral infections and the creation of global surveillance infrastructure for tracking the emergence of antiviral resistance.

Industry Sponsored Symposiums

Sunday, August 30, 2026



Room: 207

Time: 12:30 PM – 1:45 PM

Title: Moving the Needle: Expanding the Reach of Influenza Vaccination

Monday, August 31, 2026

CSL Seqirus

Room: 202

Time: 7:15 AM – 8:15 AM

Title: Flu Vaccine: From Evidence to Impact

moderna

Room: 202

Time: 12:30 PM – 1:45 PM

Title: Influenza Vaccines: Current Evidence and Future Directions

sanofi

Room: 207

Time: 12:30 PM – 1:45 PM

Title: Elevating the Patient Experience in Influenza & COVID-19 Vaccination

Tuesday, September 1, 2026

ERADIVIR

Room: 202

Time: 12:30 PM – 1:45 PM

Title: Beyond the 48-Hour Window: Redefining Success in Influenza Therapeutics

Pfizer

Room: 207

Time: 12:30 PM – 1:45 PM

Title: Reframing RSV in adults: Uncovering the hidden burden of RSV in adults and advancing evidence for prevention strategies

Sunday, August 30, 2026

4:30pm – 6:00pm	Burden of Disease and Risk Factors Sue Huang - Incidence and Risk Factors of Influenza, Respiratory Syncytial Virus, and COVID-19 within the SHIVERS-III Community Child Cohort Study Pieter de Boer - Comparison of the Annual Disease Burden of Acute COVID-19 and Seasonal Influenza in the Netherlands, 2020-2024, in Disability-Adjusted Life Years Zhe Zheng - Reporting Fractions of Laboratory-Confirmed SARS-CoV-2, Influenza, and RSV in ICD-10 Coding: Estimates of Correction Factors for Underreporting Sarah Foulkes - Targeted Metagenomic Analysis of Causes of Influenza-Like and Respiratory Illness in Healthcare Workers in the UK, Winter 2025/26: The SIREN Study Mia Zhu - Recent SARS-CoV-2 Infection and Risk of Asymptomatic Influenza Illness Giulia Pullano - Human Behavior and Built Environments Drive Influenza Seasonality in the United States
4:30pm – 6:00pm	Immune Response in Special Populations Tal Einav - Divergent Immunity in Early Life: Using High-Resolution Dynamics of Infant Influenza Vaccine Responses to Predict Future Immunity Koen Vink - The Effect of Influenza Vaccination Timing on Antibody and T-cell Responses in Older Adults: the Chrono-Vax trial Justin McClendon - Association of Pre-existing Antibodies with H3N2 Viral Shedding Duration and Clinical Outcomes in Household Transmission Study in Nicaragua Kristin Boswell - Previous Influenza Exposure and Vaccine Platform Impact CD4+ T cell Responses Following Vaccination with H2 Hemagglutinin Smrithi Sugumaran Menon - T cell Responses in Children with Influenza-related Critical Illness. Alisa Kachikis - Comparison of Maternal Influenza-specific Antibody Concentrations over Time in Consecutive Pregnancies With and Without Maternal Influenza Vaccination
4:30pm – 6:00pm	Implementation Approaches to Respiratory Virus Epidemiology and Interventions Xinyi Li - Optimal Dilution Points for Reliable Antibody Titer Prediction: Four-Parameter Logistic Model for SARS-CoV-2 Maria Zambon - Alternatives to Venepuncture for Assessment of SARS-CoV-2 and Influenza Antibodies in Care Homes Jakob Jonnerby - Resolving SARS-CoV-2 Aerosol and Fomite Transmission and Implications for Public Health Interventions Seran Hakki - HOPPER: A Scalable Household Transmission Platform for Rapid Evidence Generation in Respiratory Virus Pandemics Deborah Fuller - A Universal Influenza Nucleic Acid Vaccine Affords Broad Protection in Nonhuman Primates via Induction of Systemic and Mucosal Immune Responses Annette Fox - Recombinant Influenza Vaccines Induce Antibodies With Broader A(H3N2) Virus Reactivity Among Repeat Vaccinees Compared to Egg- or Cell-Based Vaccines

Sunday, August 30, 2026

4:30pm – 6:00pm	Virulence and Transmission of H5N1
	Yoshihiro Kawaoka - Characterization of an Avian Precursor of Bovine HPAI H5N1 Viruses
	Gracie Quirk - Determinants of Mammalian Transmission of H5N1 D1.1 Viruses in Ferret Model
	Min Levine - Population Immunity to Highly Pathogenic Avian Influenza 2.3.4.4b A(H5N1) Viruses in the United States
	Shuofeng Yuan - Key Determinants in PB2-mediated Mammalian Adaptation of Clade 2.3.4.4b A (H5N1) Virus
	Ahmed Elsayed - Enhanced Pathogenicity and Transmissibility of Human-Origin Avian Influenza H5N1 Clade 2.3.4.4b Genotype B3.13 Compared to D1.1 in Mice and Ferrets
	Jasmina Luczo - From Nose to Neuron: Evaluating H5 Clade 2.3.4.4b and Australian H7 HPAIV Replication in Human and Chicken Ex Vivo Models

Monday, August 31, 2026

11:00am – 12:30pm	Antibody Landscapes and Immune Responses
	Jade Yangyupei Yang - Antibody Landscape Following Multiple COVID-19 Vaccinations and Omicron Infections
	Min Li - Investigating the Antibody Ceiling Effect and Antibody Diversification Following Repeated Influenza Vaccination in Older Adults
	Aisha Hegab Souquette - Integrated Drivers of Basal and Acute Immunity in Diverse Human Populations
	Cecile Viboud - Nobody Is Naïve: The Role of Imprinting and Demography in Shaping Future A/H5N1 Pandemic Risk Rahul Subramanian - Quantifying Individual and Population-Level Effects of Influenza Vaccines in the Face of Imprinting and Antigenic Evolution
	Ana Atti - Influenza Neutralising Antibody Responses and Protection in Vaccinated Healthcare Workers: The 2023-24 SIREN Study
11:00am – 12:30pm	Novel Vaccines to Enhance Immunity
	Hualan Chen - A Nanobody-Based Proteolysis-Targeting Chimera Offers Broad-Spectrum Protection Against Diverse Influenza Virus Infections
	Shiho Chiba - Trivalent M2SR Intranasal Vaccine Provides Greater Mucosal Immunity than an Inactivated Influenza Vaccine in a Preclinical Model
	David Bauer - Engineering the Established Live-Attenuated Influenza Vaccine as a Mucosal Vaccination Platform for Diverse Respiratory Pathogens
	Oliver Dibben - Robust Live Attenuated Influenza Vaccine Virus Replication Drives Protection Against Antigenically Distinct Challenge
	Matthew Frieman - Optimizing an Avian Influenza Vaccine Using a Novel Bacterial Enzymatic Combinatorial Chemistry (BECC) TLR4 Adjuvant
	Ryan McNamara - Protective Neutralizing and Non-Neutralizing Antibody Networks Against Human and Avian Influenza Virus Are Influenced by Compartment

Monday, August 31, 2026

11:00am – 12:30pm	Prevention of Avian Influenza Viruses Kristina Lu - Primary Safety and Immunogenicity Assessment of A/H5N8 Inactivated Monovalent Influenza Vaccines at Different Antigen Dose Levels Adjuvanted with AS03 John Kash - Comparative Systems Biology Analysis of Nasal Mucosa and Peripheral Blood From H1N1pdm09, H3N2, and Avian H10N7 Influenza a Human Challenge Studies Frank Struyf - Homologous and Heterologous Humoral Immunogenicity of AS03-Adjuvanted H5N1 A/Indonesia/2005 and H5N8 A/Astrakhan/2020 vaccines Franklin Toapanta - Contribution of Influenza H5 Head and Stalk Domains to Functional Non-Neutralizing Antibodies After Intranasal rH5-NE Vaccination in Humans Luca Giurgea - Dose-Escalation Study of a Low Pathogenicity Avian H10N7 Influenza Virus in a Healthy Human Challenge Model Ryuta Uraki - Protective Effect of A(H5N8) Stockpiled Vaccine Against a Human Isolate of Bovine A(H5N1) Influenza Virus
11:00am – 12:30pm	Use of Implementation Science to Assess Motivation and Barriers to Vaccination at the Global, Country and Sub-Population Levels Haley Farrie - Vaccine Availability for Past Pandemics: Implications for Future Responses Nneoma Harris - Geospatial Distribution and Determinants of Laboratory-Confirmed Influenza and Vaccination Coverage in Guyana (2023-2026) Annette Regan - Timing of Influenza Vaccination Decisions During Pregnancy: Evidence from a North American Prospective Preconception Cohort Julia Petras - Leveraging U.S. President's Emergency Plan for AIDS Relief to Increase Influenza Vaccination among People Living with HIV: South Africa, 2024 Eric Osoro - Healthcare Worker Influenza Vaccination at Scale in Kenya: Two-Phase Implementation Evidence from Four Counties, 2023-2025 Ravi Jhaveri - Using "Pop-Up" Clinics and Live-Attenuated Influenza Vaccine to Promote Flu Vaccination Among College Students Over Multiple Seasons
4:30pm – 6:00pm	Assessment of Immunity Against Influenza Vaccines Spencer Stonier - Phase 1 Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Immunogenicity of an Adjuvanted Group 1/2 INF a HA Stem Vaccine Mansoor Ashraf - Increased Anti-N2 Neuraminidase Immune Responses With MF59-Adjuvanted aQIVc vs aQIV and QIVr and Implications for A/H3N2 Protection in Older Adults LaSonji Holman - A Phase 1 Trial of the Safety, Tolerability, and Immunogenicity of a Quadrivalent Mosaic Influenza Nanoparticle Vaccine in Healthy Adults James Campbell - Safety and Immunogenicity of Intranasal M2SR H3N2 Influenza Vaccine in Healthy Children: A Phase 1b Randomized Controlled Trial Arik Elfassy - MF59-Enhanced Cell Based Influenza Vaccination Elicits Superior H3 Specific T Cell Immunity in Adults ≥50 Years: Results from Phase 3 Immunogenicity S Laiba Uroog - Immunization With Novel H1 Hemagglutinin-Mini Stem Antigens Elicits Broadly Cross-Reactive, Antibody Responses and Heterosubtypic Influenza Protection

Monday, August 31, 2026

4:30pm – 6:00pm	Ecology and Immunologic Responses to H5N1 Anne Pohlmann - Successive Genotype Turnover and Multi-Host Involvement Shape Consecutive High-Pathogenicity Avian Influenza A(H5) Epizootic Waves in Germany Natalie Tarbuck - The Epizootic Continues: Natural Immunity Limits Disease but Permits Breakthrough Replication of Divergent H5N1 Strains in Dairy Cattle Walter Harrington - More Than Mallards: Experimental Infection With HPAI A(H5N1) D1.1 Reveals Species-Specific Outcomes in Dabbling, Diving, and Sea Ducks Reanna Gregory - Divergent Antibody-Mediated Population Immunity to H5, H7 and H9 Subtype Potential Pandemic Influenza Viruses Heather Machkovech - Evolutionary Constraints Limit Additional Mammalian Adaptation Of Bovine-Derived H5N1 Influenza Viruses In Ferrets Clara Malekshahi - Wild Bird Ecology is Driving the Transmission and Dissemination of HPAI H5N1 in North America
4:30pm – 6:00pm	Transmission Hualei Xin - Comparative Transmissibility of SARS-CoV-2, Influenza Virus, and Common Human Coronaviruses in the Post-Pandemic Era: A Prospective Cohort Study Wenjie Han - Epidemiological and Evolutionary Drivers Behind the Probable Extinction of Influenza B/Yamagata Joseph Carreon - Influenza in the Fields: Incidence and Household Transmission in the AGRI-CASA Study, Southwest Guatemala, 2023-2024 Yani Wu - Indirect Protection from Antibody Titers Against Influenza A Virus Infection in Households Chengyao Zhang - Host Genetic Variants Shape Influenza A Susceptibility and Transmission in Households Liping Peng - Correlated Infectiousness Between Index and Secondary Cases Shapes Transmission Heterogeneity and Epidemic Control of Respiratory Viruses
4:30pm – 6:00pm	Understanding Influenza Vaccine Immunity Ivan Kosik - C1q Expands Anti-Stem Influenza Antibody Function and Broadens Viral Escape Sook-San Wong - Systematic Profiling Reveals Breadth of Antibody Responses to Avian Influenza Neuraminidases Elicited by Past Influenza Pandemics Raveen Rathnasinghe - Neuraminidase Immunity Complements Hemagglutinin To Reduce Influenza Viral Burden Across Challenge and Transmission Models Shane Crotty - Local B-Cell Immunity and Durable Memory Following Live-Attenuated Influenza Intranasal Vaccination of Humans Justin Shephard - TLR Agonist-linked, Stabilized N1 Neuraminidase Tetramers Confer Homologous and Heterologous Protection Against Influenza A Omid Arhami - H3N2 Antigenic Cartography Identifies Viral Population Geometry, Together With Antigenic Distance Determine Seasonal Vaccine Effectiveness

Tuesday, September 1, 2026

11:00am – 12:30pm	Animal and Non-Animal Models of Influenza Hualan Chen - Control of Highly Pathogenic Avian Influenza Through Vaccination Angel Ma - Enhanced Therapeutic Potential of Hypoxia-Preconditioned Mesenchymal Stromal Cell-Derived Extracellular Vesicles for Influenza A/H5N1 Lung Injury Michael Chan - Comparison of B4.7.4 and B4.7.2 Influenza H9N2 Viruses in Human Respiratory Explants and Organoids Saira Hussain - Precision-Cut Lung Slices: Development of a High-Throughput Ex-Vivo Model To Study Influenza Virus Infections Mariana Andrioli Pinheiro - Interspecies Replication Kinetics of Avian Influenza Viruses in Chicken, Quail, and Duck Cell Lines Lucas Ferreri - The Guinea Pig as a Survival Model To Study the Evolution of H5 Highly Pathogenic Avian Influenza Viruses in Mammals
11:00am – 12:30pm	Exploring Influenza Immunity David Wentworth - Advancing Protection Against Influenza Through Neuraminidase-Targeted Immunity Shivaprakash Gangappa - Impact of Obesity on Antigen-Specific T Cell Response to 2023-24 Seasonal Influenza Vaccination Bingyi Yang - Antibody Landscapes Help Explain Influenza A(H3N2) Infection and Vaccine Responses Annette Fox - Deep Immune Characterization Following Controlled Human A/Texas/71/2017 (H3N2) Infection of Healthy Australian Adults Lilach Friedman - Immune Profiling at Hospital Admission is Associated with Influenza Disease Severity Tamara Garcia-Salum - Dysregulated Host Responses Are Associated With Severe Influenza a Virus Disease in Individuals With Arterial Hypertension
11:00am – 12:30pm	Improving Care of Influenza Infections Beatrice Sim - Post Pandemic, but Not Post Impact: Respiratory Viruses in Transplanted Patients Tristan Clark - Diagnostic Accuracy of Nasal Versus Capillary MxA for Respiratory Virus Detection in Symptomatic Adults Xin Pan - Early Prediction of Intensive Care Unit Admission in COVID-19: Development and Retrospective Validation of a Novel Risk Score Takuma Kobayashi - Bacterial Coinfection is Associated with Life-threatening Influenza Lower Respiratory Tract Infection in Children Chunyan Xiang - NK Cell Count as a Universal and Non-linear Predictor of Severity in Influenza and COVID-19 Srinivas Murthy - Oseltamivir for Critically Ill Patients with Influenza

Tuesday, September 1, 2026

11:00am – 12:30pm	Vaccine Effectiveness Xuan Yu - Within-Season Waning of Influenza Vaccine Effectiveness Against Hospitalisation Among Children in Hong Kong, 2015–2025: A Test-Negative Study Linyi Chen - Heterogeneity in Influenza Vaccine Effectiveness in Pediatric Acute Respiratory Illness in Hospital and Outpatient Settings: A Latent Class Analysis Carrie Reed - Influenza Vaccine Effectiveness Against Medically Attended Influenza, US Flu VE Network, 2025–26 Influenza Season Xiaotong Huang - Impact of Vaccine Strain Changes, Sequence Mismatch, and Prior Season Incidence on Repeated Seasonal Influenza Vaccination Effectiveness Francisco Nogareda - Influenza Vaccine Effectiveness Across Seven Latin American Countries: REVELAC i 2025 Results Meagan Fitzpatrick - Reassessing Expectations for Indirect Effects of Influenza Vaccination: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
4:30pm – 6:00pm	Assessment of New Influenza Vaccines Eve Versage - Evaluating Immunogenicity by ELLA of Formulations of an Adjuvanted Cell Culture-derived A/H2N3 Subunit Influenza Virus Vaccine in Healthy Adults Kayla Hanson - Humoral Correlates of Protection Against Influenza B Virus Infection Lorena Preciado Llanes - Increased Antibody Breadth with Two A/H3N2 Antigens in a Human Influenza Vaccine Trial Alexandre Levert - A Booster Dose of OVX836 - a Broad-Spectrum Nucleoprotein Based Influenza Vaccine - is Safe and Immunogenic in Healthy Adults Isabel Leroux-Roels - A Phase 2 Trial Assessing Immunogenicity and Safety of an mRNA-Based Seasonal Influenza Vaccine Candidate Encoding Hemagglutinin and Neuraminidase Frank Albano - Immunogenicity and Safety of Higher-Dose MF59-Adjuvanted Quadrivalent Cell-Derived Influenza Vaccine (aQIVc): A Phase 3 Randomised Controlled Trial
4:30pm – 6:00pm	Forecasting Xiangjun Du - A Comprehensive Way Forward for Control of Influenza: From Antigenic Prediction, Vaccine Recommendation to Epidemic Forecasting Simon Cauchemez - Advancing Influenza Forecasting Models for Improved Real-Time Predictions Melissa Rolfes - Beyond Test Positivity: Monitoring Influenza-Attributable Illness Signals Earlier Epidemic Activity Emily Bendall - Measuring Fitness of Imported Influenza A Lineages Through Phylodynamic Analysis of Repeated Introductions Amanda Perofsky - Linking Prior Immunity, Vaccination, and Subtype Circulation to Long-Term Projection Accuracy: An Evaluation of the U.S. Flu Scenario Modeling Hub Jennifer Zhong - A Bayesian Framework for Population Level Influenza Immunity Measurement using Routine Serology

Tuesday, September 1, 2026

4:30pm – 6:00pm	Global Threat of Influenza Viruses Lin Wang - Decoding Antigenic Evolution of Influenza H3N2 Virus by Genomics and Deep Learning Martin Muigano - Cohort-Specific Antigenic Evolution of Influenza A/H3N2 in Tropical Regions Reveals Recurrent Immune Escape Hotspots Noroso Razanajatovo - Evolutionary Dynamics and Hub-Driven Dissemination of Seasonal Influenza Viruses in Madagascar, 2019-2025 Jenna Guthmiller - Antigenic Drift in the Receptor Binding Site of H1N1 Balances Antibody Evasion and Receptor Binding Mariana Leguia - Outbreak of H9N2 Avian Influenza Viruses in Lesser Rhea in the Andean Highlands of Peru, June-July 2025 Brown Bulloch - Phylogenetic Analysis and Phenotypic Evaluation of Zoonotic Influenza A/H9N2 Viruses From Cambodia
4:30pm – 6:00pm	Zoonotic Influenza Oliver Eales - Developing On-Farm Management Strategies for Reducing H5N1 Transmission in Dairy Cattle Matthew Scotch - Rapid Expansion of HPAI H5 Clade 2.3.4.4b Genotype D1.1 Across North American Flyways During Fall 2024 Avian Migration Martha Nelson - Emergence of D1.1 Reassortant H5N1 Avian Influenza Viruses in North America Jennifer Havens - Factors Impacting Spread of A/H5N1 D1.3 in Ohio and Indiana Poultry Qiqi Yang - Dynamics and Control of Highly Pathogenic H5 Avian Influenza in a Threatened Pelican Population Anna Jaeger - Within- and Between-Host Dynamics of Highly Pathogenic Avian Influenza in Domestic Birds from Pennsylvania Farms and Live Bird Markets

Wednesday, September 2, 2026

10:30am – 12:00pm	Clinical Applications of basic Influenza Research Limin Zhang - AM-Derived IL-10 Activates IL1R1-High Fibroblasts To Drive CXCL1-Dependent Pathogenic Neutrophil Recruitment and Lung Injury in Early Severe Influenza Ian McGovern - Meta-Analysis of Relative Vaccine Effectiveness of Adjuvanted (aTIV/aQIV) vs Standard-Dose Influenza Vaccines (TIV/QIV) for Prevention of Influenza Emi Takashita - Baloxavir Susceptibility of Seasonal Influenza Viruses in Japan Since Its Introduction, 2017/18-2025/26 Saira Hussain - Development of a Novel Long-Acting Pan Antiviral to Influenza Tanya Novak - Elevated sRAGE is a Peripheral Blood Biomarker of Life-Threatening Influenza Lower Respiratory Tract Infection in Children Maclaine Parish - Combined Antiviral and NSAID Therapy Mitigates Placental Inflammation and Fetal Complications Triggered by Maternal H1N1 Infection
-------------------	--

Wednesday, September 2, 2026

10:30am – 12:00pm	Exploring Human Responses to Influenza Infection Christopher Woods - A Multicenter, Adaptive, Dose-Ranging Human Challenge Study of a Recombinant Influenza A (A/Texas/71/2017 (H3N2)) Jiamu Yang - High Resolution Temporal Physiological Signatures of Respiratory Virus Infection in Human Viral Challenge Deryn St. James - Household Dynamics of Influenza Transmission and Susceptibility Ashley Wozinak - First Clinical Validation of Bispecific Antigenic Immunotherapy (BAiT): Single-Dose EV25 Achieves 98% Viral Reduction in Human Influenza A Challenge Alex Mann - High Febrile Illness Rates in Dose-Ranging Characterisation of a Contemporary Influenza B Human Challenge Model in Healthy Adults Rachel Chun Yee Tam - Single-cell analysis revealed differential immune responses against clade 2.3.4.4b H5N1 virus and seasonal influenza virus in respiratory organoids
10:30am – 12:00pm	Late Breaking Abstract Session Amanda Payne - Influenza COVID-19 and RSV Vaccine Effectiveness Against Hospitalization Among Adults During the 2025-2026 Season in the United States Sebastian Gygli - BPL-1357 Vaccination Protects Mice Against Lethal Challenge With H5N1 Highly Pathogenic Avian Influenza Virus Clade 2.3.4.4b Aaron Blouin - Ongoing Phase 1/2 Evaluation of Subcutaneous EV25 a Novel Antibody-Recruiting Small Molecule for Influenza Including a Late-Treatment (>48hr) Cohort C. Buddy Creech - Immunogenicity of Two Doses of a Novel Influenza A/H5 Antigenically Central (AC)-Anhui mRNA-LNP Vaccine in Healthy Adults Srinivas Nanduri - Advancing Pandemic Preparedness: Phase 1/2 Safety and Immunogenicity of an H5 mRNA Influenza Vaccine Candidate Isabel Leroux-Roels - Phase 2b ASUNIVA topline results on efficacy safety and immunogenicity of OVX836 a broad-spectrum influenza A vaccine
10:30am – 12:00pm	Surveillance Mamadou Malado Jallow - Filling the Gap in Influenza Surveillance: Integrating Swine and Live bird market Surveillance into a One Health Early Warning System in Senegal Mary Sinnathamby - Strengthening Respiratory Pandemic Surveillance in the UK Using the WHO MOSAIC Approach Dikeledi Kekana - Right-Sizing Influenza Genomic Surveillance: Detection Capacity and Subclade Diversity Across Six African Countries (2023-2025) Mercy Cheptoo - Leveraging Routine Mortality Data to Detect Respiratory and Influenza Like Mortality Signals in Kenya, 2025 Juma Maleve - Clinical Outcomes Among Preterm Infants Hospitalized with Severe Acute Respiratory Illness: A Kenyan Sentinel Surveillance Study, 2021-2025. Marc Rondy - Operationalizing Collaborative Surveillance: The Mosaic Framework as an Innovative Tool for Strengthening Public Health Strategies

Poster Sessions

Poster Sessions

Posters will be on display and available for viewing throughout the duration of the conference. Presenting authors will be available at their posters during the specific days listed below.

Themes: Clinical Science, Implementation, Virology and Pathogenesis and Public Health

Clinical Science	Implementation	Virology & Pathogenesis	Public Health
------------------	----------------	-------------------------	---------------

Poster Number	Date	Title	First Name	Last Name
P01.01	Monday, August 31	Preliminary Attack Rate and Optimal Dose from an Influenza A/Arkansas/08/2020 (pH1N1) Dose Escalation Controlled Human Infection Study	Justin	Ortiz
P01.02	Tuesday, September 1	Serological Evidence of Preferential Recognition of Group 1 Influenza Viruses in Individuals with Detectable H5N1 Reactivity	Anne	Ventura
P01.03	Monday, August 31	Clinical manifestations of adult patients requiring influenza associated hospitalization during, pre-, and post-COVID-19 pandemic period	Masafumi	Seki
P01.04	Tuesday, September 1	Influenza-Associated Neurologic Complications in Hospitalized Children During and After the COVID-19 Pandemic	Byung Ok	Kwak
P01.05	Monday, August 31	Impact of Comorbidities and Prior Flu Vaccination on Acute Kidney Injury and Renal Recovery in Influenza and RSV: A retrospective study (2014-2023)	Peter	Cheung
P01.06	Tuesday, September 1	Factors Associated with Antiviral Treatment in Pediatric Hospitalized Patients with Influenza, FluSurv-NET, 2021-22 through 2024-25 Seasons	Alissa	O'Halloran
P01.07	Monday, August 31	The Underappreciated Clinical Burden of Rhinovirus in Hospitalized Adults	Marta	Nunes
P01.08	Tuesday, September 1	Nosocomial Respiratory Viral Transmissions During the Influenza Season: Incidence and Risk Factors in a Prospective Cohort	Ziyi	Chu
P01.09	Monday, August 31	Relative effectiveness of recombinant compared to standard dose influenza vaccines against hospitalization among adults 50-64 years old over 4 years	Krissy	Moehling Geffel
P01.10	Tuesday, September 1	Increased Influenza Incidence but Declining Severity in a Nicaraguan Pediatric Cohort After the SARS-CoV-2 Pandemic	Ellen	Beach
P01.11	Monday, August 31	Early Life Seasonal Coronavirus Exposures and Subsequent SARS-CoV-2 Infection Risk in the Nicaraguan Pediatric Influenza Cohort Study	Allison	Seeley
P01.12	Tuesday, September 1	Symptoms and Medical Attention Associated with Non-coinfected Influenza and RSV Infections in US children: 2019-2025	Daniel	Payne
P02.01	Sunday, August 30	Diagnostic Partnerships with the Biomedical Advanced Research and Development Authority	Karl	Erlandson
P02.02	Monday, August 31	Impact of a point of care testing programme on respiratory swabbing activity, viral detection, and acute respiratory infection coding in English prima	Ahreej	Eltayeb
P02.03	Sunday, August 30	Central Influenza Immunoassay Laboratory	Hongquan	Wan

Poster Sessions

Clinical Science

Implementation

Virology & Pathogenesis

Public Health

Poster Number	Presentation Date	Title	First Name	Last Name
P02.04	Monday, August 31	Itaconate-Linked Gene Signatures Stratify Severe Influenza Risk: A Bioinformatics-Driven Prognostic Framework	Xin	Pan
P02.05	Sunday, August 30	Sample Integrity Verification of SARS-CoV-2 Whole Genome Sequencing Data in Ensitrelvir SCORPIO-PEP Phase 3 Clinical Study	KEIKO	BABA
P02.06	Monday, August 31	Relationship between viral load and lateral flow test line intensity among outpatients in Hong Kong	Ben	Cowling
P02.07	Sunday, August 30	Reviewing Mechanism of Action of MF59-Adjuvanted Influenza Vaccine for Enhancing Innate and Adaptive Immune Responses	Emanuele	Ciglia
P03.01	Monday, August 31	JUST BREATHE: A Phase 2 Platform Trial of Multiple Host-Directed Therapeutics for Hospitalized Patients with Acute Respiratory Distress Syndrome	Cassandra	Spector
P03.02	Tuesday, September 1	Beyond Direct Antivirals: EV148 Recruits Host Antibodies to Drive Immune-Mediated RSV Clearance in Neonatal Lambs	Jeffery	Nielsen
P03.03	Monday, August 31	Phase 3 ANCHOR Study of MK-1406 for Influenza Prevention in Participants at Higher Risk for Complications	Quinn	Humes
P03.04	Tuesday, September 1	Adult patients requiring influenza associated hospitalization treated by baloxavir/marboxil in a prospective multicenter cohort study via internet surveillance	Masafumi	Seki
P04.01	Sunday, August 30	Intranasal M2SR Vaccine Induces Human Serum Fc Receptor-binding Antibodies Associated with Influenza Protection	Pamuk	Bilsel
P04.02	Tuesday, September 1	Seasonal Influenza Vaccination Induces Hemagglutinin-Specific B Cells in the Lower Airways	Tertuliano	Alves Pereira Neto
P04.03	Sunday, August 30	Reactogenicity and Safety of Co-Administered High Dose or Recombinant Influenza Vaccine with an Adjuvanted Protein-Based COVID-19 Vaccine	Rachna	Gupta
P04.04	Tuesday, September 1	Temperature Stability of BPL-1357, A BPL-Inactivated, Whole-Virus, Universal Influenza Vaccine	Camellia	Banerjee
P04.05	Sunday, August 30	Changes in Circulating Cytokines after Influenza Vaccination	Ewan	Plant
P04.06	Tuesday, September 1	A Dose-Escalation Study to Evaluate the Safety and Immunogenicity of an mRNA-LNP Encoding for Stabilized H1 HA Stem Ferritin Nanoparticle in Adults	Emmanuel	Walter
P04.07	Sunday, August 30	Study of Novavax's COVID-Influenza Combination and Stand-alone Influenza Vaccines in Adults ≥65 years	Chijioke	Bennett
P04.08	Tuesday, September 1	Clinical Evaluation of a Novel Needle-Free Injection System Utilizing Automotive Gas-Generator Technology for Influenza Immunization	Yoshiaki	Yamagishi
P04.09	Sunday, August 30	First-Time-in-Human Study to Assess Safety and Immunogenicity of a 2-dose mRNA-Based H5 Influenza Vaccine Candidate in Younger and Older Adults	Frank	Struyf
P04.10	Tuesday, September 1	Impact of COVID-19 Vaccine Waning and Variant Durability: The Booster Epidemiological Evaluation of Health, Illness and Vaccine Efficacy Study	Rebecca	Fink
P04.11	Sunday, August 30	Digitally Engineered Seasonal and Universal Influenza Vaccines Enable Broad Protection Against Seasonal and Zoonotic Threats	Jonathan	Heeney

Poster Sessions

Clinical Science	Implementation	Virology & Pathogenesis	Public Health
------------------	----------------	-------------------------	---------------

Poster Number	Presentation Date	Title	First Name	Last Name
P04.12	Tuesday, September 1	Modelling Protection for Day One: Advancing Broadly Protective Seasonal Influenza Vaccines to Mitigate Pandemic Impact	Lakshmi	Jayashankar
P04.13	Sunday, August 30	COMPARE Trial: Recombinant Protein Nuvaxovid COVID-19 Vaccine Significantly Less Reactogenic than mRNA mNEXSPIKE COVID-19 Vaccine	Marcel	Curlin
P04.14	Tuesday, September 1	Comparison of Age-Specific Side-Effect Profiles Following Inactivated and Live Attenuated Influenza Vaccination in a School-Based Programme	Jiajie	Chen
P04.15	Sunday, August 30	Immunogenicity and Safety of an mRNA-based Seasonal Influenza Vaccine Candidate Encoding Hemagglutinin and Neuraminidase: A Phase 2 Randomized Trial	Kyu Bin	Oh
P04.16	Tuesday, September 1	Evaluating Serologic Clinical Biomarkers as Correlates of Protection (CoP) in mRNA-based Influenza Vaccination	Lingyi	Zheng
P04.17	Sunday, August 30	Shared peaks, divergent kinetics: influenza subtype temporal phenotypes in a contemporary human challenge panel	Alex	Mann
P04.18	Sunday, August 30	Maternal Influenza Antibody Concentrations in Immunosuppressed Individuals following Vaccination during Pregnancy	Sharon	Kung
P04.19	Sunday, August 30	Influenza vaccine effectiveness against hospitalizations in the eastern part of the WHO European Region: Findings from the EuroSAVE Network, 2024-2025	Mark	Katz
P04.20	Tuesday, September 1	Vaccine Effectiveness of NVX-CoV2705 in Reducing COVID-19 Hospitalization in Medicare Beneficiaries vs the Unvaccinated in the 2024-2025 Season	Matthew	Rousculp
P05.01	Sunday, August 30	Patterns and predictors of antiviral prescriptions among U.S. military active duty service members with influenza: insights to advance implementation	Simon	Pollett
P06.01	Sunday, August 30	Implementing genomic surveillance for influenza in Madagascar: from human-focused surveillance to a One Health transition	JEAN-MICHEL	HERAUD
P06.02	Monday, August 31	Post-COVID-19 Pandemic Expansion of Influenza Virus Sequencing Capacity in Central America: More Locally Generated Sequences and Faster Submission	Edwin	Vásquez Fuentes
P07.01	Sunday, August 30	Association between knowledge of own antibody titer level and subsequent COVID-19 booster vaccine uptake in a prospective cohort study in Hong Kong	Caitriona	Murphy
P07.02	Monday, August 31	Vaccination Acceptance in Emerging Infectious Disease Scenarios Across Transmission and Severity Levels: Effects of Vaccine Safety Profiles	Ji Yun	Noh
P08.01	Sunday, August 30	Development of a best practice implementation guide for inpatient influenza vaccination programs	Ravi	Jhaveri
P08.02	Monday, August 31	Ongoing Manufacturing Improvements to Ensure Timely and Sustainable Supply of Influenza Vaccines	Beverly	Taylor
P08.03	Sunday, August 30	Evaluating Operational Efficiencies in School-Based Influenza Vaccination Programme of Hong Kong	CHUN WAI JEROME	LEUNG

Poster Sessions

Clinical Science	Implementation	Virology & Pathogenesis	Public Health
------------------	----------------	-------------------------	---------------

Poster Number	Presentation Date	Title	First Name	Last Name
P08.04	Monday, August 31	Parental Acceptance Profiles of a Newly Implemented “Hybrid Mode” Approach under the School Based Influenza Vaccination Programme in Hong Kong	SZE SZE	NING
P08.05	Sunday, August 30	Optimizing School-Based Influenza Vaccination: Intentions, Hybrid Mode Uptake, Vaccine Preferences, and Decision-Making in Hong Kong	Ka Yan	Ng
P09.01	Sunday, August 30	Spillover of Avian Influenza Viruses into Livestock in the Middle East	Ghazi	Kayali
P09.02	Monday, August 31	Two Decades of Highly Pathogenic Avian Influenza A(H5N1) in Germany: Shifts in Seasonality, Reassortment, and Genetic Dynamics	Ann Kathrin	Ahrens
P09.03	Sunday, August 30	Global Evolutionary Dynamics and Host Adaptation of H6 Avian Influenza Viruses in Eastern Asian Poultry	Jianhui	Wang
P09.04	Monday, August 31	The Evolution of MX1 Antiviral Escape in the 1918 H1N1 Pandemic	Stephanie	Williams
P09.05	Sunday, August 30	Mapping zoonotic Bat Coronaviruses with spill over risk to humans	Rahul	Ahuja
P09.06	Monday, August 31	Genetic Characterization, Pathogenicity, and Virulence of Highly Pathogenic Avian Influenza H5Nx Viruses Isolated in Egypt	Rabeh	El-Shesheny
P09.07	Sunday, August 30	Age-Dependent Within-Host Evolution of Influenza A Virus Across the Respiratory Tract	Katherine	Johnson
P09.08	Monday, August 31	Enhancements to next-generation sequencing strategies during the U.S. CDC’s 2024-2025 avian influenza A(H5N1) emergency response	Marie	Kirby
P09.09	Sunday, August 30	Selection Dominates Influenza A Virus Evolutionary Dynamics Within Hosts	Vedhika	Raghunathan
P09.10	Monday, August 31	H3Nx influenza virus evolution is driven by host specific patterns of reassortment and selection	Maria	Maltepes
P09.11	Sunday, August 30	Resident versus Transient: Contrasting Global Migration and Transmission Success of Influenza B Victoria and Yamagata Lineages	Huan	Liu
P09.12	Monday, August 31	Synonymous Genomic Architecture of H5Nx Influenza Virus Reveals Potential of Systemic Dissemination and Tropism	Teng	Long
P09.13	Sunday, August 30	Beyond HA1: proteome-wide assessment of sequence signals associated with HAI phenotype in influenza A(H3N2)	Bingyi	Yang
P09.14	Monday, August 31	Rapid development and optimization of a 5-plex RT-qPCR assay for sensitive detection of seasonal influenza A and B strains	Christopher	Patton
P09.15	Sunday, August 30	Regional emergence and persistence of antigenically drifted and reassorted Influenza B Virus Lineages in 2024-26	Elgin	Akin
P09.16	Monday, August 31	Regional diversification of HPAI clade 2.3.4.4b genotypes in East Asia and development of an automated genotyping system, GenoFlu-EastAsia.	Jiyun	Kim

Poster Sessions

Clinical Science

Implementation

Virology & Pathogenesis

Public Health

Poster Number	Presentation Date	Title	First Name	Last Name
P09.17	Sunday, August 30	Genetic characteristics and pathogenesis of H5Nx clade 2.3.4.4b high pathogenicity avian influenza viruses in South Korea, 2024-2025	Ra Mi	Cha
P09.18	Monday, August 31	Whole-genome sequencing of pan-influenza A virus by target capture from low-viral-load human and animal clinical specimens	Nobuhiro	Takemae
P09.19	Sunday, August 30	The consequences of adaptation of influenza virus in pigs on virus fitness in both swine and human cells.	Dorothee	Reuss
P09.20	Monday, August 31	Increased evolutionary rate of highly pathogenic avian influenza virus clade 2.3.4.4b following global spread	Dawon	Kim
P09.21	Sunday, August 30	Surveillance of Respiratory Viruses Infection among severe acute respiratory infection cases from Pune, western India (July 2021 to February 2026)	Manohar Lal	Choudhary
P09.22	Monday, August 31	Curating Influenza Zoonotic Mutation Databases by Large Language Models	Brian	Wasik
P09.23	Sunday, August 30	The Clinical and Evolutionary Landscape of SARS-CoV-2 Persistent Infections	Harm	Van bakel
P09.24	Monday, August 31	Forecasting influenza variant frequency and fitness using Multinomial Logistic Regression	Philippa	Steinberg
P09.25	Sunday, August 30	Characterization of a novel reassorted and antigenically drifted Influenza B Virus detected in the 24-25 season in the Johns Hopkins Hospital Network	Corinne	Pierce
P09.26	Monday, August 31	Natural Evolution of Human H3N2 Virus Restricts Mutational Reversibility in Hemagglutinin and Alters Viral Fitness	Weiwen	Liang
P09.27	Sunday, August 30	Age Structured Immunity Shapes Avian Influenza Dynamics in Wild Swans	Amy	Thomas
P09.28	Monday, August 31	Inferring Predictive Models of Influenza Dynamics from Genomic Surveillance Data	John	Barton
P09.29	Sunday, August 30	Sequence characteristics and phylogenetic analysis of H5 subtype avian influenza viruses in Hong Kong (2013-2023)	Chi Kit Patrick	Pun
P09.30	Monday, August 31	Genomic and Epidemiologic Insights from Sentinel Surveillance of Influenza, SARS-CoV-2, and RSV: Respiratory Viruses in Pakistan	Aamir	Amanat
P09.31	Sunday, August 30	Genomic characterization of Influenza and SARS-CoV-2 in Pakistan, 2025-2026	Nazish	BADAR
P09.32	Monday, August 31	Surveillance and Characterization of Novel Seasonal (2025 - 2026) Influenza A H3N2 Viruses Antigenic Drift and Viral Fitness	Guangyu	Zhao
P10.01	Monday, August 31	Maternally Acquired and Infection-Induced Antibody Dynamics Against Influenza B in early childhood: a longitudinal, paired mother-infant cohort study	Wei	Wang
P10.02	Tuesday, September 1	Development of a Multiplex Binding Assay to Investigate Early Childhood Exposure to Influenza Viruses	Shuk Hang	Li
P10.03	Monday, August 31	Hemagglutination inhibition and alternate serologic responses following Influenza A(H3N2) virus infection	Jose	Zambrana

Poster Sessions

Clinical Science

Implementation

Virology & Pathogenesis

Public Health

Poster Number	Presentation Date	Title	First Name	Last Name
P10.04	Tuesday, September 1	Structural basis for sustained recognition of H1N1 hemagglutinin by a subtype-specific monoclonal antibody	Monica	Thakur
P10.05	Monday, August 31	Asymmetric Cross-Reactive Immunity linked to the Global Disappearance of Influenza B/Yamagata	Max	Lee
P10.06	Tuesday, September 1	Structural insights into antibody responses against influenza A virus in its natural reservoir	HUIBIN	LYU
P10.07	Monday, August 31	Comparative Prophylactic Effects of IgG and IgM Targeting SARS-CoV-2 Spike Epitopes	Martina	Kosikova
P10.08	Tuesday, September 1	MERS-CoV antibody landscape is decentralized in infection and occupational camel exposure, with an S2-focused cross-reactivity from SARS-CoV-2	Sophie	Valkenburg
P10.09	Monday, August 31	A Self-Assembling N8 Neuraminidase Enables Antigenic Loop Grafting for Vaccine Design	Pramila	Rijal
P10.10	Tuesday, September 1	Reversing antigen exposure order reprograms epitope targeting and control of infectious influenza virus	Pradeep	Balamalaliyage
P10.11	Monday, August 31	Antigen Affinity Regulates CD8+ Tissue-Resident Memory T cell Development and Protective Immunity in Influenza	Nairita Ahsan	Faruqui
P10.12	Tuesday, September 1	Characterization of a Human Monoclonal Antibody Targeting a Conserved Epitope at the Base of the HA Head of Influenza A(H3N2) Virus	SEIYA	YAMAYOSHI
P10.13	Monday, August 31	A monoclonal antibody targeting the conserved equatorial epitope on the viral neuraminidase from an H5N1 influenza survivor	Lam	Nguyen
P10.14	Tuesday, September 1	Investigating The Role of Antibody Orientation in Fc Receptor Signaling	Dominic	Ansah
P10.15	Monday, August 31	Development of a Fluorescent Microneutralization Assay on Vero Cells for the Analysis of Preclinical Sera Neutralizing Capacity	Charlotte	Anderson
P10.16	Tuesday, September 1	SARS-CoV-2 Antibody-Dependent Natural Killer Cell Activation: A longitudinal study	Mercy	Cheptoo
P10.17	Monday, August 31	Immune History Shapes Specificity of Birth Year-Dependent Antibodies to Emerging A/H3N2 Drifted Viruses	Sydney	Gang
P10.18	Tuesday, September 1	Cross-Reactive Antiviral Activity of EV148 Against Human Metapneumovirus: Preclinical Evidence for a Pan-Pneumovirus BAiT Therapeutic	Conrrad	Nicholls
P10.19	Monday, August 31	Characterization of broadly cross-reactive group 2 hemagglutinin stalk-specific antibodies elicited by H7N9 or H3N2 vaccines in humans.	Gabrielle	Russell
P10.20	Tuesday, September 1	Preliminary Evaluation of CD8+ T Cell Distribution Across Upper and Lower Human Respiratory Compartments During Acute Influenza Infection	Tertuliano	Alves Pereira Neto
P10.21	Monday, August 31	Influenza nucleoprotein response restricted by HLA C*06:02 allele cross-recognizes influenza B and influenza A H3N2 but not influenza A H1N1	Adam	Saidu
P10.22	Tuesday, September 1	Engineering Immunostimulatory Nanoparticles for Antiviral Prevention against Influenza A Infection	Shadin	Doski

Poster Sessions

Clinical Science	Implementation	Virology & Pathogenesis	Public Health
------------------	----------------	-------------------------	---------------

Poster Number	Presentation Date	Title	First Name	Last Name
P10.24	Tuesday, September 1	Isolation of potentially neutralizing antibodies from individuals infected with HPAI H5N1 in Cambodia	Daniel	Islas
P11.01	Sunday, August 30	Development of hMX1 Knock-In Mice for Zoonotic Influenza Risk Assessment	Anastasija	Cupic
P11.02	Tuesday, September 1	Household transmission of influenza before (2016-2020) and after (2020-2024) the seeding and subsequent endemicity of SARS-CoV-2	Jonathan	Temte
P11.03	Sunday, August 30	Characterising the epidemic spread of influenza A(H1N1)pdm09 and A(H3N2) viruses at geographically defined regions	David	Owuor
P11.04	Tuesday, September 1	Whole-body plethysmography of mice as a tool for assessing efficacy of pre-exposure mAb prophylaxis in mice challenged with a TX001, a clade 2.3.4.4b	Douglas	Reed
P11.05	Sunday, August 30	RNA-Based Sex Determination of Mallards Using Oropharyngeal, Cloacal, and Fecal Samples from Avian Influenza Surveillance	Thomas	Hurt
P11.06	Tuesday, September 1	BALB/c and C57BL/6 Mouse Strains Differ in Their Immune Response to Inactivated Influenza Vaccine and Viral Challenge	Malena	Hales
P11.07	Sunday, August 30	Global Remodeling of ADP-Ribosylation by PARP1 Suppresses Influenza A Virus Infection	Zhenyu	Zhang
P11.08	Tuesday, September 1	TRIM21 is a molecular rheostat for influenza A virus replication	Qi Wen	Teo
P11.09	Sunday, August 30	Screening of immune response regulator for drug target of SARS-CoV-2	Joo-Yeon	Lee
P11.10	Tuesday, September 1	Different Pathogenicity of High Pathogenicity Avian Influenza A (H5N1) Viruses Isolated from Poultry in Japan During the 2024–2025 Season	Yoshihiro	Takadate
P11.11	Sunday, August 30	Updated A(H1N1)pdm09 Influenza Virus Ferret Infection Model Permits Refined Antiviral Assessment Using Aerosol Inhalation Challenge	Jessica	Belser
P11.12	Tuesday, September 1	Comparisons of preclinical models for evaluating reactogenicity for self-amplifying mRNA vaccines	Giuseppe	Palladino
P11.13	Sunday, August 30	Highly Pathogenic Avian Influenza H5N1-induced Lung Injury, Regeneration and Remodelling	Tonia	Kam
P11.14	Tuesday, September 1	SARS-CoV-2 Omicron BA.2.86 and JN.1 Demonstrate Differential Respiratory and Intestinal Tropism	Tonia	Kam
P11.15	Sunday, August 30	Comparative Analysis of the Transmissibility of Highly Pathogenic Avian Influenza A(H5N1) Viruses in a Ferret Model	Masayuki	Shirakura
P11.16	Tuesday, September 1	Spatio-Temporal Analysis and Genomic Epidemiology of the SARS-CoV-2 Omicron Variant in Madagascar, 2022-2024 (Observational Study)	Noroso	Razanajatovo
P11.17	Sunday, August 30	Epithelial-Mesenchymal Transition Derived Fibroblasts Are Infected by HPAIV H5 in Mouse Lung Tissues	LI	QI
P11.18	Tuesday, September 1	Evaluation of antiviral treatments for highly pathogenic avian influenza virus infections in feline species	Alivia	Ishee

Poster Sessions

Clinical Science	Implementation	Virology & Pathogenesis	Public Health
------------------	----------------	-------------------------	---------------

Poster Number	Presentation Date	Title	First Name	Last Name
P11.19	Sunday, August 30	Defining the role of interferons in influenza A virus within-host spatial dynamics	Nahara	Vargas-Maldonado
P11.20	Tuesday, September 1	Development of a H1N1 pdm09 Influenza strain for use in a CHIM study to evaluate an intranasal broadly protective influenza vaccine	Amy	Aspelund
P11.21	Sunday, August 30	Development of an Influenza A(H3N2) Ferret Infection Model That Permits Lung Viral Replication Following Intranasal or Aerosol Inhalation Challenge	Harry	Stannard
P11.22	Tuesday, September 1	IL-1 β and TNF Drive Endothelial Dysfunction and Coagulopathy in Acute COVID-19	Helen	Mostafavi
P11.23	Sunday, August 30	Understanding variability in Influenza-associated hospitalization rates and influenza virus genetic characteristics	Yoo-Ah	Kim
P11.24	Tuesday, September 1	Host responses differentiating avian influenza virus transmission phenotypes in ferrets and human respiratory cells	Mark	Zanin
P11.25	Sunday, August 30	Microbiome Alterations in Respiratory Syncytial Virus Infection: A Comparative Analysis	Himanshu	Kaushal
P11.26	Tuesday, September 1	Sex and Obesity Influence Influenza-Associated Cardiac Dysfunction Following Viral Clearance	Reanna	Hales
P11.27	Sunday, August 30	Obesity alters temporal cardiac and transcriptional responses to influenza infection	Brigitte	Martin
P11.28	Tuesday, September 1	Influenza Gene Products as Drivers of Clinically Relevant Epithelial Reprogramming	Michael	Schwoerer
P11.29	Sunday, August 30	Environmental Air Monitoring Captures Respiratory Virus Diversity Across Human and Wildlife Healthcare Facilities	Andrew	Boylan
P11.30	Tuesday, September 1	Clinical Systemic Impact of Severe Respiratory Influenza Virus Infection Hospitalized in Adults After Discharge At Long-Term Follow-Up:INFLU 1-2 Study	Natalia	Martínez
P11.31	Sunday, August 30	Characterization of Influenza H5N1 (A/Texas/37/2024) Virus Infection in Fitch Ferret and BALB/c Mouse Models	Sathisha	Upparahalli Venkateshaiah
P11.32	Tuesday, September 1	Analysing the household transmission dynamics of influenza A(H1N1) and B Victoria, New Zealand, 2025	Lauren	Jelley
P11.33	Sunday, August 30	Characteristics and Consequences of Polyploidy in Influenza Virus Populations	Tongyu	Liu
P11.34	Tuesday, September 1	Influenza B Virus Induces Cardiac Damage and Dysfunction in a Novel, Juvenile Mouse Model	Lauren	Rowland
P11.35	Sunday, August 30	Identification of reactive CpGs and RNA expression in early COVID-19 through cis-eQTM analysis in light of disease severity and recovery	Asaph	Chun
P11.36	Tuesday, September 1	A Nasal Inflammatory Atlas Reveals IFN γ -Driven Programs That Promote Influenza Shedding and Transmission	Stacey	Bartlett
P11.37	Sunday, August 30	H1N1 infection during pregnancy in mice causes greater neurodevelopmental delays, cognitive, and social impairments in male offspring	Jennifer	Liu

Poster Sessions

Clinical Science

Implementation

Virology & Pathogenesis

Public Health

Poster Number	Presentation Date	Title	First Name	Last Name
P11.38	Tuesday, September 1	Early Differential Cellular Immune Responses to Avian Influenza Virus Subtypes in Chicken Embryos	Vinicius	Apolloni
P12.01	Sunday, August 30	Quantitative Modeling of Defective Interfering Particle (DIP) Therapy for Influenza A Infection In Vivo	Rogelio	Rodriguez Gonzalez
P12.02	Monday, August 31	A compendium of influenza virus host dependency factors revealed by parallel CRISPR screening	Nicholas	Heaton
P12.03	Sunday, August 30	Mucus Physically Restricts Influenza A Viral Particle Access to the Epithelium	Elizabeth	Engle
P12.04	Monday, August 31	Influenza Infection Alters Immunomodulatory Mucin 1 Expression in Airway Epithelium and Immune Cells	Shrestha	Mathur
P12.05	Sunday, August 30	Small molecule inhibition of the mitochondrial lipid transfer protein STARD7 attenuates influenza viral replication	Oyahida	Khatun
P12.06	Monday, August 31	Nanoscale Visualization of Membrane-Associated Infection Events During Influenza A Virus Virion Formation	I-Hsuan	Wang
P12.07	Sunday, August 30	comparison of virus concentration methods for avian influenza virus and infectious bronchitis virus in environmental water	Yejin	Lee
P12.08	Monday, August 31	Thermal Remodelling of the Host Proteome: How Influenza A Virus Exploits Temperature-Dependent RNA Regulation in the Upper Respiratory Tract	David	Courtney
P12.09	Sunday, August 30	Repurposing Clinically Advanced HIV-1 Integrase Inhibitors against the Influenza A Virus Endonuclease	Veronika	Liščáková
P12.10	Monday, August 31	Susceptibility to mammalian myxovirus resistance 1 (Mx1) protein of Highly Pathogenic Avian Influenza (HPAI) H5N1 viruses	Kaijun	Jiang
P12.11	Sunday, August 30	Influenza Virus Targets the JAK-STAT and Gap Junction Signaling Pathways in Fully Differentiated Human Bronchial Cells in Air Liquid Interface Culture	Sreekumar	Othumpangat
P12.12	Monday, August 31	Understanding the Role of NS1 in Influenza A Virus Host Tropism Through Genetic and Epitranscriptomic Profiling	Sara	El Zahed
P12.13	Sunday, August 30	Reverse Genetics as a Robust Strategy to Rescue Antigenically Faithful Influenza Viruses for Vaccine Efficacy Trials	Byungjoon	Kwon
P12.14	Monday, August 31	Identification of inflammatory responses for host-directed therapies by avian influenza virus	Sehee	Park
P12.15	Sunday, August 30	Effectiveness of baloxavir marboxil in nonhuman primates infected with highly pathogenic avian influenza A(H7N9) virus	Kiyoko	Iwatsuki-Horimoto
P12.16	Monday, August 31	Discovery and Functional Characterization of PB1-F2b: A Novel Accessory Protein Encoded by the Influenza A Virus PB1 Segment	Shaofeng	DENG
P12.17	Sunday, August 30	Discovery and Functional Characterization of PB1-F2b: A Novel Accessory Protein Encoded by the Influenza A Virus PB1 Segment	Shaofeng	DENG
P12.18	Monday, August 31	Human Respiratory Tropism and Replication of a B3.13 Cattle Origin Influenza A(H5N1) Virus Ex Vivo	Michael	Chan
P12.19	Sunday, August 30	The PB2-199-PB1-634H interface: a novel 627K-independent molecular risk marker for mammalian spillover of avian influenza A viruses	Yaqin	Bai

Poster Sessions

Clinical Science

Implementation

Virology & Pathogenesis

Public Health

Poster Number	Presentation Date	Title	First Name	Last Name
P12.20	Monday, August 31	NS2 Splicing Rewiring Drives Mammalian Adaptation of An Internally Deleted NS Segment in H5N2 HPAIV	Ruei-Sheng	Tsai
P12.21	Sunday, August 30	T438I in the Neuraminidase of Clade 2.3.4.4b H5N1 Influenza Viruses Confers Antiviral Resistance and Impacts Host-virus Interactions	Norma	Chan
P12.22	Monday, August 31	Optimization of Influenza B Virus Propagation in MDCK STAT1 Knockout Cells	Samantha	Maldonado Puga
P12.23	Sunday, August 30	A Proximity Proteomics Approach to Map the Interactome of Influenza A Replication-Transcription Complex	Lydia	Newton
P12.24	Monday, August 31	Establishment of a CRISPR Knockout Mouse Library and In Vivo Screening System for Functional Analysis of Influenza Virus Host Factors	Hiroshi	Ueki
P12.25	Sunday, August 30	Omicron Evolution Drives Increased Ciliated Cell Tropism and Dysfunction in Nasal Epithelia	Helen	Mostafavi
P12.26	Monday, August 31	Efficacy of next-generation 3CL protease inhibitor S-892216 (secutrelvir) on SARS-CoV-2 infected immunocompromised hamster	Takayuki	Kuroda
P12.27	Sunday, August 30	Optimization of long-read target capture sequencing for full-length respiratory RNA viral genomes	Yumani	Kuba
P12.28	Monday, August 31	Unravelling The Role Of Influenza A Virus Neuraminidase In Facilitating Airborne Transmission Using Primary Airway Cells And Two Animal Models.	Ksenia	Sukhova
P12.29	Sunday, August 30	Dynamics of defective interfering particles in Influenza A infection of the airway epithelium	Shiraz	Belblidia
P12.30	Monday, August 31	Mechanism of action of EDA, a novel nucleoside analogue with dual activity against influenza and coronaviruses	Lieve	Naesens
P12.31	Sunday, August 30	A Host Tripwire Restricts Influenza Virus Replication via Self-Sensing and is Antagonized by Viral Nucleoprotein	Thomas	Nipper
P12.32	Monday, August 31	Comparative replication fitness of human-origin HPAI and LPAI and antiviral responses in human primary epithelial cultures	Annie	Werner
P12.33	Sunday, August 30	Small-molecule inhibitors targeting the MAX transcriptional network limit viral infection through host regulatory reprogramming	Soner	Yildiz
P12.34	Monday, August 31	Fitness-based Screening to Identify Influenza A Virus Host Determinants In Vivo	Christopher	Gelbmann
P12.35	Sunday, August 30	Identification and Characterization of Mutations Affecting Rescue and Growth of Wild-Type pdm09 H1N1 Influenza A Strains in Vero and MDCK Cells	Alaura	Hoag
P12.36	Monday, August 31	Efficacy of BECC470s In Formulation Against Influenza Infection	Sayan	Das
P12.37	Sunday, August 30	Exploring the Role of Extracellular Matrix-modifying Enzymes in Influenza Virus Infection	Rodrigo	Canas Arranz
P12.38	Monday, August 31	Ciliary Motion and Receptor Destruction Promote Influenza A Virus Entry into Multi-Ciliated Cells	Yangjie	Tan

Poster Sessions

Clinical Science	Implementation	Virology & Pathogenesis	Public Health
------------------	----------------	-------------------------	---------------

Poster Number	Presentation Date	Title	First Name	Last Name
P12.39	Sunday, August 30	Resolving Methodological Barriers in Seasonal Human Coronavirus Research through Optimized Propagation, Titration, and Neutralization Platforms	Rose	Miller
P12.40	Monday, August 31	Membrane composition controls influenza viral binding and entry	Peter	Kasson
P12.41	Sunday, August 30	Visualizing influenza A virus genome bundling	Sho	Miyamoto
P12.42	Monday, August 31	Specific lipidomic changes control virion shape during influenza virus infection	Antonio	Santos del Peral
P12.43	Sunday, August 30	Exploring the Mechanisms of Matrix Protein 1 Effects on Influenza Virion Shape.	Balindile	Motsa
P12.44	Monday, August 31	Development and Application of Recombinant Reporter Influenza Viruses for Rapid and Quantitative Screening of Antiviral Compounds	Wei-Lun	Deng
P13.01	Sunday, August 30	Human B Cell Response to a Multivalent Mosaic Display of Influenza Antigens	Brigette	Boast
P13.02	Tuesday, September 1	Fight or Flight: Investigating Stockpile H5N1 Vaccination on Host Response	Mollie	Black
P13.03	Sunday, August 30	Human Seasonal Influenza Vaccination Boosts H5N1-Protective Antibodies Targeting the Hemagglutinin Stalk	Jordan	Ort
P13.04	Tuesday, September 1	Highly Ordered Oligomeric Proteins (HOOPs) Generated via Enzymatic Concatenation as a Novel Vaccine Antigen Display Platform	Priya	Christensen
P13.05	Sunday, August 30	Seasonal Influenza Vaccines Mixed with OVX836 - a Nucleoprotein Based Influenza Vaccine - Provide Improved Efficacy and Immunogenicity Profile in Mice	Delphine	Guyon-Gellin
P13.06	Tuesday, September 1	Using novel RNA oligos to reduce reactogenicity of unmodified self-amplifying mRNA	Cheng	Chang
P13.07	Sunday, August 30	Preclinical Immunogenicity of modRNA Vaccines Encoding Hemagglutinin and Neuraminidase from Highly Pathogenic Avian Influenza H5 Clade 2.3.4.4b Virus	Teresa	Hauguel
P13.08	Tuesday, September 1	Discovery of antiviral antibodies against respiratory syncytial virus using immune libraries from patients and humanized mice	Yoon-Seok	Chung
P13.09	Sunday, August 30	Development of an ELISA to quantify functional neuraminidase from seasonal influenza viruses using isolated NA as standards	Hyeog	Kang
P13.10	Tuesday, September 1	Genetic Mapping of the Cold-Adapted and Temperature-Sensitive Phenotypes of a New Live Attenuated Influenza A(H1N1)pdm09 Master Donor Virus	Brenda	Calderon
P13.11	Sunday, August 30	Comparing Performance of Mucosal and Injectable Influenza Vaccination: A Systematic Review of Vaccine Efficacy in Human Challenge Trials	Rachel	Luthcke
P13.12	Tuesday, September 1	Influenza mRNA vaccine reduces pathogenicity and transmission of A(H5N1) virus in a ferret model	Bin	Zhou

Poster Sessions

Clinical Science	Implementation	Virology & Pathogenesis	Public Health
------------------	----------------	-------------------------	---------------

Poster Number	Presentation Date	Title	First Name	Last Name
P13.13	Sunday, August 30	Live-attenuated Influenza Virus-Vectored mucosal RSV Vaccines Elicit Both Broad, Rapid Innate Protection and Long-lasting Adaptive Immunity	Shuang	Ren
P13.14	Tuesday, September 1	Vaccine effectiveness and the impact of genetic and antigenic distances of circulating viruses with the potential stabilizing role of neuraminidase	Yoo-Ah	Kim
P13.15	Sunday, August 30	Efficacy Evaluation of a Recombinant Clade 2.3.4.4b H5N3 Vaccine for Antigen Bank Use in preparation for HPAI incursions	Ki-Sun	Kim
P13.16	Tuesday, September 1	An integrated serological platform for airway-delivered next gen and universal vaccine and mAb immunogenicity readouts	Nigel	Temperton
P13.17	Sunday, August 30	OVX836 a Nucleoprotein-Based Influenza Vaccine Reduces Viral Load and Lung Lesion in Pre-Infected Non-Human Primates Challenged with Aerosolized pH1N1	Delphine	Guyon-Gellin
P13.18	Tuesday, September 1	Antigenic-site Replacement and Selective N-linked Glycan Masking in an mRNA-encoded Influenza B HA immunogen Broaden Cross-lineage Protection	Jineui	Kim
P13.19	Sunday, August 30	Characterizing the Antigenic Landscape of Contemporary SARS-CoV-2 Variants to inform Annual Vaccine Strain Selection	Jacob	Mischka
P13.20	Tuesday, September 1	Elicitation of anti-hemagglutinin stem neutralizing antibody response by immunizing with HA stem immunogens in ferrets with pre-existing influenza	Adrian	Creanga
P13.21	Sunday, August 30	Self-Attenuated Influenza Virus as a Potential Therapeutic Influenza Vaccine	Mingtao	Zeng
P13.22	Tuesday, September 1	A Trivalent Pre-fusion F Vaccine Confers Protective Immunity Against RSV, hMPV, and PIV-3 in Cotton Rat Challenge Models	William	Schutt
P13.23	Sunday, August 30	mRNA influenza vaccination elicits functional hemagglutinin stalk-specific antibodies	Ericka	Roubidoux
P13.24	Tuesday, September 1	Application of Structural Modeling in Egg-based Influenza Vaccine Seed Selection	Gwo-Yu	Chuang
P13.25	Sunday, August 30	Immunization with Exosome-Displayed H5 Enhances the Magnitude and Breadth of B cell Responses	Katherine	McIntire
P13.26	Tuesday, September 1	Newcastle Disease Virus vector elicits cytotoxic T-cell-mediated protection against influenza	Ishita	Roy Chowdhury
P13.27	Sunday, August 30	An Attenuated Influenza-Vectored Vaccine Platform for Mucosal Delivery of SARS-CoV-2 RBD Confers Broad Protection Against SARS-CoV-2 and Heterologous	Yuner	Gu
P13.28	Tuesday, September 1	An Attenuated Influenza-Vectored Vaccine Platform for Mucosal Delivery of SARS-CoV-2 RBD Confers Broad Protection Against SARS-CoV-2 and Heterologous	yuner	gu
P13.29	Sunday, August 30	Efficacy of Live and Inactivated Recombinant NDV Vaccines with H5 Clade 2.3.4.4b and Genotype VII Fusion Against H5N1 and NDV	Seung-un	Song
P13.30	Tuesday, September 1	A Recombinant NDV-Vectored Vaccine Expressing Structurally Stabilized HA Suppresses Y280-Lineage H9N2 Avian Influenza Virus Replication in Chickens	Seung-un	Song

Poster Sessions

Clinical Science

Implementation

Virology & Pathogenesis

Public Health

Poster Number	Presentation Date	Title	First Name	Last Name
P14.01	Sunday, August 30	Oseltamivir Usage Among Adults Aged 18–60 Years Hospitalized with Severe Acute Respiratory Infections in Public Hospitals in India	Siddhartha	Saha
P14.02	Monday, August 31	Investigating the balance of antibody responses to hemagglutinin and neuraminidase after influenza A(H3N2) virus infection in older adults	Isaac	Chow
P14.03	Tuesday, September 1	Persistently high SARS-CoV-2 infection burden during the transition from pandemic to endemic: a three-year community-based, longitudinal cohort study	Hongjie	Yu
P14.04	Sunday, August 30	Timing of Oseltamivir Initiation and Outcomes in Hospitalized Elderly Influenza Patients	Yu	Jiang
P14.05	Monday, August 31	Antibody responses to different influenza vaccine types among older adults over a period of 4 years: a randomized trial	Ben	Cowling
P14.06	Tuesday, September 1	Performance of Multi-Indicator COVID-19 Surveillance Across Five Endemic-Phase Waves in Singapore, 2023–2025	Kangwei	Zeng
P14.07	Sunday, August 30	Protein or Peptide Platform Approaches for Pre-Exposure Prophylaxis (PrEP)	Ramya	Natarajan
P14.08	Monday, August 31	Influenza antibody immunity across three continents: the West Africa, West Indies, West London Consortium	David	Bauer
P14.09	Tuesday, September 1	Identification of Acute Respiratory Symptoms for Efficient Use of Point-of-Care Influenza and COVID-19 Testing for Clinical Management	Krissy	Moehling Geffel
P14.10	Sunday, August 30	Pre-Exposure Prophylaxis for Influenza: Insights from Modeling to Inform Long-Acting Preventive Strategies	Hanumantha Rao	Paritala
P14.11	Monday, August 31	Comparative immunogenicity of several inactivated influenza vaccines among healthcare workers in Hong Kong	Lim	Wey Wen
P14.12	Tuesday, September 1	Antibody correlates of protection against multiple COVID-19 Omicron waves	Jade Yangyupei	Yang
P14.13	Sunday, August 30	Antiviral susceptibility of a novel highly pathogenic avian influenza A(H5N5) virus isolated from a human in the United States	Larisa	Gubareva
P14.14	Monday, August 31	Modifiers of Vaccine Immunity from over Ten Years of Serological Data	Luis	Fenoy
P14.15	Tuesday, September 1	Causal Insights into COVID-19 Vaccine Effectiveness: A Multi-Method Evaluation Against Omicron Variants in a Prospective Household Cohort	Jade Yangyupei	Yang
P14.16	Sunday, August 30	Estimation of Real-time, Catchment-level Respiratory Virus Prevalence from Decedent Surveillance, Accounting for Non-representative Sampling	Annie Yannan	Niu
P14.17	Monday, August 31	Difference in Breadth and Durability of Cross-reactive Antibody Responses to SARS-CoV-2 Omicron Subvariant Infections	Yuk Ching	Sze
P14.18	Tuesday, September 1	SARS-CoV-2 Spike IgG antibody concentrations as mediators of COVID-19 vaccine effectiveness against symptomatic SARS-CoV-2 Omicron variant infections	Jade Yangyupei	Yang

Poster Sessions

Clinical Science

Implementation

Virology & Pathogenesis

Public Health

Poster Number	Presentation Date	Title	First Name	Last Name
P14.19	Sunday, August 30	Real-time county-level effective reproductive number (R_t) estimates for seasonal respiratory epidemics using hierarchical generalized additive models	Katelyn	Gostic
P14.20	Monday, August 31	Nasal mucosal and serum IgA and IgG antibody responses following influenza A virus infections	Zhunan	Li
P14.21	Tuesday, September 1	Reduction of Morbidity and Mortality by COVID-19 therapeutics distributed by the federal government in the United States, Nov 2020-Sept 2025	Pragna	Patel
P14.22	Sunday, August 30	Beyond Emergency Response: Sustaining Vaccine Innovation for Coronavirus and Influenza Preparedness	Jessica	Taaffe
P14.23	Monday, August 31	Magnitude and durability of nasal mucosal antibody responses after repeated influenza vaccination with Flublok	Taoyang	WANG
P14.24	Tuesday, September 1	Routine SARS-CoV-2 Testing Frequency and Risk of Severe COVID-19: A Nationwide Population-Based Study	HIAM	CHEMAITELLY
P14.25	Sunday, August 30	A Bayesian framework for influenza A(H3N2) hemagglutination titers prediction, applied to 2023-2025 measures from France national surveillance system	Ombeline	Jollivet
P14.26	Monday, August 31	Pre-Vaccination Population Immunity Can Bias and Cause Negative Measurements of Vaccine Effectiveness.	Alexander	Pillai
P14.27	Tuesday, September 1	Risk of Stroke Following SARS-CoV-2 Infection in A Nationwide Self-Controlled Case Series Study in Qatar	Laith	Abu-Raddad
P14.28	Sunday, August 30	From Introduction to Re-Emergence: Sustained HPAI H5N1 Surveillance in Argentina, 2023-2026	Estefania	Benedetti
P14.29	Monday, August 31	Early 2025/26 influenza season seroprevalence study	Sammy	Ho
P14.30	Tuesday, September 1	Preclinical and Clinical Assessment of Immunogenicity and Cartography of Self-Amplifying SARS-CoV-2 Vaccines.	William	Schutt
P14.31	Sunday, August 30	Drivers and barriers of influenza vaccination in the Federation of Bosnia and Herzegovina, 2025: Qualitative study with risk groups and physicians	Sanjin	Musa
P14.32	Monday, August 31	Serological Responses to Influenza Vaccination in a Longitudinal Human Infant Cohort	Grace	Mantus
P14.33	Tuesday, September 1	Estimating the severity and impact of influenza in the post-COVID-19 pandemic period in Hong Kong using Bayesian evidence synthesis	Ben	Cowling
P14.34	Sunday, August 30	Estimating Incubation Periods in a School-Based Respiratory Outbreak: Evidence from Pertussis, South Korea, 2024	Sukhyun	Ryu
P14.35	Monday, August 31	Advancing Development of Improved Influenza Vaccines: The Influenza Vaccines R&D Roadmap (IVR) Initiative	Julie	Ostrowsky
P14.36	Tuesday, September 1	Symptomatic SARS-CoV-2 infection risk across six Omicron waves in Hong Kong older adults: a prospective cohort study	Xuanrui	Zhang
P14.37	Sunday, August 30	Establishing Preclinical Models for Evaluating the Protective Efficacy of Next-Generation Influenza Vaccines	Nicholas	Swanson

Poster Sessions

Clinical Science

Implementation

Virology & Pathogenesis

Public Health

Poster Number	Presentation Date	Title	First Name	Last Name
P14.38	Monday, August 31	Recombinant influenza vaccine restores immunogenicity in individuals with reduced antibody responses to influenza B viruses upon repeated vaccination	Isaac	Chow
P14.39	Tuesday, September 1	Population immunity dynamics under influenza-COVID-19 co-circulation reveal a lasting regime change	Jiaqi	Chen
P14.40	Sunday, August 30	Influenza A(H3N2) vaccine effectiveness during the early 2025-2026 season: Global evidence synthesis and real-world data from Korea	Hye Young	Kim
P14.41	Monday, August 31	Inactivated Influenza Vaccine and Mortality among Breakthrough Hospitalized Adults Aged ≥ 70 Years: A Retrospective Cohort Study in China, 2023-2025	Xinli	Jiang
P14.42	Tuesday, September 1	Symptom profiles of SARS-CoV-2 infection across six Omicron waves in Hong Kong older adults: a prospective cohort study	Xuanrui	Zhang
P14.43	Sunday, August 30	Effectiveness of educational interventions to improve influenza vaccine uptake among healthcare workers in Peru during 2024-2025	Joan	Neyra
P14.44	Monday, August 31	Real-World Effectiveness of a Cell Culture-Derived Influenza Vaccine Across Consecutive Pediatric Influenza Seasons in South Korea	Hye Young	Kim
P14.45	Tuesday, September 1	Systematic Review of COVID-19 Surveillance Indicators for the Endemic Phase: Insights from Singapore	Rhea	Khanna
P14.46	Sunday, August 30	The Role of Human Factors Engineering in the FDA Approval Process for Self-/Caregiver Administration of Live Attenuated Influenza Vaccine	Allyn	Bandell
P14.47	Monday, August 31	Safety and immunogenicity of Butantan's split-virion inactivated quadrivalent influenza vaccine in children aged 6-35 months: a phase 3 clinical trial	Carolina	Barbieri
P14.48	Tuesday, September 1	Understanding the Impact of Respiratory Infections on Occupational Fitness: COVID-19 Phenotyping in U.S. Army Servicemembers	Stephanie	Richard
P14.49	Sunday, August 30	Incidence of symptomatic influenza virus infection among unvaccinated Thai healthcare personnel: A prospective observational cohort study	Wanitchaya	Kittikraisak
P14.50	Monday, August 31	What Drives Acceptance of mRNA Influenza Vaccines? US Preferences from Two Discrete-Choice Experiments	Joost	Simons
P14.51	Tuesday, September 1	Lessons Learned in Conducting Observational Epidemiological Studies During the COVID-19 Pandemic in Japan: Implications for Future Influenza Pandemics	Takeshi	Arashiro
P14.52	Sunday, August 30	Healthcare Utilization and Costs of Influenza-Like Illness Among Military Health System Beneficiaries Vaccinated Against Influenza in a Phase IV Trial	Mofan	Gu
P14.53	Monday, August 31	Influenza vaccine reduces odds of invasive mechanical ventilation among adults with chronic obstructive pulmonary disease hospitalized with influenza	Catherine	Bozio

Poster Sessions

Clinical Science	Implementation	Virology & Pathogenesis	Public Health
------------------	----------------	-------------------------	---------------

Poster Number	Presentation Date	Title	First Name	Last Name
P14.54	Tuesday, September 1	FROM ANCESTRAL LINEAGES TO OMICRON: SIX YEARS OF SARS-COV-2 EVOLUTION IN ARGENTINA THROUGH A NATIONAL SURVEILLANCE NETWORK	María Elena	Dattero
P14.55	Sunday, August 30	Mediation Analysis of Demographic Factors, Influenza Vaccination, Infection, and Perceived Severity of Acute Respiratory Illness	GK	Balasubramani
P14.56	Monday, August 31	Effectiveness of Live Attenuated and Inactivated Influenza Vaccines in Children: Interim Data From the 2025/26 Influenza Season	Allyn	Bandell
P14.57	Tuesday, September 1	COVID-19 Household Transmission Risk and Relative Susceptibility: An Analysis Using a Change-Point Bayesian Individual-Based Model	Yue	Sui
P14.58	Sunday, August 30	Hemagglutinin Antigen from an H5N8 CVV Protects Ferrets and Mice Against HPAI H5 Clade 2.3.4.4b Virus Infection	Xing	Li
P14.59	Monday, August 31	Impact of Pediatric Influenza Vaccination Coverage and Cell-Based Vaccine Effectiveness on Clinical and Economic Outcomes in the United States	Joaquin	Mould-Quevedo
P14.60	Tuesday, September 1	Quantifying SARS-CoV-2 Viral Shedding Through Lateral-Flow Rapid Antigen Test Band Intensity: Insights from a Large-Scale Community Surveillance in HK	Hau Chi	So
P14.61	Sunday, August 30	Clinical Trial cGMP Tool: A free tool to facilitate early phase 1/2 vaccine partnerships for manufacturing	Melissa	Malhame
P14.62	Monday, August 31	Effect of Reduced Population Immunity on Seasonal Influenza Vaccine Effectiveness in the Northern Hemisphere: A Systematic Evaluation	George	Okoli
P14.63	Tuesday, September 1	Estimating Infectiousness Profiles for SARS-CoV-2 Omicron Subvariants Using Household Rapid Antigen Test Results	Chengyao	Zhang
P14.64	Sunday, August 30	Protein Language Model Embedding Distances Predict H3N2 Outbreak Intensity Beyond Epitope Hamming Distance	Tim	Tsang
P14.65	Monday, August 31	A Systematic Meta-analytic Assessment of Variations in Seasonal Influenza Vaccine Effectiveness from Test-negative Studies due to Study Features	George	Okoli
P14.66	Tuesday, September 1	Viral load clusters across transmission generations and its impacts on epidemic control: evidence from SARS-CoV-2 infector-infectee pairs	Yu	Meng
P14.67	Sunday, August 30	The Trend of respiratory viruses circulation in Korea: 10 years national surveillance	Nam-Joo	Lee
P14.68	Monday, August 31	Cardioprotective effects of flu vaccination: The good news that isn't quite out there yet	Nikki	Turner
P14.69	Tuesday, September 1	Predicting real-time severity and its impact on time-varying epidemiological parameters of COVID-19 across first six waves in Hong Kong	Sheikh Taslim	Ali
P14.70	Sunday, August 30	Global Human A/H5Nx Cases (2011-2026): Case-Level Analysis to Inform Surveillance and Pandemic Vaccine Preparedness	Aimee	Ferraro
P14.71	Monday, August 31	Comparative Effectiveness of Cell-based versus Egg-based Influenza Vaccines: Network Meta-analysis in <65Y	Alicia	Stein

Poster Sessions

Clinical Science	Implementation	Virology & Pathogenesis	Public Health
------------------	----------------	-------------------------	---------------

Poster Number	Presentation Date	Title	First Name	Last Name
P14.72	Tuesday, September 1	Impact of on-arrival quarantine strategies on delaying SARS-CoV-2 entry in the Asia-Pacific Region during the COVID-19 pandemic	Caitriona	Murphy
P14.73	Sunday, August 30	Assessment of human immunity to A/H3N2 influenza subclade K during 2025 emergence	Phoebe	Stevenson-Leggett
P14.74	Monday, August 31	Superior Effectiveness of Cell- Versus Egg-Based Influenza Vaccines in Patients With Specific High-Risk Conditions, 2023-24 Season, United States	Alicia	Stein
P14.75	Tuesday, September 1	Integration of Genomic Surveillance of Respiratory Pathogens into an Existing National COVID-19 Sequencing Platform	PETER	RADVAK
P14.76	Sunday, August 30	PhIP-Seq for mapping coronavirus cross-species transmission: from epitope signatures to zoonotic spillover surveillance	Xintong	HUANG
P14.77	Monday, August 31	Universal Influenza Vaccine Technology Landscape: Tracking the Global Pipeline of Universal, Broadly Protective, & Next-Generation Influenza Vaccines	Julie	Ostrowsky
P14.78	Tuesday, September 1	Enhancing Influenza Surveillance Capacity Through Post COVID-19 Workflow Optimization at a Local Public Health Laboratory	Kirstin Abigail	Catapang
P14.79	Sunday, August 30	A Calibration-Free SPR-Based Assay for Rapid Potency Determination of Pandemic Influenza Vaccines	Wei	Tu
P14.80	Monday, August 31	Self- or Caregiver-Administered Live Attenuated Influenza Vaccine (LAIV) for Home Use: Pilot Year Update	Allyn	Bandell
P14.81	Tuesday, September 1	Summary Analysis of the 2025 WHO GISRS External Quality Assessment Programme for detection of influenza and SARS-CoV-2 viruses by RT-PCR	Juliana	Leite
P14.82	Sunday, August 30	A Changing Landscape: Post-Pandemic Influenza Dynamics in Canada	Andrea	Nwosu
P14.83	Monday, August 31	Impact of School-Based Influenza Vaccination Programme on Vaccine Uptake and Pediatric Influenza Hospitalization in Hong Kong, 2015-2025	Yanlin	Cao
P14.84	Tuesday, September 1	Enhanced Surveillance of Respiratory Syncytial Virus (RSV) and Its Public Health Importance in Mongolia	Urtnasan	Chuluunbat
P14.85	Sunday, August 30	Clade-Specific Incidence Of Influenza-Associated Severe Acute Respiratory Infections In Bangladesh, 2019-2025	Mohammad	Aleem
P14.86	Monday, August 31	Adjuvanted inactivated zoonotic influenza A(H5N8) vaccination induces subtype-wide antibody responses in previously immunized individuals	Willemijn	Rijnink
P14.87	Tuesday, September 1	Human metapneumovirus (hMPV) and RSV: differences in Seasonality and Clinical Presentation in Hospitalized Children between 2022-2025 in Argentina	ANGELA	GENTILE
P14.88	Sunday, August 30	Demographic Correlates of Clinical Testing for Respiratory Viruses: Implications for Test-Negative Study Design	Aleda	Leis
P14.89	Monday, August 31	Relative Vaccine Efficacy of Enhanced versus Standard-dose Inactivated Influenza Vaccine Inferred from antibody titers	Shuyi	Zhong
P14.90	Tuesday, September 1	Modeling the direct and indirect effects of expanded respiratory syncytial virus (RSV) vaccine indication in the United States	Pragati	Prasad

Poster Sessions

Clinical Science	Implementation	Virology & Pathogenesis	Public Health
------------------	----------------	-------------------------	---------------

Poster Number	Presentation Date	Title	First Name	Last Name
P14.91	Sunday, August 30	Strengthening Florida's Respiratory Surveillance through APHL-CDC Fellowships	Kate	Namey
P14.92	Monday, August 31	Comparable Effectiveness of Adjuvanted & High-Dose Vaccines Against Test-Confirmed Flu, Including Hospitalizations, in Overall/ High-Risk Older Adults	Mahrukh	Imran
P14.93	Tuesday, September 1	Impact of Respiratory Syncytial Virus Subgroup on Disease Severity in Hospitalized Pediatric Patients in Guatemala	Edwin	Vásquez Fuentes
P14.94	Sunday, August 30	Over Four Decades of Influenza Surveillance in Uruguay: National Contributions to GISRS, Vaccine Strain Selection, and Genomic Monitoring	Natalia	Goñi
P14.95	Monday, August 31	Five Seasons of Evidence Showing Superior Vaccine Effectiveness and Substantial Public Health Impact of Cell-Based Versus Egg-based Influenza Vaccines	Mendel	Haag
P14.96	Tuesday, September 1	PAHO Evidence-Based Recommendations for the Clinical Management of RSV in the Americas	Angel	Rodriguez
P14.97	Sunday, August 30	Pitfalls in Modeling Leaky Vaccine Effects	Oliver	Eales
P14.98	Monday, August 31	Pediatric Vaccine Effectiveness against Medically Attended Influenza, 2025-2026, United States	Sascha	Ellington
P14.99	Tuesday, September 1	Burden of Respiratory Syncytial Virus (RSV) among children under 12 months in Western Kenya, 2023-2024	DENIS	OMONDI
P14.100	Sunday, August 30	Susceptibility of Influenza Virus to 222nm Germicidal UV	Amrita	Mandal
P14.101	Monday, August 31	No Severe Outcomes in Vaccinated Influenza Cases: Evidence from Sentinel Surveillance in Georgia, 2021-2024	Nadezhda	Zhgenti
P14.102	Tuesday, September 1	Effectiveness and Impact of Maternal RSV Immunization and Nirsevimab in U.S. Children, 2024-2025	Fatimah	Dawood
P14.103	Sunday, August 30	Integrating RAT Prevalence with PCR Case Data for Robust Rt Estimation Under Time-Varying Ascertainment	XIAOTONG	HUANG
P14.104	Monday, August 31	Comparison of Influenza Vaccine Effectiveness Estimates Using Prospective Enrollment and Electronic Health Record Data, United States, 2024-2025	Sascha	Ellington
P14.105	Tuesday, September 1	Cost-Effectiveness of Nirsevimab in Preventing Respiratory Syncytial Virus Hospitalizations Among Infants in Hong Kong	Ben	Cowling
P14.106	Sunday, August 30	Fourth Population-based study on Infectious diseases and Exposures in the Netherlands To Evaluate trends and Risks (PIENTER-4): Design and Prospects	Eric	Vos
P14.107	Monday, August 31	Direct and indirect benefits of the US influenza vaccination program: ensemble estimates from the Scenario Modeling Hub	Cecile	Viboud
P14.108	Tuesday, September 1	Epidemiology and Hospitalization Burden of Human Metapneumovirus and Respiratory Syncytial Virus among Paediatric Patients in Hong Kong, 2018-2025	Zirui	Guo

Poster Sessions

Clinical Science	Implementation	Virology & Pathogenesis	Public Health
------------------	----------------	-------------------------	---------------

Poster Number	Presentation Date	Title	First Name	Last Name
P14.109	Sunday, August 30	Secondary Complications of Influenza That Could Be Prevented by Cell-Based Compared to Egg-Based Influenza Vaccines, United States, 2023-2024	Aimee	Ferraro
P14.110	Monday, August 31	Comorbid Conditions in Test-Negative Influenza Vaccine Effectiveness Studies	Sabir	Meah
P14.111	Tuesday, September 1	Burden of RSV and HMPV-associated hospitalizations in adults in New Zealand before and after the COVID-19 Pandemic, 2012-2024	Sue	Huang
P14.112	Sunday, August 30	Design and development of a mRNA vaccine candidate encoding clade 2.3.4.4b H5-HA for pandemic preparedness	Maryann	Giel-Moloney
P14.113	Monday, August 31	Impacts of Repeated Influenza Vaccinations on Serological Responses Across Multiple Seasons	Christina	Frymire
P14.114	Tuesday, September 1	Implementation and gaps in RSV Surveillance in Albania: Focus on High-Risk Pediatric and Older Adult Populations, 2023-2026	Iris	Hasibra
P14.115	Sunday, August 30	Surveillance and Monitoring for Human Infections with Influenza A(H5) Viruses, United States	Carrie	Reed
P14.116	Monday, August 31	The Return on Investment and Social Value of Seasonal Influenza Vaccines in Armenia	Cara	Tupps Stacey
P14.117	Tuesday, September 1	Activity of Influenza, respiratory syncytial virus (RSV) and SARS-CoV-2 in Georgia during 2024-2025 and 2025-2026 seasons	Ann	Machablashvili
P14.118	Sunday, August 30	Drivers of Respiratory Vaccine Acceptance and Refusal Among U.S. Nursing Home Staff: A Cross-Sectional Survey	H.	Davidson
P14.119	Monday, August 31	Influenza Vaccine Effectiveness Amongst a Young Influenza-Virus-Naïve Cohort by Dose: A Target Trial Emulation Study Using Routinely Collected Data	Jessie	Goldsmith
P14.120	Tuesday, September 1	Building Maternal Immunization Platforms for RSV Prevention: Multi-Country Evidence to Inform Vaccine Introduction, 2025	Joseph	Bresee
P14.121	Sunday, August 30	Exploring the Relationship Between Daily Contacts and Influenza Infection Risk in Guangzhou, China	Kelly	Geith
P14.122	Monday, August 31	Predictors of in-hospital mortality among patients aged 18-60 years with severe acute respiratory infection in India	Rakesh	Kumar
P14.123	Tuesday, September 1	Characterizing the 2025/26 Influenza Season in Japan: Findings from the First Year of Nationwide Acute Respiratory Infection Surveillance	Fangyu	Yan
P14.124	Sunday, August 30	H5N1 (B3.13) avian influenza persistence in dairy cattle in Minnesota, USA	Alvin	Crespo-Bellido
P14.125	Monday, August 31	A Multi-Source Data Analysis to Estimate Incidence and Hospitalization for Nine Viruses: A Cross-Sectional Study from October 2021 to May 2024	Mingyue	Jiang
P14.126	Tuesday, September 1	Medical resource utilization in adults with influenza-associated associated severe acute respiratory infection at 12 public hospitals, India 2024-2026	Venkatesh	Narayan
P14.127	Sunday, August 30	Influenza A H3N2 Subclade K Activity and Severity in New York City, 2025-26	Ana	Gonzalez-Reiche

Poster Sessions

Clinical Science	Implementation	Virology & Pathogenesis	Public Health
------------------	----------------	-------------------------	---------------

Poster Number	Presentation Date	Title	First Name	Last Name
P14.128	Monday, August 31	Sensitivity and Specificity of Microscale Air Sampling for Respiratory Viruses within Households	Jonathan	Temte
P14.129	Tuesday, September 1	Out-of-Pocket Expenditure Among Adults Aged 18-60 Years With Severe Acute Respiratory Infection in Public Hospitals in India: A Multi-Centre Study	Mansi	Mathur
P14.130	Sunday, August 30	Effect of Donor Influenza Virus Aerosol Shedding on Recipient Breathing-zone Exposure During a Transmission Trial	Anna	Pulley
P14.131	Monday, August 31	Virus genomics and pandemic perturbations reveal the global lineage dynamics underlying measles transmission and resurgence	Jiabao	Xing
P14.132	Tuesday, September 1	Global Epidemiology and Transmission Dynamics of Human HPAI A(H5) Virus Infections, 1997-2025	Hongjie	Yu
P14.133	Sunday, August 30	Host Shedding Kinetics and Environmental Contamination in a Controlled Human Infection Model Using a Contemporary Influenza Virus Strain	Karin	Brett
P14.134	Monday, August 31	Discovery and Full Genome Characterization of a Genetically Divergent Bat Influenza A Virus Identified in Artibeus planirostris in Iquitos-Peru	Jennifer	Havens
P14.135	Tuesday, September 1	Acute hospitalizations, long-term stays, and societal burden averted with high-dose versus adjuvanted inactivated influenza vaccine in U.S. adults ≥ 65	Thomas	Shin
P14.136	Sunday, August 30	Validate capture-recapture estimated true symptomatic influenza cases using scenario simulation with regional parameters	Zirui (Troy)	Zhou
P14.137	Monday, August 31	A living systematic review and web-app to perform dynamic meta-analysis of influenza vaccine effectiveness estimates	Sheena	Sullivan
P14.138	Tuesday, September 1	Comparative Effectiveness of Influenza Blocking Measures in a Multi-Species Stochastic Model Linking Swine and Poultry CAFOs to Rural Communities	Amanda	Irish
P14.139	Sunday, August 30	Countervailing Confounding and Selection Biases in Test-Negative Studies: A Directed Acyclic Graph-Parameterized Monte Carlo Simulation	Sabir	Meah
P14.140	Monday, August 31	Sequence Verification of Transmission and Potential Impact of Glycol Vapor in a Human-to-Human Influenza Virus Transmission Trial	Donald	Milton
P14.141	Tuesday, September 1	Genomic characterisation of Respiratory syncytial virus at a tertiary care centre in India (South)	Mahesh	Moorthy
P14.142	Sunday, August 30	The Return on Investment and Social Value of Seasonal Influenza Vaccines in Armenia	Cara	Tupps Stacey
P14.143	Monday, August 31	Post-infection conditions following severe acute respiratory infection hospitalisation in Albania and Kazakhstan, 2025-2026	Mark	Katz
P14.144	Tuesday, September 1	Piloting Household Transmission Investigations in Melbourne, Australia to Improve Representativeness of Surveillance in the 2026 Respiratory Season	Jessica	Miller
P14.145	Sunday, August 30	Mira: Scalable, Reproducible Software for High-Quality Viral Genomic Surveillance	Benjamin	Rambo-Martin

Poster Sessions

Clinical Science

Implementation

Virology & Pathogenesis

Public Health

Poster Number	Presentation Date	Title	First Name	Last Name
P14.146	Monday, August 31	Interepidemic Influenza A(H3N2) Activity and Genomic Diversity in Argentina During 2025–2026	Estefania	Benedetti
P14.147	Tuesday, September 1	Estimated impact of 2022–2023 influenza vaccines on annual hospital burden in the United States	Shraddha	Bandekar
P14.148	Sunday, August 30	Sex-differential cross-recognition of H5N1 neuraminidase following H1N1 vaccination in mice	Sabal	Chaulagain
P14.149	Tuesday, September 1	Association of Human Mobility with Influenza Transmission Dynamics in Pre-, During-, and Post-COVID Seasons.	Benjamin	Cristol
P14.150	Monday, August 31	Developing a cloud-based One Health genomics platform for HPAI source tracking and risk intelligence in a Canadian hotspot region	Shannon	Russell
P14.151	Sunday, August 30	Advancing Single-Administration Vaccines Against Pandemic H5N1 Influenza: The Single Shield Prize	Susannah	Littlewood
P14.152	Tuesday, September 1	Influenza Epidemiology and Vaccine Effectiveness among Hospitalized Children in Argentina, 2025	ANGELA	GENTILE
P14.153	Monday, August 31	Evolutionary optimization of influenza vaccines	Denis	Ruchnewitz
P14.154	Sunday, August 30	Upper respiratory bacteria and virus detection and influenza viral shedding in exhaled breath among symptomatic young adults	Jacob	Bueno de Mesquita
P14.155	Monday, August 31	A Framework for Continuous Evaluation of Pandemic Influenza Manufacturing to Inform Actionable Investment Strategies for Pandemic Preparedness	Lisa Marie	Bentley
P14.156	Tuesday, September 1	Duration of illness and clinical outcomes among patients with medically-attended respiratory infections in Central Wisconsin, USA	Huong	Nguyen
P14.157	Monday, August 31	Who gets worse, who gets better?: Umbrella review of risk and resilience factors associated with the progression to severe influenza outcomes	Ji Yeon	Park
P14.158	Tuesday, September 1	Seasonal Patterns and Timing of Influenza and COVID-19 Vaccine Receipt in the United States, 2023–24 and 2024–25.	Jennifer	Radin
P14.159	Monday, August 31	A decade of Severe Acute Respiratory Infection Surveillance in the Republic of Srpska, Bosnia and Herzegovina	Nina	Rodic Vukmir
P14.160	Tuesday, September 1	The Badger Method: Statewide Influenza Surveillance Powered by Wisconsin's Clinical Laboratory Network	Erika	Hanson
P14.161	Monday, August 31	Utilizing Serological Testing in addition to Clinical Diagnostic Assays Improves Influenza Ascertainment: Insights for Public Health Surveillance	Kat	Schmidt
P14.162	Tuesday, September 1	Estimating Variant-Specific Population Susceptibility by Bayesian Deconvolution of Seroprevalence Data	Tim	Tsang
P14.163	Monday, August 31	Inactivated influenza virus vaccines induce type B neuraminidase antibodies with age-dependent inhibitory mechanisms	Jin	Gao
P14.164	Tuesday, September 1	Entropy-based Selective Prediction to Enhance the Reliability of Influenza-like Illness Forecasting in the United States	Haoling	Chen
P14.165	Monday, August 31	Quantifying Viral Interactions and Vaccination Impacts Among COVID-19, Influenza, and RSV in Post-Pandemic Hong Kong	Yanfang	Xu

Poster Sessions

Clinical Science	Implementation	Virology & Pathogenesis	Public Health
------------------	----------------	-------------------------	---------------

Poster Number	Presentation Date	Title	First Name	Last Name
P14.166	Tuesday, September 1	A Surveillance Framework for Early Seasonal Influenza Detection with Validation Across Respiratory Virus Surveillance Systems	Sofia	Myrup Otero
P14.167	Monday, August 31	Housepi: an Open Source R Package for the Statistical Analysis and Modelling of Epidemiological Data from Household Outbreaks	Simon	Cauchemez
P14.168	Tuesday, September 1	Timing and Extent of Influenza-Associated Morbidity and Mortality During an Influenza A(H3N2) Subclade K Predominant Season in the United States	Alicia	Budd
P14.169	Monday, August 31	Household Transmission Risk of Influenza A and Influenza B, United States, 2017-2025	Alexandra	Mellis
P14.170	Tuesday, September 1	Sustaining preparedness through 20 years of rapid response training for avian influenza virus threats	Sonja	Olsen
P14.171	Monday, August 31	One Health Exploratory Survey of Avian Influenza Exposure Among Poultry Industry Workers	Rachael	Pung
P14.172	Tuesday, September 1	Association Between Smoking and Susceptibility to Influenza A Virus Infection in Households	Yue	Sui
P14.173	Monday, August 31	Seasonal Influenza in U.S. Adults: Economic and Humanistic Burden Highlighting the Importance of Influenza Protection	Joost	Simons
P14.174	Tuesday, September 1	Unsupervised Learning Reveals Distinct Influenza Vaccine Hesitancy Profiles Among Tunisian Healthcare Workers	Sami	Fitouri
P14.175	Monday, August 31	Dynamic Systems Modelling of Seasonal Influenza in New Zealand Utilizing Hospitalisation Data	Ewan	Smith
P14.176	Tuesday, September 1	Monitoring Anxiety and Risk Behaviors with Influenza/COVID-19 Surveillance Data During the COVID-19 Pandemic: Implications for Future Pandemics	Takeshi	Arashiro
P14.177	Monday, August 31	Respiratory virus detection trends and influenza virus characterization in Korea, 2024-2025	Nam-Joo	Lee
P14.178	Tuesday, September 1	Genomic Surveillance Of Influenza A(H3N2): Subclade K (genetic group J.2.4.1) In Latin America And The Caribbean Regions	Juliana	Leite
P14.179	Monday, August 31	A New Method for Estimating Seasonal Onset and Intensity of Respiratory Infections Aligns with Clinical Influenza Observations	Hanne-Dorthe	Emborg
P14.180	Tuesday, September 1	Prediction of co-circulation for multiple respiratory viruses by assessing their dynamical interaction in pre-, during and post-pandemic periods	Sheikh Taslim	Ali
P14.181	Monday, August 31	Evaluating Illness-related and Contact-based School Predictors for Weekly ILI Forecasting in Hong Kong	Haoling	Chen
P14.182	Tuesday, September 1	Impact of a Ventilation Retrofitting Programme on Influenza and SARS-Cov-2 Transmission in a Residential Care Home for the Elderly	Min Whui	Fong
P14.183	Monday, August 31	Changing Factors Associated With Influenza Vaccination in Older Adults in Japan, 2017/18-2024/25: A Study Using Municipal Data Across Pandemic Phases	Ayu	Kasamatsu
P14.184	Tuesday, September 1	Hospitalizations and deaths from influenza and other respiratory viruses in the US: An ensemble time series modelling study, 2016-2024	Nabila	Shaikh

Poster Sessions

Clinical Science	Implementation	Virology & Pathogenesis	Public Health
------------------	----------------	-------------------------	---------------

Poster Number	Presentation Date	Title	First Name	Last Name
P14.185	Monday, August 31	An Integrated Potency Control Strategy to Accelerate and Improve Pandemic Influenza Vaccines Preparedness	Victor	Ayala
P14.186	Tuesday, September 1	Public knowledge and attitudes on influenza and other respiratory viruses in Aotearoa New Zealand (NZ).	Nikki	Turner
P14.187	Monday, August 31	Impact assessment of typhoon-induced population confinement on multi-pathogen of respiratory diseases dynamics in Hong Kong	Jiaqi	Chen
P14.188	Tuesday, September 1	Tolerability and Vaccine Experience with Recombinant Influenza Vaccination among Working-age Adults with Chronic Conditions	Laurence	Torcel-Pagnon
P14.189	Monday, August 31	Immunogenicity and Breadth of a Protein Based XFG SARS-CoV-2 Vaccine Against Contemporary Variants	Justin	Iampietro
P14.190	Tuesday, September 1	Influenza-related Hospitalizations Among Adults With and Without High-risk Medical Conditions, 2018-2025	Jennifer	Radin
P14.191	Monday, August 31	Seroprevalence of Influenza A(H5N1) in Domestic Cats in the Epicenter of the California Dairy Cattle Outbreaks	Ian	Bemis
P14.192	Tuesday, September 1	Breastfeeding Duration and Time to First Symptomatic Human Metapneumovirus Infection (HMPV)	Mia	Zhu
P14.193	Monday, August 31	Changing attendance patterns for acute respiratory infection and influenza-like illness patients before and after the SARS-CoV-2 pandemic	Jonathan	Temte
P14.194	Tuesday, September 1	Healthcare-seeking behavior of persons with acute respiratory infection symptoms in the post-pandemic period in Hong Kong and its implications	Ben	Cowling
P14.195	Monday, August 31	Genetic and Antigenic Characterization of a High Pathogenicity Avian Influenza A(H5N5) Virus Isolated from the First Globally Reported Human Case	Han	Di
P14.196	Tuesday, September 1	Modeling epidemic and economic trade-offs under COVID-19 isolation exit scenarios in South Korea	Asaph	Chun
P14.197	Monday, August 31	Temporal trends of 12 respiratory pathogens in Mongolia from 2015-2026	Oliver	Eales
P14.198	Tuesday, September 1	Integrated respiratory surveillance and time-series modeling to anticipate SARI hospitalizations in Albania, 2021-2025	Silvia	Bino
P14.199	Monday, August 31	Reconciling Influenza B Virus Evolution with Cohort-Specific Patterns of Human Antibody Cross-Reactivity	Chang	Liu
P14.200	Tuesday, September 1	Inferring Who Acquires Infection From Whom Based on Phylogenies	Tommy	Nyberg
P14.201	Monday, August 31	Cross-Linking Mass Spectrometry-Based Structural Analysis of Influenza Hemagglutinin for Development of a Novel Antibody-Independent Potency Assay	Noriko	Shimasaki
P14.202	Tuesday, September 1	Influenza D Virus at the Swine-Human Interface: Rising Detection in Exhibition Swine and Seropositivity Among Youth Exhibitors	Brady	O'Boyle
P14.203	Monday, August 31	Assessing the validity of threshold setting methods to monitor the activity and severity of influenza and other respiratory viruses	Mary	Sinnathamby

Poster Sessions

Clinical Science

Implementation

Virology & Pathogenesis

Public Health

Poster Number	Presentation Date	Title	First Name	Last Name
P14.204	Tuesday, September 1	The Americas Mortality Monitoring Network (AMoMo): A Regional Framework to Support Respiratory Virus Surveillance	Paula	Couto
P14.205	Monday, August 31	Evaluating the Impact of Filamentous Influenza Morphology on the Decay of Influenza A Virus in the Environment	Sterling	Knight
P14.206	Tuesday, September 1	Cohort for Acute Respiratory Disease Surveillance among Pregnant Women and their Babies in Western Kenya (Maternal-Child Cohort Platform).	Victor	Opere
P14.207	Monday, August 31	Symptom phenotypes of human parainfluenza virus illness in the HIVE cohort	Joshua	Foster-Tucker
P14.208	Tuesday, September 1	Burden and clinical outcomes of PIV1, PIV2, and PIV3 among acute respiratory infection-associated hospitalisations in New Zealand, 2012 to 2024	Sue	Huang
P14.209	Monday, August 31	Selection of Peptides Used as Standards in Isotope Dilution Mass Spectrometry: Influenza A(H10N3) as an Example	Jing	Lin
P14.210	Tuesday, September 1	Roommate Cohort Study of Influenza and Other Respiratory Virus Transmission in University Residence Halls	Jianyu	Lai
P14.211	Monday, August 31	Distinguishing Influenza from Co-circulating Pathogens for Improved Syndromic Surveillance	Ronan	Corgel
P14.212	Tuesday, September 1	Effect of Singing on Influenza Virus Aerosol Shedding	Anna	Pulley
P14.213	Monday, August 31	Forecasting Hospital Census from Admission Incidence of Respiratory Pathogens Using Length-of-Stay Estimation	Cyril	Geismar
P14.214	Tuesday, September 1	Disease burden of respiratory syncytial virus and influenza in Korea: A nationwide analysis using national health insurance data	Doo Ri	Kim
P14.215	Monday, August 31	A New Controlled Trial of Influenza Virus Transmission from Naturally Infected Donors in a Controlled Environment: Preliminary Results	Anna	Pulley
P14.216	Tuesday, September 1	Insufficiency of Cycle Threshold (Ct) Value as a Proxy for Viral Infectivity: Implications for Host Response Profiling	Ip Man	Lam
P14.217	Monday, August 31	Assess healthcare seeking behavior changes since influenza subclade K emergence in July 2025 within Michigan	Zirui (Troy)	Zhou
P14.219	Monday, August 31	Between and Early-Season Household Transmission of Respiratory Viruses in Vellore, India	Lauren	Pischel
P14.221	Monday, August 31	Laser Fabrication of Copper-Containing Highly hydrophobic Antimicrobial Surface for Influenza Control	Alex Wing Hong	Chin
P14.223	Monday, August 31	Epidemiological surveillance of seasonal influenza in Tunisia during the 2025/2026 season (Weeks 40/2025-11/2026)	Emna	Gara

Sponsor and Exhibitor Profiles



AstraZeneca Booth # 206

Website: www.astrazeneca.co.uk

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca's innovative medicines are sold in more than 125 countries and used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on social media @AstraZeneca.



BEI Resources Booth # Tabletop 01

Website: www.beiresources.org

BEI Resources, funded by NIAID, is the leading source for high-quality cultures and reagents for studying antibiotic resistance, vector borne, emerging and opportunistic microbial diseases, AIDS, epidemiology and public health. Explore the catalog and benefits we offer at www.beiresources.org, and let us serve as a catalyst for your research efforts.



Centers of Excellence for Influenza Research and Response (CEIRR) Booth # Tabletop 02

Website: www.ceirr-network.org

The Centers of Excellence for Influenza Research and Response (CEIRR) Network is a multidisciplinary and collaborative research network funded by the National Institute of Allergy and Infectious Diseases (NIAID) to study the natural history, transmission, and pathogenesis of influenza and provide an international research infrastructure to address influenza outbreaks.



Cerba Research
Booth # 311

Website: www.cerbaresearch.com

Cerba Research is a global leader in specialty and central lab services, offering extensive virology expertise across pre clinical to post market phases. With experience in 600+ infectious disease trials and broad capabilities spanning viral indications, vaccines, and antiviral development, it delivers agile support for advancing precision medicine.

CSL Seqirus

CSL Seqiris
Booth # 103/202/101/200

Website: www.csllseqirus.us

Derived from the expression 'securing health for all of us', CSL Seqirus has public health protection at its core. This reflects the promise of our parent company CSL, founded in 1916 to save lives and protect the health of people. Our first true test came with the Spanish Influenza pandemic and we have been committed to the fight against influenza ever since.



Eradivir

Website: www.eradivir.com

We are a privately held, clinical-stage biotech company focused on the power of the immune system to treat disease. We develop antibodyrecruiting molecules that selectively target diseased cells and activate a precise immune response to eliminate them. Using our proprietary BAITM(Bispecific Antigenic immuno-Therapy) platform, we are advancing a pipeline of antibody-recruiting small molecules, including our lead therapeutic EV25 for influenza and EV148 for RSV, with additional candidates in the pipeline targeting multiple diseases. Our team of industry veterans has a strong track record of developing and bringing drugs to market.



Gilead

Website: www.gilead.com



GISAID

Booth #: 309

Website: www.gisaid.org



GSK

Website: www.gsk.com



Moderna

Booth # 201/300

Website: www.modernatx.com/en-US

Moderna is one of the leaders in the creation of the field of mRNA medicine. Through the advancement of mRNA technology, Moderna is reimagining how medicines are made with the goal of transforming how we treat and prevent disease for everyone.



Pfizer

Website: www.pfizer.com

At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines.



Sanofi

Booth # 205/207/304/306

Website: www.sanofi.com

Sanofi is an R&D driven, AI-powered biopharma company committed to improving people's lives and delivering compelling growth. We apply our deep understanding of the immune system to invent medicines and vaccines that treat and protect millions of people around the world, with an innovative pipeline that could benefit millions more. Our team is guided by one purpose: we chase the miracles of science to improve people's lives; this inspires us to drive progress and deliver positive impact for our people and the communities we serve, by addressing the most urgent healthcare, environmental, and societal challenges of our time.



TOTAL TRIALS
MISSION-LED. OUTCOME-DRIVEN

Total Trials

Booth # 204

Website: www.totaltrials.com

Total Trials is a full-service contract research organization (CRO) with the global expertise, responsive approaches and proven solutions to manage complex clinical research around the world.



Vaccines at Pfizer

Website: www.pfizer.com




VisMerdi

Website: www.vismerdiholding.com
VisMederi is a globally competent, well-resourced laboratory and research organization supporting vaccine and infectious disease programs through assay development, immunogenicity testing, and related services.

Exhibition Floorplan

LEVEL 3



Options XIII Program-at-a-Glance

Saturday, August 29		Sunday, August 30		Monday, August 31		Tuesday, September 1		Wednesday, September 2		Time
7:00 AM										7:00 AM
7:30 AM										7:30 AM
8:00 AM	ISRV Mini-School of Respiratory Viruses <i>Marriott Marquis</i> 8:00 am - 5:00 pm	Opening Remarks <i>Ballroom AB 8:00 - 8:30 am</i>				Antiviral Group SIG Meeting (open to all) Room 304 7:30 - 8:30 am				8:00 AM
8:30 AM		Understanding and Addressing Vaccine Hesitancy and Misinformation Plenary Session <i>Ballroom AB 8:30 - 10:30 am</i>				Contemporary Diagnosis and Management of Seasonal and Pandemic Influenza Plenary Session <i>Ballroom AB 8:30 - 10:30 am</i>		Respiratory Viruses in Transition: Evolution, Adaptation, and Function Plenary Session <i>Ballroom AB 8:00 - 10:00 am</i>		8:30 AM
9:00 AM										9:00 AM
9:30 AM										9:30 AM
10:00 AM										10:00 AM
10:30 AM		Refreshment Break <i>Ballroom C & Foyer 10:30 - 11:00 am</i>				Refreshment Break <i>Ballroom C & Foyer 10:30 - 11:00 am</i>		Refreshment Break <i>Ballroom C & Foyer 10:00 - 10:30 am</i>		10:30 AM
11:00 AM		ISRV Award Presentations <i>Ballroom AB 11:00 - 12:30 pm</i>						Exploring Human Responses to Influenza Infection <i>Room 202</i> 10:30 am - 12:00 pm	Surveillance <i>Room 206</i> 10:30 am - 12:00 pm	11:00 AM
11:30 AM								Late Breaking Abstract Session <i>Ballroom AB</i> 10:30 am - 12:00 pm	Clinical Applications of Basic Influenza Research <i>Room 207</i> 10:30 am - 12:00 pm	11:30 AM
12:00 PM								Lunch on Own 12:00 - 1:30 pm		12:00 PM
12:30 PM		Industry Lunch Symposium (Sponsored by AstraZeneca) <i>Room 207 12:45 - 1:45 pm</i>								12:30 PM
1:00 PM		Innovative Tools and Their Contributions to Public Health Strategies <i>Ballroom AB</i> 2:00 - 4:00 pm								1:00 PM
1:30 PM								Measuring the Impact of Interventions <i>Room 206</i> 1:30 - 3:30 pm		1:30 PM
2:00 PM										2:00 PM
2:30 PM		Optimizing Antiviral Utilization for Influenza <i>Room 202</i> 2:00 - 4:00 pm								2:30 PM
3:00 PM		Implementation Science to Drive Influenza Vaccine Update in LMICs <i>Room 206</i> 2:00 - 4:00 pm						Refreshment Break <i>Ballroom C & Foyer 3:30 - 4:00 pm</i>		3:00 PM
3:30 PM		Next Generation Technology to Study Influenza <i>Room 207</i> 2:00 - 4:00 pm								3:30 PM
4:00 PM		Refreshment Break <i>Ballroom C & Foyer 4:00 - 4:30 pm</i>						Plenary Session and Closing Remarks <i>Ballroom AB 4:00 - 5:30 pm</i>		4:00 PM
4:30 PM		Burden of Disease and Risk Factors <i>Ballroom AB</i> 4:30 - 6:00 pm								4:30 PM
5:00 PM		Immune Response in Special Populations <i>Room 202</i> 4:30 - 6:00 pm								5:00 PM
5:30 PM	TWV (This Week in Virology) Live Podcast Recording <i>Marriott Marquis</i> 5:45 - 7:00 pm	Virulence and Transmission of H5N1 <i>Room 207</i> 4:30 - 6:00 pm						Ancillary Meeting		5:30 PM
6:00 PM		Implementing Approaches to Respiratory Virus Epidemiology and Interventions <i>Room 206</i> 4:30 - 6:00 pm								6:00 PM
6:30 PM		Neglected Influenza Virus/NEXUS SIG Meeting (open to all) <i>Room 306</i> 6:30 - 7:45 pm								6:30 PM
7:00 PM		Poster Session I and Exhibitor Viewing <i>Ballroom C & Foyer 6:00 - 7:00 pm</i>				Poster Session II and Exhibitor Viewing <i>Ballroom C & Foyer 6:00 - 7:00 pm</i>		Sponsored Seminar		7:00 PM
7:30 PM		ECR Trivia Night <i>Marriott Marquis 7:00 - 10:00 pm</i>				Closing Banquet (pre-registration required) <i>The Puttery 7:15 - 10:15 pm</i>		Abstract Session		7:30 PM
8:00 PM								Symposia Session		8:00 PM
8:30 PM								ECR Event		8:30 PM
9:00 PM								Posters/Exhibits		9:00 PM